Compositions with improved SPF and UVA photoprotection

Abstract

The present invention relates to a sunscreen product, a cosmetic or pharmaceutical formulation or a home care product with UVA and / or UVB protection comprising an inorganic UV filter and certain mycosporine-like amino acid compounds. The products and formulations provide improved SPF performance and UVA photoprotection. In addition, the products and formulations according to the invention provide a broad spectrum of photoprotection against UV radiation. In addition, the present invention relates to the use of such mycosporine-like amino acid compounds for promoting SPF and / or UVA photoprotection of a sunscreen product, a cosmetic or pharmaceutical formulation or a home care product comprising an inorganic UV filter. Furthermore, the present invention relates to a method of enhancing the SPF and / or UVA photoprotection of a sunscreen product, a cosmetic or pharmaceutical formulation or a home care product comprising an inorganic UV filter by adding a certain kind of mycosporine amino acid compounds. Finally, the invention relates to a method for providing anti-aging benefits to the skin, whitening the skin or preventing the blackening of the skin, improving the appearance of the skin, reducing the visible signs of skin aging and improving the gloss and compactness of the skin by topically applying to the skin a sunscreen product, a cosmetic or pharmaceutical formulation or a home care product according to the invention.

Description

Technical Field

[0001] The present invention relates to a sunscreen product, a cosmetic or pharmaceutical preparation or a home care product with UVA and / or UVB protection, which comprises an inorganic UV filter and certain mycosporin-like amino acid compounds. The products and preparations provide improved SPF performance and UVA light protection. In addition, the products and preparations according to the present invention provide broad-spectrum light protection against UV radiation. In addition, the present invention relates to the use of such mycosporin-like amino acid compounds for boosting the SPF and UVA light protection of sunscreen products, cosmetic or pharmaceutical preparations or home care products comprising inorganic UV filters. In addition, the present invention relates to a method for enhancing the SPF and UVA light protection of sunscreen products, cosmetic or pharmaceutical preparations or home care products comprising inorganic UV filters by adding certain mycosporin-like amino acid compounds. Finally, the present invention relates to a method for providing anti-aging benefits to the skin, whitening the skin or preventing skin darkening, improving the appearance of the skin, reducing visible signs of skin aging, and improving the radiance and firmness of the skin by topically applying the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the present invention to the skin. Background Art

[0002] The negative effects of exposure to UV rays are well known. Prolonged exposure to the sun can cause damage to the skin, such as sunburn, and can make hair dry and brittle. When the skin is exposed to UV rays with wavelengths between 290nm and 400nm, long-term damage can lead to serious conditions, such as skin cancer, and the type of damage depends on the wavelength of the radiation.

[0003] Sunlight includes two types of UV rays: long-wave ultraviolet A (UVA: wavelength 320nm to 400nm) and short-wave ultraviolet B (UVB: wavelength 280nm to 320nm). UVA is further divided into two wavelength ranges, namely UVA1 (340nm to 400nm) and UVA2 (320nm to 340nm).

[0004] UVA rays make up the majority (95%) of UV radiation. They have a longer wavelength than UVB and UVC rays, which means they have less energy (shorter wavelengths have more energy than longer wavelengths). Due to their longer wavelengths, they can penetrate into the dermis, which is primarily made up of collagen. When UVA rays are absorbed by the skin, they produce free radicals that can damage cells and DNA and break down collagen. This is why UVA rays are highly associated with premature aging. Skin damage caused by UVA radiation accelerates the appearance of aging, such as loss of skin elasticity and the appearance of wrinkles. This process is often referred to as photoaging. As the skin ages, the outer skin layer (epidermis) becomes thinner, even though the number of cells remains largely unchanged. However, the number of pigment-containing cells (melanocytes) decreases. As a result, the skin looks pale and translucent. Large pigment spots (age spots, liver spots, or freckles) may appear in areas exposed to the sun. Changes in connective tissue reduce the strength and elasticity of the skin, which becomes more noticeable in areas exposed to the sun (solar elastosis). Elastosis produces the leathery, weathered appearance common to farmers and sailors who spend a lot of time outdoors. In addition, UVA radiation can trigger phototoxic or photoallergic skin reactions.

[0005] UVB rays make up less than 5% of UV radiation and, due to their shorter wavelength, can only penetrate the epidermis. Here they are directly absorbed by DNA and melamine and can cause genetic mutations which, if not corrected by the cells' natural defenses, can lead to rapid proliferation of mutated cells and ultimately skin cancer. The damage caused by UVB rays can be seen almost immediately in the form of sun spots, which are an inflammatory response to skin damage.

[0006] UVC rays are by far the most damaging of the three types of UV rays. However, due to their short wavelength, they are completely absorbed by the atmosphere and therefore cannot reach our skin.

[0007] In order to attenuate these negative effects of UV radiation, ie for the purpose of protecting the skin and keratin materials from UV radiation, use is generally made of sunscreen compositions which contain screening agents active in the UVA range and in the UVB range, ie over the entire range from 280 nm to 400 nm.

[0008] UV filters are compounds with a pronounced absorption capacity for ultraviolet radiation. They are used, inter alia, in sunscreen products, cosmetic, dermatological and pharmacological preparations or sunscreen products, but also for improving the light fastness of industrial products, such as paints, varnishes, plastics, textiles, polymers, such as, for example, polymers and copolymers of mono- and diolefins, polystyrenes, polyurethanes, polyamides, polyesters, polyureas and polycarbonates, packaging materials and rubber.

[0009] UV filters are divided into UVA filters and UVB filters depending on the position of their absorption maximum; if a UV filter absorbs both UVA and UVB, it is called a UVA / UVB broadband absorber or UVA / UVB broadband filter.

[0010] In order to obtain the desired maximum UV radiation protection, sunscreen products or cosmetics, especially dermatological and pharmacological preparations, are formulated to contain mixtures of UV filters with different concentrations, and the selection of the UV filters used is determined by the regulations in the country or economic region. For example, UV filters that can be used for skin protection are managed by the U.S. FDA via its OTC monograph system in the United States and by cosmetic regulations in the European Union. There are also regulations on the use of UV filters in other countries and regions. These regulations not only specify the filters that can be used, but also determine the maximum usage content of each UV filter.

[0011] To achieve broad-spectrum UV protection, sunscreen formulations usually contain a combination of several organic UV filters, which may be supplemented with inorganic UV filters in order to increase the efficacy.

[0012] However, the use of organic UV filters is subject to increasing concern, since they are suspected to be a possible cause of skin irritation and allergies in sensitive persons as well as their potential harmful effects on the environment. Furthermore, some organic UV filters suffer from photostability.

[0013] In contrast, inorganic UV filters are photostable and give a broader spectrum of protection covering UVA and UVB. Inorganic UV filters are also known to cause less skin irritation. However, one of the main disadvantages of inorganic UV filters is that they may cause a "whitening" effect on the skin, which is less appreciated by consumers from an aesthetic point of view. Another problem with inorganic UV filters is that in order to provide effective light shielding capabilities in the UV region while maintaining high transparency in the visible light region, inorganic UV filters are usually used in the form of nanoscale pigments. The smaller size of these mineral particles increases the acceptability of their cosmetics to users, as they are less visible after application. On the other hand, such nanoscale pigments tend to be less effective in terms of UV shielding.

[0014] The number of known UVA filters and specifically approved UVA filters is small, and therefore products are limited in the UVA filters that can be used to provide broad spectrum protection.

[0015] Therefore, there is still a continuing need to provide further substances which improve the SPF properties and UVA photoprotection of sunscreen products, cosmetic or pharmaceutical preparations or home care products comprising inorganic UV filters.

[0016] It is therefore an object of the present invention to provide sunscreen products, cosmetic or pharmaceutical preparations or home care products comprising inorganic UV filters with UVA and / or UVB protection, which exhibit improved SPF performance as well as improved UVA photoprotection. Ideally, the sunscreen products, cosmetic or pharmaceutical preparations or home care products provide improved UV filter performance, in particular UVA photoprotection, and thus may allow a reduction in the amount of inorganic UV filters without affecting the envisaged SPF.

[0017] Another object of the present invention is to provide the use of substances for boosting SPF performance and UVA photoprotection in sunscreen products, cosmetic or pharmaceutical preparations or home care products comprising inorganic UV filters.

[0018] It is a further object of the present invention to provide a method for enhancing or boosting the SPF performance and UVA photoprotection in sunscreen products, cosmetic or pharmaceutical preparations or home care products comprising inorganic UV filters.

[0019] It is a further object of the present invention to provide a method of providing anti-aging benefits to the skin, whitening the skin or preventing skin darkening, improving the appearance of the skin, reducing visible signs of skin aging and improving the radiance and firmness of the skin via a sunscreen product or a cosmetic or pharmaceutical formulation comprising an inorganic UV filter.

[0020] Surprisingly, it has been found that the SPF performance and UVA photoprotection in sunscreen products, cosmetic or pharmaceutical preparations or home care products with UVA and / or UVB protection can be significantly improved by adding certain mycosporin-like amino acid compounds.

[0021] This problem is solved by the subject matter of the independent claims. However, further aspects of the invention are apparent from the wording of the dependent claims, from the following detailed description in conjunction with the accompanying examples and drawings. Summary of the invention

[0022] In order to solve the above problems, the present invention provides a sunscreen product, cosmetic or pharmaceutical preparation in the first aspect, which comprises or consists of:

[0023] (a) at least one inorganic UV filter; and

[0024] (b) at least one mycosporine-like amino acid compound,

[0025] The at least one mycosporin-like amino acid compound is represented by the general formula (V):

[0026]

[0027] as defined herein, or a tautomer or stereoisomer or salt thereof;

[0028] or

[0029] Represented by the general formula (VI)

[0030]

[0031]

[0032] as defined herein, or a tautomer or stereoisomer or salt thereof;

[0033] or any mixture of the above compounds.

[0034] In a second aspect, the present invention provides the use of at least one mycosporine-like amino acid compound or a mixture thereof (b) as defined herein for boosting the SPF performance and UVA photoprotection of a sunscreen product, a cosmetic or pharmaceutical preparation or a home care product comprising at least one inorganic UV filter.

[0035] In a further aspect, the present invention relates to a method for enhancing or boosting the SPF performance and UVA photoprotection of a sunscreen product, a cosmetic or pharmaceutical preparation or a home care product comprising at least one inorganic UV filter, said method comprising adding to said sunscreen product, cosmetic or pharmaceutical preparation or home care product an effective amount of a mycosporin-like amino acid compound (b) as defined herein or a mixture thereof.

[0036] Finally, the present invention relates to a method of providing anti-aging benefits to the skin, whitening the skin or preventing skin darkening, improving the appearance of the skin, reducing visible signs of skin aging and improving the radiance and firmness of the skin by topically applying to the skin a sunscreen product, cosmetic or pharmaceutical formulation or home care product according to the present invention.

[0037] The present invention is specified in the appended claims. However, the invention itself and its preferred variations, other objects and advantages will become apparent from the following detailed description taken in conjunction with the accompanying examples. DETAILED DESCRIPTION

[0038] In the context of the present invention, the following general meanings apply:

[0039] The terms “including” and “comprising” should be understood as open terms and mean that the named components following the terms are essential, but not “limited to” these named components and other components may be added and still be encompassed by the invention.

[0040] The term "consisting of" as used according to the present invention means that the total amount of components (a) and (b) adds up to up to 100 wt.-%, based on the total weight of the sunscreen product, cosmetic or pharmaceutical preparation or household care product, and indicates that the subject matter is closed and may include only the limitations explicitly stated.

[0041] Whenever "comprising" is mentioned, it is intended to encompass both meanings as alternatives, ie, the meaning may be "including" or "consisting of..." unless the context clearly indicates otherwise.

[0042] The term "optionally" means that the subsequently described compound may but need not be present in the composition, and that the description includes variants where the compound is included and variants where the compound is not present.

[0043] The terms "or" or "and / or" are used as function words to indicate that two words or phrases are to be taken together or separately.

[0044] The endpoints of all ranges directed to the same component or property are inclusive and individually combinable.

[0045] The term "compound" or "compound of the present invention" refers to all compounds covered by structural formula (V) and / or formula (VI) and / or formula (VII) and / or formula (XIII) and / or formula (IX) and / or formula (X) and / or formula (A) and their subformulae disclosed herein, and includes each subgenus and all specific compounds within the formula whose structure is disclosed herein.

[0046] Compounds can be identified by their chemical structure and / or chemical name. When there is a conflict between the chemical structure and the chemical name, the chemical structure determines the identity of the compound.

[0047] The term "at least one ... compound" means that the food or cosmetic or pharmaceutical preparation according to the invention, in particular a sunscreen product or a home care product may contain any one of the subsequently described individual compounds or a mixture of two, three, four, five, six or even more different subsequently described compounds.

[0048] The term "cosmetic or pharmaceutical preparation" in the context of the present invention is a composition for cosmetic or pharmaceutical purposes which contains UV filters to protect the skin, hair or nails from UV radiation. In addition to providing photoprotection, the cosmetic or pharmaceutical preparation according to the present invention may also be used to provide anti-aging benefits to the skin, whiten or prevent darkening of the skin, improve the appearance of the skin, reduce visible signs of skin aging and improve the radiance and firmness of the skin.

[0049] The term "sunscreen composition" or "sunscreen" or "skin care product" (also called "sun oil", "sun cream" or "sunscreen lotion") refers to any topical product that reflects and / or absorbs some portion of the UV radiation, thereby helping to prevent sunburn and, most importantly, skin cancer. Therefore, the term "sunscreen composition" should be understood to include not only sunscreen compositions, but also any cosmetic composition that provides UV protection. According to the present invention, a sunscreen composition may include one or more active agents (e.g., organic UV filters) and other ingredients or additives (e.g., emulsifiers, emollients, viscosity regulators, stabilizers, preservatives or fragrances). Sunscreens are lotions, sprays, gels, foams (such as expanding foam lotions or whipped emulsions), sticks, powders and other topical products. UV absorbing compounds are used not only in sunscreens, but also in other personal care products, such as lipsticks, shampoos, hair sprays, shower gels, hand soaps and insect repellents.

[0050] In the context of the present invention, the term "home care products" are necessities for daily care and cleaning of the household. They are used to maintain hygiene and a good home atmosphere. Home care products typically include laundry detergents (powders, liquids and tablets), fabric conditioners, dishwashing detergents (liquids and tablets), hard floor and surface cleaners, glass cleaners, carpet cleaners, oven cleaners, air fresheners, disinfectants, detergents, car wash products. These products are typically manufactured in the form of liquids, powders, sprays, granules, etc. Such sunscreen-containing formulations prevent premature photodamage and photobleaching of surfaces and the home care formulation itself.

[0051] The sunscreen product, cosmetic or pharmaceutical preparation or home care product of the present invention provides enhanced SPF performance and UVA photoprotection, as well as broad-spectrum photoprotection against UV radiation.

[0052] As used herein, the term "light stabilizer" is a compound useful for protecting body care and household cleaners and treatments from photolytic degradation.

[0053] The term "photostability" refers to the ability of a UV filter or any other molecule exposed to sunlight to remain stable under radiation. In particular, this means that the compound does not undergo degradation processes under UV radiation.

[0054] Sun protection factor (SPF) indicates the ability of sunscreen, cosmetic or pharmaceutical preparation or home care product to prevent UVB rays, but does not fully specify the extent (if any) of sunscreen composition to prevent UVA radiation. SPF is a measure of the amount of solar energy (UV radiation) required to produce sunburn on protected skin (i.e., in the presence of sunscreen) relative to the amount of solar energy required to produce sunburn on unprotected skin. As the SPF value increases, sunburn protection increases. With and without sunscreen, an artificial UV source is used to irradiate the skin until there is erythema (minimum erythema dose-MED). Then the SPF is calculated by dividing the MED of the protected skin by the MED of the unprotected skin, i.e., how long does it take for the skin to be sunburned with and without sunscreen. In theory, this means that a sunscreen with an SPF of 50 means that it can be exposed to UV radiation 50 times longer before sunburn.

[0055] UVA photoprotection is expressed as UVA protection factor (UVA-PF). UVA-PF is similar to SPF in that it is a measure of the extent to which a sunscreen protects the skin from UVA radiation. This is done in a similar manner by irradiating the skin with UVA. This can be done in vivo with human skin or in vitro by applying the sunscreen to an acrylic or plastic slide and measuring how much UVA passes through the slide with or without the sunscreen. In order to characterize protection against UVA radiation, the PPD (persistent pigment darkening) method is used, which measures the skin color observed 2 to 4 hours after the skin is exposed to UVA radiation. The PPD method appears to correlate well with the in vitro UVA-PF test.

[0056] The UVA protection factor based on persistent pigmentation (PPD) is designated as “UVA PPD PF" and is mathematically represented by the ratio of the dose of UVA radiation necessary to reach the pigmentation threshold with the use of UV screeners (MPPDp) to the dose of UVA radiation necessary to reach the pigmentation threshold without the use of UV screeners (MPPDnp), as shown below:

[0057]

[0058] UVA in sunscreen products, cosmetic or pharmaceutical preparations or household care products PPD PF is usually at least 4. Use UVA PPD Skin properly treated with a cosmetic composition with a PF of 4 means that it takes about 4 times longer for the skin to darken (ie reach the threshold level of melanin) than skin which has not been treated with a sunscreen product, cosmetic or pharmaceutical preparation or home care product.

[0059] The term "broad spectrum photoprotection" means photoprotection against both UVA and UVB radiation. Broad spectrum is based on the breadth of protection provided by a sunscreen in both the UVA and UVB spectra. In order for a sunscreen to be considered broad spectrum, it must achieve a critical wavelength of at least 370 nm. A critical wavelength of >370 nm is the strict minimum that a sunscreen product should achieve to be labeled "broad spectrum."

[0060] The term "critical wavelength" is defined as the wavelength at which the area under the UV protection curve (% protection vs. wavelength) accounts for 90% of the total area under the curve in the UV region (280 nm-400 nm). For example, a critical wavelength of 370 nm indicates that the protection of the sunscreen composition is not limited to wavelengths of UV-B (i.e. wavelengths of 280 nm-320 nm), but extends to 370 nm, so that 90% of the total area under the protection curve in the UV region is reached at 370 nm. The higher the critical wavelength, the better the protection against UV radiation.

[0061] To calculate the critical wavelength The measured spectral absorption from 290nm to 400nm is mathematically integrated to calculate the area under the absorbance curve. The critical wavelength value is based on the inherent shape and width of the absorbance curve, not its amplitude. The critical wavelength is the wavelength below which 90% of the area under the absorbance curve lies. The critical wavelength of a UVB sunscreen is smaller than that of a sunscreen that protects against both UVB and UVA. A higher critical wavelength ensures more UV protection, especially protection from longer wavelength UVA rays. For example, a sunscreen with a critical wavelength of 370nm provides more protection against UVA rays than a sunscreen with a critical wavelength of 350nm.

[0062] The combination of in vivo SPF rating and critical wavelength provides a complete description of the photoprotective properties of a product.

[0063] According to the invention, the main object of the invention is solved by a sunscreen product, a cosmetic, especially a dermatological or pharmaceutical preparation or a home care product, which comprises or consists of:

[0064] (a) at least one inorganic UV filter; and

[0065] (b) at least one mycosporine-like amino acid compound,

[0066] The at least one mycosporin-like amino acid compound is represented by the general formula (V):

[0067]

[0068] in

[0069] -Z is selected from the group consisting of O-R2' or amide';

[0070] -R1' is selected from the group consisting of: CH 2 , unsubstituted or substituted CH(alkyl), unsubstituted or substituted C(alkyl) 2 , unsubstituted or substituted CH(cycloalkyl), unsubstituted or substituted CH(aryl), unsubstituted or substituted CH(heterocycloalkyl), unsubstituted or substituted CH(heteroaryl), CR7'R8', C=O, halogen, O, S, SO, SO 2 , NH, unsubstituted or substituted N(alkyl), unsubstituted or substituted N(alkenyl), unsubstituted or substituted N(alkynyl), unsubstituted or substituted N(alkoxy), unsubstituted or substituted N(alkylthio), unsubstituted or substituted N(cycloalkyl), unsubstituted or substituted N(aryl), unsubstituted or substituted N(heterocycloalkyl), and unsubstituted or substituted N(heteroaryl), and unsubstituted or substituted C-spiro;

[0071] -R2' is selected from the group consisting of H, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl;

[0072] -amide' is selected from the group consisting of: NH 2 , unsubstituted or substituted NH(alkyl), unsubstituted or substituted NH(alkenyl), unsubstituted or substituted NH(alkynyl), unsubstituted or substituted NH(alkoxy), unsubstituted or substituted NH(alkylthio), unsubstituted or substituted NH(cycloalkyl), unsubstituted or substituted NH(aryl), unsubstituted or substituted NH(heterocycloalkyl), unsubstituted or substituted NH(heteroaryl), and unsubstituted or substituted NR9'R10', unsubstituted or substituted -N(O-alkyl)(alkyl)(Weinreb amide), -N(OH)(H)(hydroxamic acid), and unsubstituted or substituted -N(OH)(alkyl)(alkylated hydroxamic acid);

[0073] -R3' is selected from the group consisting of: H, OH, halogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted alkanoyl / acyl RC(=O)-, -CH 2 -OH, -R-CH 2 -OH, -C(=O)-OY, -RC(=O)-OY, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, SO, SO 2 NH 2 , unsubstituted or substituted NH(alkyl), unsubstituted or substituted NH(cycloalkyl), unsubstituted or substituted NH(aryl), unsubstituted or substituted NH(heterocycloalkyl), unsubstituted or substituted NH(heteroaryl), unsubstituted or substituted NR9'R10', and unsubstituted or substituted C-spiro;

[0074] - the substituents R4', R5' and R6', which may be the same or different, are independently selected from the group consisting of: H, OH, halogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted alkanoyl / acyl RC(=O)-, -CH 2 -OH, -R-CH 2 -OH, -C(=O)-OY, -RC(=O)-OY, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, SO, SO 2 、-S(=O) 2 OH, sulfonyl, NH 2 , unsubstituted or substituted NH(alkyl), unsubstituted or substituted NH(alkenyl), unsubstituted or substituted NH(alkynyl), unsubstituted or substituted NH(alkoxy), unsubstituted or substituted NH(alkylthio), unsubstituted or substituted NH(cycloalkyl), unsubstituted or substituted NH(aryl), unsubstituted or substituted NH(heterocycloalkyl), and unsubstituted or substituted NH(heteroaryl),

[0075] substituted or substituted NR9'R10' and unsubstituted or substituted C-spirocyclic ring; - R7' and R8' which can be the same or different are independently selected from the group consisting of:

[0076] H, OH, halogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted alkanoyl / acyl RC(═O)-, —CH 2 -OH, -R-CH 2 -OH, -C(=O)-OY, -RC(=O)-OY, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, SO, SO 2 NH 2 , unsubstituted or substituted NH(alkyl), unsubstituted or substituted NH(alkenyl), unsubstituted or substituted NH(alkynyl), unsubstituted or substituted NH(alkoxy), unsubstituted or substituted NH(alkylthio), unsubstituted or substituted NH(cycloalkyl), unsubstituted or substituted NH(aryl), unsubstituted or substituted NH(heterocycloalkyl), unsubstituted or substituted NH(heteroaryl), and unsubstituted or substituted NR9'R10';

[0077] - R9' and R10', which may be the same or different, are independently selected from the group consisting of H, OH, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted alkanoyl / acyl RC(=O)-, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycloalkyl and unsubstituted or substituted heteroaryl;

[0078] -Y is selected from the group consisting of H and unsubstituted or substituted alkyl; and

[0079] -R is unsubstituted or substituted alkyl;

[0080] or a tautomer or stereoisomer or salt of the above compounds;

[0081] Or represented by general formula (VI)

[0082]

[0083] in

[0084] -R1" is selected from the group consisting of: CH 2, unsubstituted or substituted CH(alkyl), unsubstituted or substituted C(alkyl) 2 , unsubstituted or substituted CH(cycloalkyl), unsubstituted or substituted CH(aryl), unsubstituted or substituted CH(heterocycloalkyl), unsubstituted or substituted CH(heteroaryl), -CR7"R8", C=O, halogen, O, S, SO, SO 2 , NH, unsubstituted or substituted N(alkyl), unsubstituted or substituted N(alkenyl), unsubstituted or substituted N(alkynyl), unsubstituted or substituted N(alkoxy), unsubstituted or substituted N(alkylthio), unsubstituted or substituted N(cycloalkyl), unsubstituted or substituted N(aryl), unsubstituted or substituted N(heterocycloalkyl), unsubstituted or substituted N(heteroaryl), and unsubstituted or substituted C-spiro;

[0085] -R2" is selected from the group consisting of: H, OH, halogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted alkanoyl / acyl RC(=O)-, -CH 2 -OH, -R-CH 2 -OH-C(=O)-OY, -C(=O)-amide", unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, SO, SO 2 NH 2 , unsubstituted or substituted NH(alkyl), unsubstituted or substituted NH(alkenyl), unsubstituted or substituted NH(alkynyl), unsubstituted or substituted NH(alkoxy), unsubstituted or substituted NH(alkylthio), unsubstituted or substituted NH(cycloalkyl), unsubstituted or substituted NH(aryl), unsubstituted or substituted NH(heterocycloalkyl), unsubstituted or substituted NH(heteroaryl), unsubstituted or substituted NR9"R10", and unsubstituted or substituted C-spiro;

[0086] -X is selected from the group consisting of: CH 2, unsubstituted or substituted CH(alkyl), unsubstituted or substituted CH(alkenyl), unsubstituted or substituted CH(alkynyl), unsubstituted or substituted CH(alkoxy), unsubstituted or substituted CH(alkylthio), unsubstituted or substituted CH(cycloalkyl), unsubstituted or substituted CH(aryl), unsubstituted or substituted CH(heterocycloalkyl), unsubstituted or substituted CH(heteroaryl), -CR7"R8", C=O, O, S, SO, SO 2 , NH, unsubstituted or substituted N(alkyl), unsubstituted or substituted N(alkenyl), unsubstituted or substituted N(alkynyl), unsubstituted or substituted N(alkoxy), unsubstituted or substituted N(alkylthio), unsubstituted or substituted N(cycloalkyl), unsubstituted or substituted N(aryl), unsubstituted or substituted N(heterocycloalkyl), unsubstituted or substituted N(heteroaryl), and unsubstituted or substituted C-spiro;

[0087] - the substituents R4", R5" and R6" which may be the same or different are independently selected from the group consisting of: H, OH, halogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted alkanoyl / acyl RC(=O)-, -CH 2 -OH, -R-CH 2 -OH, -C(=O)-OY, -RC(=O)-OY, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, SO, SO 2 、-S(=O) 2 OH, sulfonyl, NH 2 , unsubstituted or substituted NH(alkyl), unsubstituted or substituted NH(alkenyl), unsubstituted or substituted NH(alkynyl), unsubstituted or substituted NH(alkoxy), unsubstituted or substituted NH(alkylthio), unsubstituted or substituted NH(cycloalkyl), unsubstituted or substituted NH(aryl), unsubstituted or substituted NH(heterocycloalkyl), and unsubstituted or substituted NH(heteroaryl), unsubstituted or substituted NR9"R10", and unsubstituted or substituted C-spiro;

[0088] - R7" and R8" which may be the same or different are independently selected from the group consisting of: H, OH, halogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted alkanoyl / acyl RC(=O)-, -CH 2 -OH, -R-CH 2 -OH, -C(=O)-OY, -RC(=O)-OY, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, SO, SO 2 NH 2 , unsubstituted or substituted NH(alkyl), unsubstituted or substituted NH(alkenyl), unsubstituted or substituted NH(alkynyl), unsubstituted or substituted NH(alkoxy), unsubstituted or substituted NH(alkylthio), unsubstituted or substituted NH(cycloalkyl), unsubstituted or substituted NH(aryl), unsubstituted or substituted NH(heterocycloalkyl), unsubstituted or substituted NH(heteroaryl), and unsubstituted or substituted NR9"R10";

[0089] -amide" is selected from the group consisting of: NH 2 , unsubstituted or substituted NH(alkyl), unsubstituted or substituted NH(alkenyl), unsubstituted or substituted NH(alkynyl), unsubstituted or substituted NH(alkoxy), unsubstituted or substituted NH(alkylthio), unsubstituted or substituted NH(cycloalkyl), unsubstituted or substituted NH(aryl), unsubstituted or substituted NH(heterocycloalkyl), unsubstituted or substituted NH(heteroaryl), unsubstituted or substituted NR9"R10", unsubstituted or substituted -N(O-alkyl)(alkyl)(Weinreb amide), -N(OH)(H)(hydroxamic acid), and unsubstituted or substituted -N(OH)(alkyl)(alkylated hydroxamic acid);

[0090] - R9" and R10" which may be identical or different are independently selected from the group consisting of H, OH, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted alkanoyl / acyl RC(=O)-, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycloalkyl and unsubstituted or substituted heteroaryl;

[0091] -Y is selected from the group consisting of H and unsubstituted or substituted alkyl; and

[0092] -R is unsubstituted or substituted alkyl;

[0093] or a tautomer or stereoisomer or salt of the above compounds;

[0094] or any mixture of the above compounds.

[0095] The sunscreen products, cosmetic or pharmaceutical preparations or home care products according to the invention comprise at least one inorganic UV filter (a) which provides protection against UVA and / or UVB radiation.

[0096] UV filters are compounds or mixtures of compounds that block or absorb ultraviolet (UV) rays. UV classifications include UVA (320nm to 400nm), UVB (290nm to 320nm), and UVC (200nm to 280nm). UV absorbing compounds are used not only in sunscreens, but also in other personal care products such as lipstick, shampoo, hair spray, shower gel, hand soap, and insect repellent. Chemical filters prevent UV radiation by absorption, reflection, or scattering. Reflection and scattering are achieved by materials such as titanium dioxide (TiO 2 ) and zinc oxide (ZnO) are used to achieve this. The absorption (mainly of UVB) is achieved by organic UV filters, which are called chemical UV filters. The sunscreen product or cosmetic or pharmaceutical preparation according to the invention provides broad-spectrum light protection, i.e. protection against UVA and UVB.

[0097] According to the invention, at least one inorganic UV filter (a) is selected from the group of pigments consisting of: titanium dioxide (TiO 2 ) (amorphous or crystalline, rutile and / or anatase form), zinc oxide (ZnO), iron oxide (Fe 2 O 3 ), zirconium oxide (ZrO 2 ), silicon dioxide (SiO 2 ), manganese oxide (such as MnO), aluminum oxide (Al 2 O 3 ), cerium oxide (Ce 2 O 3 ), barium carbonate (BaCO 3 ), calcium carbonate (CaCO 3 ) and mixtures thereof.

[0098] Preferably, the at least one inorganic UV filter is titanium dioxide, zinc oxide and mixtures thereof, more preferably, the at least one inorganic UV filter is titanium dioxide and / or zinc oxide, and most preferably, the at least one inorganic UV filter is zinc oxide. ZnO has a broad UVA / UVB absorption curve, while TiO 2 Provides better UVB protection.

[0099] According to another variant, at least one inorganic UV filter is in the form of particles having a weight average particle size d 50 1 nm to 1000 nm, preferably 3 nm to 800 nm, more preferably 5 nm to 600 nm and most preferably 10 nm to 400 nm.

[0100] Inorganic UV filters also encompass nanopigments of untreated or treated metal oxides (average size of the primary particles: typically 1 nm to 100 nm, preferably 3 nm to 90 nm, more preferably 5 nm to 80 nm and most preferably 10 nm to 70 nm), such as, for example, titanium dioxide (TiO 2 ) (amorphous or crystalline, rutile and / or anatase form), zinc oxide (ZnO), iron oxide (Fe 2 O 3 ), zirconium oxide (ZrO 2 ), silicon dioxide (SiO 2 ), manganese oxide (such as MnO), aluminum oxide (Al 2 O 3 ), cerium oxide (Ce 2 O 3 ), barium carbonate (BaCO 3 ), calcium carbonate (CaCO 3 ) or a mixture thereof.

[0101] Treated nanopigments and non-nanopigments are pigments that have been subjected to one or more surface treatments of a chemical, electronic, mechanochemical and / or mechanical nature with compounds such as amino acids, beeswax, fatty acids, fatty acid esters, fatty alcohols, anionic surfactants, lecithin, sodium, potassium, zinc, iron or aluminum salts of fatty acids, metal (titanium or aluminum) alkoxides, polyethylene, silicones, proteins (collagen or elastin), alkanolamines, silica, metal oxides, sodium hexametaphosphate, alumina or glycerol, hydrated silica, stearic acid, jojoba esters or glutamic acid derivatives.

[0102] The treated nanopigments and non-nanopigments may more particularly be titanium oxide treated with silica and alumina, alumina and aluminum stearate, alumina and aluminum laurate, aluminum hydroxide, iron oxide and iron stearate, silica, alumina and silicone, sodium hexametaphosphate, octyl trimethoxy silane, alumina and stearic acid, alumina and glycerol, or alumina and silicone or polyhydroxystearic acid, hydrated silica, jojoba esters, stearoyl glutamic acid, glutamic acid and derivatives, trimethoxy caprylyl silane, glycerol, dimethicone hydrogen dimethicone, dimethicone or a combination thereof. Other titanium dioxide nanopigments treated with silicone are preferably TiO treated with octyl trimethyl silane. 2 , preferably, the average size of its elementary particles is 25nm to 40nm; TiO treated with polydimethylsiloxane 2 Preferably, the average size of its elementary particles is 21 nm; or TiO treated with polydimethylhydrogensiloxane 2 , preferably, the average size of its elementary particles is 25 nm.

[0103] Coated zinc oxide nanopigments and zinc oxide non-nanopigments are, for example, ZnO coated with polymethylhydrogensiloxane; ZnO dispersions in cyclomethicone / oxyethylated polydimethylsiloxane, containing 30% or 80% of nano or non-nano zinc oxide coated with silica and polymethylhydrogensiloxane; ZnO coated with perfluoroalkyl phosphate and perfluoroalkylethyl-based copolymers as dispersions in cyclopentasiloxane; ZnO coated with a cross-linked polymer of dimethoxydiphenylsilane triethoxyoctylsilane; ZnO coated with glutamic acid; ZnO coated with octyltriethoxysilane; ZnO coated with dimethicone; ZnO coated with silicone grafted acrylic polymer dispersed in cyclomethicone ZnO coated with triethoxycaprylylsilane; ZnO coated with polyhydroxystearic acid; ZnO treated with alumina dispersed in a mixture of ethylhexyl methoxycinnamate / PVP-hexadecene / polymethicone copolymer; ZnO coated with silica and polymethylsilsesquioxane; ZnO dispersed in a hydroxystearic acid polycondensate; or ZnO coated with a mixture of stearoyl glutamate, jojoba esters, polyhydroxystearic acid, isopropyl titanium triisostearate, hydrogenated olive oil stearyl, cetearyl nonanoate, white wax, dimethicone, crosspolymer of dimethoxydiphenylsilane triethoxycaprylylsilane, octyl triethoxysilane, glutamic acid and sodium stearoyl lactylate.

[0104] Likewise preferred are particulate UV filters or inorganic pigments, which may be optionally hydrophobized, such as iron (Fe 2 O 3 ), zirconium (ZrO 2 ), silicon (SiO 2), manganese oxide (e.g., MnO), aluminum oxide (Al 2 O 3 ), cerium (e.g., Ce 2 O 3 ), barium carbonate (BaCO 3 ), calcium carbonate (CaCO 3 ) or oxides of mixtures thereof.

[0105] The previously specified inorganic UV filters are used in sunscreen products, cosmetic or pharmaceutical preparations or household care products as single component or in mixtures with two, three, four or more of the inorganic UV filters mentioned.

[0106] Component (b) in the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the first aspect of the present invention is at least one mycosporine-like amino acid compound, and the at least one mycosporine-like amino acid compound is represented by the general formula (V):

[0107]

[0108] As defined herein;

[0109] or

[0110] Represented by the general formula (VI)

[0111]

[0112] As defined herein.

[0113] Mycosporin-like amino acids (MAAs) are small secondary metabolites produced by organisms living in environments with high amounts of sunlight, typically marine environments. MAAs are imine derivatives of mycosporins and contain an amino-cyclohexene-imine ring linked to an amino acid, amino alcohol, or amino group. The compounds are capable of achieving electron delocalization. In addition, the compounds demonstrate antioxidant qualities.

[0114] Unless otherwise stated, in the context of the present invention, in particular for the definition of mycosporin-like amino acid compounds represented by any of the general formulae, the following general meanings apply:

[0115] According to the present invention, the term "halogen" residue / moiety or group refers to F, Cl, Br or I alone or as part of another substituent.

[0116] According to the present invention, the term "alkyl" alone or as part of another substituent refers to a saturated or monounsaturated or polyunsaturated straight or branched monovalent hydrocarbon radical obtained by removing a hydrogen atom from a single carbon atom of the corresponding parent alkane.

[0117] In preferred variations, the term "alkyl" also includes any alkyl moiety in the radical derived therefrom, such as alkoxy, alkylthio, alkylsulfonyl, saturated straight or branched chain hydrocarbon radicals having 1 to 10, 1 to 8, 1 to 6 or 1 to 4 carbon atoms.

[0118] If the alkyl group is further bonded to another atom, the group becomes an alkylene group or an alkylene group. In other words, the term "alkylene" also refers to a divalent straight or branched chain alkyl group. For example, -CH 2 CH 3 is ethyl, and -CH 2 CH 2 -It's vinyl.

[0119] The term "alkylene" alone or as part of another substituent refers to a saturated straight or branched chain divalent hydrocarbon radical derived by the removal of two hydrogen atoms from a single carbon atom or from two different carbon atoms of a starting alkane.

[0120] In a preferred variant according to the invention, the linear or branched alkyl or alkylene group comprises 1 to 10 carbon atoms. In other still more preferred variants, the linear or branched alkyl or alkylene group comprises 1 to 6 carbon atoms.

[0121] According to the present invention, more preferred are saturated straight chain or branched C1 to C6 alkyl groups or saturated straight chain or branched C1 to C6 alkylene groups.

[0122] Most preferred are straight or branched chain alkyl or alkylene groups having 1 to 4 carbon atoms.

[0123] Preferred alkyl radicals / moieties or alkyl groups include, but are not limited to, C1 to C6 alkyl groups including methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl and 1-ethyl-2-methylpropyl.

[0124] In preferred variations, the alkyl radical / moiety is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl, more preferably from the group consisting of methyl and ethyl.

[0125] An alkyl group or alkylene group as defined above may be further substituted.

[0126] The term "alkyl" or "alkylene" also includes radicals / groups having any degree of saturation, i.e., radicals having only carbon-carbon single bonds ("alkyl" or "alkylene"), radicals having one or more carbon-carbon double bonds ("alkenyl"), radicals having one or more carbon-carbon triple bonds ("alkynyl"), and radicals having mixtures of carbon-carbon single, double and / or triple bonds.

[0127] According to the present invention, the term "alkenyl" alone or as part of another substituent refers to an unsaturated straight or branched monovalent hydrocarbon radical having at least one carbon-carbon double bond (C=C double bond). The group may be in a cis or trans configuration about the double bond. Thus, the term "alkenyl" also includes the corresponding cis / trans isomers.

[0128] In a preferred variant according to the invention, the straight-chain or branched alkenyl group comprises 2 to 10 carbon atoms. In a further preferred variant, the straight-chain or branched alkenyl group comprises 2 to 6 carbon atoms.

[0129] In a still further preferred variation, the straight-chain or branched alkenyl group comprises 2 to 4 carbon atoms.

[0130] According to the invention, preference is given to mono- or di-unsaturated straight-chain or branched C1 to C6 alkenyl groups.

[0131] Typical alkenyl or alkenyl groups include, but are not limited to, vinyl; propenyl, such as prop-1-en-1-yl, prop-1-en-2-yl, prop-2-en-1-yl (allyl), prop-2-en-2-yl, cycloprop-1-en-1-yl, cycloprop-2-en-1-yl; butenyl, such as but-1-en-1-yl, but-1-en-2-yl, 2-methyl-prop-1-en-1-yl, but-2-en-1-yl, but-2-en-2-yl, buta-1,3-dien-1-yl, buta-1,3-dien-2-yl, and the like.

[0132] Alkenyl groups as defined above may be further substituted.

[0133] According to the present invention, the term "alkynyl" alone or as part of another substituent refers to an unsaturated straight or branched monovalent hydrocarbon radical having at least one carbon-carbon triple bond (C≡C triple bond).

[0134] In preferred variants according to the invention, the straight or branched alkynyl group comprises 2 to 10 carbon atoms. In other preferred variants, the alkynyl group has 2 to 6 carbon atoms. In still other preferred variants, the alkynyl group comprises 2 to 4 carbon atoms.

[0135] Most preferred according to the invention are monounsaturated or diunsaturated straight-chain or branched C1 to C6 alkynyl groups.

[0136] Typical alkynyl / moieties or alkynyl groups include, but are not limited to, ethynyl; propynyl, such as prop-1-yn-1-yl, prop-2-yn-1-yl, etc.; butynyl, such as but-1-but-1-yl, but-1-but-3-yl, but-3-but-1-yl, etc.

[0137] An alkynyl group as defined above may be further substituted. An alkyl group or an alkylene group as defined above may be further substituted.

[0138] According to the present invention, the term "alkoxy" alone or as part of another substituent refers to a straight or branched chain radical of the formula -OR, wherein R is alkyl or a net substituted alkyl, as defined herein.

[0139] In preferred variants according to the invention, the straight-chain or branched alkoxy group comprises 2 to 10 carbon atoms. In other preferred variants, the straight-chain or branched alkoxy group comprises 2 to 6 carbon atoms. In still other preferred variants, the straight-chain or branched alkoxy group comprises 2 to 4 carbon atoms.

[0140] Most preferred according to the present invention are linear or branched C1 to C6 alkoxy groups.

[0141] Typical alkoxy / moieties or alkoxy groups include C1 to C6 alkoxy, including C1 to C4 alkoxy such as methoxy, ethoxy, n-propoxy, 1-methylethoxy, butoxy, 1-methylpropoxy, 2-methylpropoxy or 1,1-dimethylethoxy; and pentoxy, 1-methylbutoxy, 2-methylbutoxy, 3-methylbutoxy, 1,1-dimethylpropoxy, 1,2-dimethylpropoxy, 2,2-dimethylpropoxy, 1-ethylpropoxy, hexyloxy , 1-methylpentoxy, 2-methylpentoxy, 3-methylpentoxy, 4-methylpentoxy, 1,1-dimethylbutoxy, 1,2-dimethylbutoxy, 1,3-dimethylbutoxy, 2,2-dimethylbutoxy, 2,3-dimethylbutoxy, 3,3-dimethylbutoxy, 1-ethylbutoxy, 2-ethylbutoxy, 1,1,2-trimethylpropoxy, 1,2,2-trimethylpropoxy, 1-ethyl-1-methylpropoxy or 1-ethyl-2-methylpropoxy.

[0142] In a preferred variant, the alkoxy radical or alkoxy group is selected from the group consisting of methoxy (-O-methyl), ethoxy (-O-ethyl), propoxy (-O-propyl) and butoxy (-O-butyl), more preferably from the group consisting of methoxy (-O-methyl) and ethoxy (-O-ethyl).

[0143] An alkoxy group or an alkylene group as defined above may be further substituted.

[0144] According to the present invention, the term "alkylthio" or "thioalkoxy" alone or as part of another substituent refers to a radical of formula -SR, wherein R is alkyl or substituted alkyl, as defined herein.

[0145] According to the present invention, the term "alkyl" or "alkylene" also includes heteroalkyl or heteroalkyl groups. The term "heteroalkyl" by itself or as part of another substituent refers to an alkyl group in which one or more of the carbon atoms are independently replaced by the same heteroatom or another heteroatom or by the same heteroatom group or another heteroatom group. Typical heteroatoms or heteroatom groups that can replace carbon atoms include, but are not limited to, -O-, -S-, -N-, -Si-, -NH-, -S(O)-, -S(O)- 2 -、-S(O)NH-、-S(O) 2 The heteroatom or heteroatom group may be placed at any interior position of the alkyl group.

[0146] Typical heteroatom groups that may be included in these groups include, but are not limited to, -O-, -S-, -OO-, -SS-, -OS-, -NRR-, =NN=, -N=N-, -N=N-NRR, -PR-, -P(O) 2 -、-POR-、-OP(O) 2 -、-SO-、-SO 2 -,-SR 2 OR-, etc., wherein R is independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, or substituted heteroarylalkyl, as defined herein.

[0147] An alkyl group or alkylene group as defined above may be further substituted.

[0148] According to the present invention, the term "acyl" or "alkanoyl" alone or as part of another substituent refers to the group RC(=O)-, wherein R is hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, arylalkyl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted heteroarylalkyl, as defined herein.

[0149] Representative examples include, but are not limited to, formyl, acetyl, propionyl, butyryl, valeryl, benzoyl, cyclohexylcarbonyl, cyclohexylmethylcarbonyl, benzylcarbonyl, and the like.

[0150] According to the present invention, the term "cycloalkyl" alone or as part of another substituent refers to a saturated or mono- or poly-unsaturated, non-aromatic, cyclic monovalent hydrocarbon radical in which the carbon atoms are ring-linked and there are no heteroatoms.

[0151] Carbocycles may occur as monocyclic compounds having only a single ring, or as polycyclic compounds having two or more rings.

[0152] In a preferred variant, the term "cycloalkyl" includes a three-membered to ten-membered monocyclic cycloalkyl or cycloalkyl group or a nine-membered to twelve-membered polycyclic cycloalkyl or cycloalkyl group. In other still more preferred variants, the cycloalkyl moiety includes a five-membered, six-membered or seven-membered monocyclic cycloalkyl moiety or a nine-membered to twelve-membered bicyclic cycloalkyl moiety.

[0153] In preferred embodiments according to the present invention, the cycloalkyl or group comprises 3 to 20 carbon atoms. In even more preferred embodiments, the cycloalkyl comprises 6 to 15 carbon atoms. In the most preferred embodiments, the cycloalkyl comprises 6 to 10 carbon atoms. Most preferably, a monocyclic C3 to C7 cycloalkyl group.

[0154] Typical cycloalkyl or cycloalkyl groups include, but are not limited to, saturated carbocyclic groups having 3 to 20 carbon atoms, such as C3 to C12 carbocyclic groups, including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl and cyclododecyl; cyclopentyl, cyclohexyl, cycloheptyl and cyclopropyl-methyl, cyclopropyl-ethyl, cyclobutyl-methyl, cyclobutyl-ethyl, cyclopentyl-methyl, cyclopentyl-ethyl, cyclohexyl-methyl, or C3-C7 carbocyclic groups, which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopropyl-methyl, cyclopropyl-ethyl, cyclobutyl-methyl, cyclopentyl-ethyl, cyclohexyl-methyl, cyclobut-1-en-1-yl, cyclobut-1-en-3-yl, 3-dien-1-yl, etc.

[0155] Preferred polycyclic cycloalkyl groups or cycloalkyl groups according to the present invention include, but are not limited to, naphthyl, indenyl, and the like.

[0156] According to the invention, the term "cycloalkyl" also includes cycloalkenyl, i.e. an unsaturated cyclic hydrocarbon radical containing a C=C double bond between two carbon atoms of the ring molecule. In a broader sense, cycloalkenyl is a compound with one, two or more double bonds, wherein the number of possible, mostly conjugated double bonds in the molecule depends on the ring size.

[0157] Typical cycloalkenyl groups include, but are not limited to, cyclopropenyl, cyclopentenyl, cyclohexenyl, cyclopentadienyl, and the like.

[0158] According to the invention, the term "cycloalkyl" also includes cycloalkynyl groups, ie unsaturated -C≡C- triple bonds, comprising a cyclic hydrocarbon group between two carbon atoms of the ring molecule, the triple bond depending on the ring size due to ring strain.

[0159] Typical cycloalkynyl groups include cycloheximide.

[0160] The cycloalkyl, cycloalkenyl or cycloalkynyl moieties or groups as defined above may be further substituted.

[0161] According to the present invention, the term "aryl" alone or as part of another substituent refers to a monovalent aromatic hydrocarbon radical derived by removing a hydrogen atom from a single carbon atom of an aromatic ring system.

[0162] In a preferred variant, the term "aryl" includes three- to ten-membered monocyclic aryl or aryl groups or nine- to twelve-membered polycyclic aryl or aryl groups. In other still more preferred variants, carboaryl includes five-, six- or seven-membered monocyclic carboaryl or nine- to twelve-membered bicyclic carboaryl.

[0163] In a preferred embodiment according to the invention, the aryl group comprises 3 to 20 carbon atoms. In a preferred variant, the aryl moiety comprises 6 to 15 ring atoms. In an even more preferred embodiment, the aryl group comprises 6 to 10 carbon atoms.

[0164] According to the present invention, most preferred are monocyclic C3 to C10 aryl groups.Most preferred are monocyclic C3 to C7 aryl groups.

[0165] Typical aryl groups include, but are not limited to, benzene, phenyl, biphenyl, naphthyl (such as 1- or 2-naphthyl, tetrahydronaphthyl), fluorenyl, indenyl and phenanthryl. Typical carboaryl moieties also include, but are not limited to, groups derived from: aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, hexabenzophenone, fluoranthene, fluorene, hexaphenylene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene, naphthalene, octacene ... ctaphene), octalene, ovalene, pentane-2,4-diene, pentacene, cyclopentadiene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, trinaphthalene, etc.

[0166] Preferred aromatic polycyclic aromatic groups or aryl groups according to the present invention include, but are not limited to, naphthalene, biphenyl and the like.

[0167] The aryl moieties or groups as defined above may be further substituted.

[0168] According to the present invention, the term "arylalkyl" alone or as part of another substituent refers to a non-cyclic alkyl group in which one of the hydrogen atoms attached to a carbon atom (usually a terminal or sp carbon atom) is replaced by an aryl group as defined herein. In other words, arylalkyl can also be considered to be an alkyl substituted with an aryl group. Typical arylalkyls include, but are not limited to, benzyl, 2-phenylethane-1-yl, 2-phenylethene-1-yl, naphthylmethyl, 2-naphthylethane-1-yl, 2-naphthylethene-1-yl, naphthylbenzyl, 2-naphthylphenylethane-1-yl, etc.

[0169] The term "heteroarylalkyl" alone or as part of another substituent refers to a cyclic alkyl group in which one of the hydrogen atoms attached to the carbon atom is replaced by a heteroaryl group. In a preferred embodiment according to the present invention, the heteroarylalkyl group is a 6- to 20-membered heteroarylalkyl group, for example, the alkyl, alkenyl or alkynyl group of the heteroarylalkyl group is a C1 to C6 alkyl group, and the heteroaryl group is a 5- to 15-membered heteroaryl group. In other embodiments, the heteroarylalkyl group is a 6- to 13-membered heteroarylalkyl group, for example, the alkyl, alkenyl or alkynyl group is a C1 to C3 alkyl group, and the heteroaryl group is a 5- to 10-membered heteroaryl group.

[0170] According to the present invention, the term "heterocycloalkyl" alone or as part of another substituent refers to a saturated or monounsaturated or polyunsaturated non-aromatic cyclic monovalent hydrocarbon radical in which one or more carbon atoms are replaced individually by the same or different heteroatoms. Typical heteroatoms replacing carbon atoms include, but are not limited to, N, P, O, S, Si, etc. Typical heterocycloalkyls include, but are not limited to, groups derived from epoxides, azine rings, thiirane rings, imidazolidines, morpholine, piperazine, piperidine, pyrazolidine, pyrrolidone, quinuclidine, etc.

[0171] In a preferred embodiment according to the invention, the heterocycloalkyl moiety or group comprises 3 to 20 ring atoms. In a preferred variant, the heterocycloalkyl moiety comprises 6 to 15 ring atoms. In an even more preferred embodiment, the heterocycloalkyl moiety comprises 6 to 10 carbon atoms.

[0172] The heterocycloalkyl moiety may occur as a monocyclic compound having only a single ring, or as a polycyclic compound having two or more rings such as a bicyclic, tricyclic or spirocyclic ring.

[0173] Preferably, the term "heterocycloalkyl" includes a three- to seven-membered saturated or mono- or poly-unsaturated heterocycloalkyl moiety including one, two, three or four heteroatoms selected from the group consisting of O, N and S. One or more heteroatoms may occupy any position in the heterocycloalkyl ring.

[0174] In a preferred variation, the term "heterocycloalkyl" includes three- to ten-membered monocyclic heterocycloalkyl or nine- to twelve-membered polycyclic heterocycloalkyl. In other still more preferred variations, the heterocycloalkyl moiety includes a five-, six- or seven-membered monocyclic heterocycloalkyl moiety or a nine- to twelve-membered bicyclic heterocycloalkyl moiety.

[0175] According to the present invention, most preferred are monocyclic heterocycloalkyl groups comprising 3 to 12 carbon atoms.Most preferred are monocyclic heterocycloalkyl groups having 5 to 7 ring atoms.

[0176] Typical heterocycloalkyl moieties include, but are not limited to, five-membered or six-membered saturated or monounsaturated heterocycloalkyl groups containing one or two nitrogen atoms and / or one oxygen atom or sulfur atom or one or two oxygen atoms and / or sulfur atoms as ring members, including 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrothienyl, 3-tetrahydrothienyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 3-isoxazolidinyl, 4-isoxazolidinyl, 5-isoxazolidinyl, 3-isothiazolidinyl, 4-isothiazolidinyl, 5-isothiazolidinyl, 3-pyrazolidinyl, 4-pyrazolidinyl, 5-pyrazolidinyl, 2-oxazolidinyl, 3-pyrazolidinyl, 3-isothiazolidinyl, 4-isothiazolidinyl, 5-isothiazolidinyl, 2-oxazolidinyl, 3-pyrazolidinyl, 3-pyrazolidinyl, 2-oxazolidinyl, 3-pyrazolidinyl, 3-pyrazolidinyl, 3-isothiazolidinyl, 4-isothiazolidinyl, 5-isothiazolidinyl, 3-pyrazolidinyl, 4-pyrazolidinyl, 5-pyrazolidinyl, 2-oxazolidinyl, 3-pyraz ... alkyl, 4-oxazolidinyl, 5-oxazolidinyl, 2-thiazolidinyl, 4-thiazolidinyl, 5-thiazolidinyl, 2-imidazolidinone, 4-imidazolidinone, 2-pyrrolin-2-yl, 2-pyrrolin-3-yl, 3-pyrrolin-2-yl, 3-pyrrolin-3-yl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 1,3-dioxane-5-yl, 2-tetrahydropyranyl, 4-tetrahydropyranyl, 2-tetrahydrothienyl, 3-hexahydropyridazinyl, 4-hexahydropyridazinyl, 2-hexahydropyrimidinyl, 4-hexahydropyrimidinyl, 5-hexahydropyrimidinyl, 2-piperazinyl and the like.

[0177] The heterocycloalkyl moieties or groups as defined above may be further substituted.

[0178] According to the present invention, the term "heteroaryl" by itself or as part of another substituent refers to a monovalent heteroaromatic radical obtained by removing a hydrogen atom from a single atom of a heteroaromatic ring system. Typical heteroaryl or heteroaryl groups include, but are not limited to, groups derived from acridine, β-carboline, chroman, cinnoline, furan, imidazole, indazole, indole, indoline, indolizine, isobenzofuran, isochromium, isoindole, isoindolin, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, phenanthridine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazole, xanthene, etc.

[0179] The heteroaryl moiety may occur as a monocyclic compound having only a single ring, or as a polycyclic compound having two or more rings.

[0180] In a preferred variation, the term "heteroaryl" includes three- to ten-membered monocyclic heteroaryl or nine- to twelve-membered polycyclic heteroaryl. In other still more preferred variations, the heteroaryl moiety includes a five-, six- or seven-membered monocyclic heteroaryl moiety or a nine- to twelve-membered bicyclic heteroaryl moiety.

[0181] Preferably, the term "heteroaryl" includes three- to seven-membered monocyclic heteroaryl groups including one, two, three or four heteroatoms selected from the group consisting of O, N and S. One or more heteroatoms may occupy any position in the heteroaryl ring.

[0182] In preferred embodiments according to the present invention, the heteroaryl moiety or group includes 3 to 20 ring atoms. In even more preferred variants, the heteroaryl moiety includes 6 to 15 ring atoms. In the most preferred embodiment, the heteroaryl group includes 6 to 10 ring atoms. According to the present invention, most preferred is a monocyclic C3 to C7 heteroaryl group.

[0183] Particularly preferred heteroaryl moieties or groups include, but are not limited to, groups derived from furan, thiophene, pyrrole, benzothiophene, benzofuran, benzimidazole, indole, pyridine, pyrazole, quinoline, imidazole, oxazole, isoxazole and pyrazine.

[0184] Five-membered aromatic heteroaryl radicals which contain, in addition to carbon atoms, one, two or three nitrogen atoms or one or two nitrogen atoms and one sulfur or oxygen atom as ring atoms include 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-imidazolyl, 4-imidazolyl and 1,3,4-triazol-2-yl.

[0185] Five-membered aromatic heteroaryl groups containing one, two, three or four nitrogen atoms as ring atoms include 1-, 2- or 3-pyrrolyl, 1-, 3- or 4-pyrazolyl, 1-, 2- or 4-imidazolyl, 1,2,3-[1H]-triazol-1-yl, 1,2,3-[2H]-triazol-2-yl, 1,2,3-[1H]-triazol-4-yl, 1,2,3-[1H]-triazol-5-yl, 1,2,3-[2H]-triazol-6-yl, 1,2,3-[1H]-triazol-7-yl, 1,2,3-[1H]-triazol-8-yl, 1,2,3-[1H]-triazol-9-yl, 1,2,3-[1H]-triazol-10-yl, 1,2,3-[1H]-triazol-20-yl, 1,2,3-[1H]-triazol-40-yl, 1,2,3-[1H]-triazol-50-yl, 1,2,3-[1H]-triazol-60-yl, 1,2,3-[1H]-triazol-70-yl, 1,2,3-[1H]-triazol-80-yl, 1,2,3-[1H]-triazol-90-yl, 1,2,3-[1H]-triazol-100-yl, 1,2,3-[1H]-triazol-20-yl, 1,2,3-[1H]-triazol-40-yl, 1,2,3-[1H]-triazol-50-yl, 1,2,3-[1H]-triazol- ]-triazol-4-yl, 1,2,4-[1H]-triazol-1-yl, 1,2,4-[1H]-triazol-3-yl, 1,2,4-[1H]-triazol-5-yl, 1,2,4-[4H]-triazol-4-yl, 1,2,4-[4H]-triazol-3-yl, [1H]-tetrazole-1-yl, [1H]-tetrazole-5-yl, [2H]-tetrazole-2-yl, [2H]-tetrazole-5-yl, and the like.

[0186] Five-membered aromatic heteroaryl groups comprising as ring atoms a heteroatom selected from oxygen or sulfur and optionally one, two or three nitrogen atoms include 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 3- or 4-isoxazolyl, 3- or 4-isothiazolyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, 1,2,4-thiadiazol-3-yl, 1,2,4-thiadiazol-5-yl, 1,3,4-thiadiazol-2-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl and 1,3,4-oxadiazol-2-yl.

[0187] Six-membered heteroaryl groups contain, in addition to carbon atoms, one or two or one, two or three nitrogen atoms as ring atoms and include, for example, 2-pyridyl, 3-pyridyl, 4-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, 1,2,4-triazin-3-yl; 1,2,4-triazin-5-yl, 1,2,4-triazin-6-yl and 1,3,5-triazin-2-yl.

[0188] Heteroaryl moieties or groups as defined above may be further substituted.

[0189] The term "C-spiro" in the context of the present application means a compound having at least two molecular rings with only one common atom. The simplest spiro compound is bicyclic (only two rings) or has a bicyclic part as a part of a larger ring system, and in either case, the two rings are connected by a single common atom defined. A common atom that connects the participating rings distinguishes spiro compounds from other following bicyclic structures: isolated ring compounds without connecting atoms such as biphenyl, condensed ring compounds with two rings connected by two adjacent atoms such as decalin, and bridged ring compounds with two rings connected by two non-adjacent atoms such as norbornane. Spiro compounds can be all-carbon rings (all carbon) or heterocycles (with one or more non-carbon atoms, such as N, O and S). The common atom connecting two (or sometimes three) rings is referred to as spiro atoms. Preferably, spiro atoms are carbon atoms. More preferably, C-spiro compounds mean compounds of all-carbon rings (all carbon).

[0190] In the context of the present invention, the term "substituted" means that one or more hydrogen atoms of the indicated radical / group are independently replaced by the same or different substituents. In addition, the term "substituted" specifically provides one or more, i.e., two, three, four, five, six or more substituents commonly used in the art. However, it is well known that substituents should be selected so that these substituents do not adversely affect the useful properties of the compound or its function.

[0191] Suitable substituents in the context of the present invention preferably include halogen, perfluoroalkyl groups, perfluoroalkoxy groups, alkyl groups, alkenyl groups, alkynyl groups, hydroxyl groups, oxo groups, mercapto groups, alkylthio groups, alkoxy groups, aryl groups or heteroaryl groups, aryloxy groups or heteroaryloxy groups, arylalkyl groups or heteroarylalkyl groups, arylalkoxy groups or heteroarylalkoxy groups, amino groups, alkyl groups and dialkylamino groups, carbamoyl groups, alkylcarbonyl groups, carboxyl groups, alkoxycarbonyl groups, alkylaminocarbonyl groups, dialkylaminocarbonyl groups, arylcarbonyl groups, aryloxycarbonyl groups, alkylsulfonyl groups, arylsulfonyl groups, cycloalkyl groups, cyano groups, C1 to C6 alkylthio groups, arylthio groups, nitro groups, keto groups, acyl groups, boronic acid groups or boryl groups, phosphate groups or phosphonyl groups, sulfonamido groups, sulfonyl groups, sulfinyl groups and combinations thereof.

[0192] Substituents or substituent groups that can be used to replace saturated carbon atoms in the indicated groups more preferably include, but are not limited to, halogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, -NH 2 , amino (primary, secondary or tertiary), nitro, thiol, thioether, imine, cyano, amido, phosphono, phosphine, carboxyl, thiocarbonyl, sulfonyl, sulfonamide, ketone, aldehyde, ester, acetyl, acetoxy, carbamoyl, oxygen (O); haloalkyl (e.g., trifluoromethyl); aminoacyl and aminoalkyl, carbocyclic cycloalkyl (which can be monocyclic or fused or non-fused polycyclic (e.g., cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl)), or heterocyclic alkyl (which can be monocyclic or fused or non-fused polycyclic (e.g., pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl or thiazinyl)), carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic aromatic (e.g., phenyl, naphthyl, pyrrolyl, indolyl, furanyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, pyrazolyl, pyridinyl, quinolyl, isoquinolyl, acridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, benzimidazolyl, benzothienyl or benzofuranyl), -CO 2 CH 3 、-CONH 2 、-OCH 2 CONH 2 ;-SO 2 NH 2 、-OCHF 2 , -CF 3 、-OCF 3 .

[0193] According to the invention, the substituents used to replace a particular group or groups may in turn be further substituted, typically by one or more groups selected from the same or different groups of the various groups indicated above and as defined in detail above. In the case of substituted combinations such as substituted arylalkyl, either the aryl or alkyl groups may be substituted, or both the aryl and alkyl groups may be substituted by one or more substituents.

[0194] In a preferred variant, Z in the general formula (V) is -O-R2' or amide'.

[0195] In another preferred variant, R1' in the general formula (V) is CH 2 .

[0196] In another preferred variant, R1' in the general formula (V) is C(alkyl) 2 .

[0197] In another preferred variant, R1' in the general formula (V) is O.

[0198] In another preferred variant, R1′ in the general formula (V) is S.

[0199] In another preferred variant, R1' in the general formula (V) is SO.

[0200] In another preferred variant, R1' in the general formula (V) is SO 2 .

[0201] In another preferred variant, R1' in the general formula (V) is NH.

[0202] In yet another preferred variant, R1' in general formula (V) is N(alkyl).

[0203] Most preferably, R1' in the general formula (V) is CH 2 or C(alkyl) 2 .

[0204] In a preferred variant, R2' in the general formula (V) is H.

[0205] In another preferred variant, R2' in the general formula (V) is methyl.

[0206] In another preferred variant, R2' in the general formula (V) is ethyl.

[0207] In another preferred variant, R2' in the general formula (V) is propyl.

[0208] In another preferred variant, R2' in the general formula (V) is isopropyl.

[0209] In another preferred variant, R2' in the general formula (V) is butyl.

[0210] In another preferred variant, R2' in the general formula (V) is isobutyl.

[0211] In another preferred variant, R2' in the general formula (V) is tert-butyl.

[0212] In another preferred variant, R2' in the general formula (V) is

[0213] In another preferred variant, R2' in the general formula (V) is

[0214] In a preferred variant, R2' in the general formula (V) is (2-ethyl-hexyl).

[0215] In yet another preferred variant, R2' in general formula (V) is phenyl.

[0216] Most preferably, R2' in general formula (V) is H or ethyl or isopropyl or 2-ethylhexyl or phenyl.

[0217] In a preferred variant, the amide in the general formula (V) is NH 2 .

[0218] In a further preferred variant, the amide' in the general formula (V) is NH(alkyl), wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0219] In another preferred variant, the amide in the general formula (V) is N(alkyl) 2 , wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0220] In another preferred variant, the amide' in formula (V) is -N(O-alkyl)(alkyl)(Weinreb amide), wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0221] In yet another preferred variation, the amide' in general formula (V) is -N(OH)(H)(hydroxamic acid).

[0222] Most preferably, the amide in formula (V) is NH 2 、N(Methyl) 2 or N(ethyl) 2 or -N(O-alkyl)(alkyl)(Weinreb amide), wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl or -N(OH)(H)(hydroxamic acid).

[0223] In a preferred variant, R3' in general formula (V) is H.

[0224] In another preferred variant, R3' in the general formula (V) is methyl.

[0225] In another preferred variant, R3' in the general formula (V) is ethyl.

[0226] In another preferred variant, R3' in the general formula (V) is -O-methyl.

[0227] In another preferred variant, R3' in the general formula (V) is -C(=O)-OH.

[0228] In another preferred variant, R3' in the general formula (V) is -C(=O)-CH 3 .

[0229] In another preferred variant, R3' in the general formula (V) is -C(=O)-C 3 H 7 .

[0230] In yet another preferred variant, R3' in general formula (V) is -C(=O)-O-methyl.

[0231] Most preferably, R3' in the general formula (V) is H or methyl or -O-methyl.

[0232] In a preferred variation according to the first aspect of the present invention, the mycosporin-like amino acid compound (b) of general formula (V) is an acid compound or an ester compound represented by general formula (VII):

[0233]

[0234] wherein R1′, R2′, R3′, R4′, R5′ and R6′ have the same meanings as defined herein for Formula (V).

[0235] In a preferred variant according to the first aspect of the present invention, the mycosporin-like amino acid compound (b) of general formula (V) is an acid compound represented by general formula (VII-acid)

[0236]

[0237] wherein R1′, R3′, R4′, R5′ and R6′ have the same meanings as defined herein for Formula (V).

[0238] The mycosporin-like amino acid compounds according to the general formula (VII-acid) are particularly light-stable and temperature-stable compounds and show stability in pH solutions or in different emulsion types and do not degrade.

[0239] In particular, the mycosporin-like amino acid compounds as defined herein have better pH stability over a wider pH range, compared to their respective ester compounds which undergo hydrolysis and are therefore unstable in alkaline solutions above pH 9.

[0240] In addition, the mycosporin-like amino acid compounds also have better solubility in water than their corresponding ester compounds. Due to their better solubility in water, the mycosporin-like amino acid compounds can be incorporated into the aqueous phase of the formulation at a higher concentration, resulting in an improved SPF performance boosting effect and resulting in improved UVA light protection in sunscreen products, cosmetic or pharmaceutical preparations or home care products.

[0241] In a preferred variant according to the first aspect of the present invention, the mycosporin-like amino acid compound (b) of general formula (V) is an ester compound represented by general formula (VII-ester):

[0242]

[0243] wherein R1′, R3′, R4′, R5′ and R6′ have the same meanings as defined herein for Formula (V).

[0244] Preferably, the alkyl residue in the general formula (VII-ester) is methyl or ethyl or propyl or isopropyl or butyl or isobutyl or tert-butyl. Most preferably, the alkyl residue in the general formula (VII-ester) is methyl. Such ester compounds are particularly stable.

[0245] In an alternative preferred variation according to the first aspect of the present invention, the mycosporin-like amino acid compound (b) of general formula (V) is an amide compound represented by general formula (VIII):

[0246]

[0247] wherein R1′, Amide′, R3′, R4′, R5′ and R6′ have the same meanings as defined herein for Formula (V).

[0248] In a more preferred variant according to the first aspect of the present invention, the mycosporin-like amino acid compound (b) of general formula (V) is an amide compound represented by general formula (VIII-amide):

[0249]

[0250] wherein R1′, R3′, R4′, R5′ and R6′ have the same meanings as defined herein for formula (V), and R11′ and R12′ are independently selected from the group consisting of H, OH and alkyl.

[0251] In a preferred variant according to the first aspect of the invention, in the general formula (VIII-amide), R11′ and / or R12′ is H.

[0252] In another preferred variant, R11′alkyl and R12′alkyl in the general formula (VIII-amide) are independently selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0253] Preferably, R11′ and / or R12′ in the general formula (VIII-amide) are each H or are each methyl.

[0254] In a still more preferred variation, the mycosporin-like amino acid compound (b) of formula (V) is a Weinreb amide compound represented by the formula (VIII-Weinreb amide)

[0255]

[0256] wherein R1′, R3′, R4′, R5′ and R6′ have the same meanings as defined herein for formula (V).

[0257] In a preferred variant, the alkyl residue in the general formula (VIII-Weinreb amide) is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl, more preferably, the alkyl residue is methyl.

[0258] Alternatively, in a still more preferred variant, the mycosporin-like amino acid compound (b) of general formula (V) is a hydroxamic acid compound represented by general formula (VIII-hydroxamic acid derivative)

[0259]

[0260] wherein R1′, R3′, R4′, R5′ and R6′ have the same meanings as defined herein for Formula (V).

[0261] Alternatively, in a further preferred variation, the mycosporin-like amino acid compound (b) of general formula (V) is an alkylated hydroxamic acid compound represented by general formula (VIII-alkylated hydroxamic acid derivative):

[0262]

[0263] wherein R1′, R3′, R4′, R5′ and R6′ have the same meanings as defined herein for Formula (V).

[0264] In a preferred variant, the alkyl residue in the general formula (VIII - alkylated hydroxamic acid derivative) is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl, more preferably, the alkyl group is methyl.

[0265] In a preferred alternative variant, the mycosporin-like amino acid compound (b) is represented by the general formula (A):

[0266]

[0267] wherein R1′, R3′, R4′, R5′ and R6′ have the same meanings as defined herein for Formula (V).

[0268] In the present invention, the same preferred variants as defined herein for the mycosporin-like amino acid compounds according to general formula (V) apply analogously to the mycosporin-like amino acid compounds according to general formula (VII) or (VIII) and their variants or general formula (A).

[0269] In another preferred variant, R1″ in the general formula (VI) is CH 2 .

[0270] In another preferred variant, R1″ in the general formula (VI) is C(alkyl) 2 .

[0271] In another preferred variant, R1″ in the general formula (VI) is O.

[0272] In another preferred variant, R1″ in the general formula (VI) is S.

[0273] In another preferred variant, R1″ in the general formula (VI) is SO.

[0274] In another preferred variant, R1" in the general formula (VI) is SO 2 .

[0275] In another preferred variant, R1″ in the general formula (VI) is NH.

[0276] In yet another preferred variant, R1″ in the general formula (VI) is N(alkyl).

[0277] Most preferably, R1" in the general formula (VI) is CH 2 or C(alkyl) 2 .

[0278] In a preferred variant, R2" in the general formula (VI) is -CH 2 -OH.

[0279] In another preferred variant, R2″ in the general formula (VI) is —C(═O)—OY.

[0280] In another preferred variant, R2" in the general formula (VI) is -C(=O)-amide".

[0281] Most preferably, R2" in the general formula (VI) is -C(=O)-OY or -C(=O)-amide".

[0282] In another preferred variant, X in the general formula (VI) is CH 2 .

[0283] In another preferred variant, X in the general formula (VI) is C═O.

[0284] In another preferred variant, X in the general formula (VI) is O.

[0285] In another preferred variant, X in the general formula (VI) is S.

[0286] In another preferred variant, X in the general formula (VI) is SO.

[0287] In another preferred variant, X in the general formula (VI) is SO 2 .

[0288] In another preferred variant, X in the general formula (VI) is NH.

[0289] In yet another preferred variation, X in formula (VI) is N(alkyl), wherein alkyl is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0290] Most preferably, X in the general formula (VI) is S, SO or SO 2 .

[0291] In a preferred variant, Y in the general formula (VI) is H.

[0292] In another preferred variant, Y in the general formula (VI) is methyl.

[0293] In another preferred variant, Y in the general formula (VI) is ethyl.

[0294] In another preferred variant, Y in the general formula (VI) is propyl.

[0295] In another preferred variant, Y in the general formula (VI) is isopropyl.

[0296] In another preferred variant, Y in the general formula (VI) is butyl.

[0297] In another preferred variant, Y in the general formula (VI) is isobutyl.

[0298] In another preferred variant, Y in the general formula (VI) is tert-butyl.

[0299] In another preferred variant, Y in the general formula (VI) is

[0300] In another preferred variant, Y in the general formula (VI) is

[0301] In a preferred variant, Y in the general formula (VI) is (2-ethyl-hexyl).

[0302] In yet another preferred variant, Y in the general formula (VI) is phenyl.

[0303] Most preferably, Y in the general formula (VI) is H or ethyl or isopropyl or 2-ethylhexyl or phenyl.

[0304] In a preferred variant, the amide in the general formula (VI) is NH 2 .

[0305] In a further preferred variant, the "amide" in the general formula (VI) is NH(alkyl), wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0306] In another preferred variant, the "amide" in the general formula (VI) is N(alkyl) 2 , wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0307] In another preferred variant, the "amide" in the general formula (VI) is -N(O-alkyl)(alkyl)(Weinreb amide), wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0308] In yet another preferred variant, the "amide" in general formula (V) is -N(OH)(H)(hydroxamic acid).

[0309] Most preferably, the amide in formula (V) is NH 2 、N(Methyl) 2 or N(ethyl)2 or -N(O-alkyl)(alkyl)(Weinreb amide), wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl or -N(OH)(H)(hydroxamic acid).

[0310] In a more preferred variant according to the first aspect of the present invention, the mycosporin-like amino acid compound (b) is an alcohol compound represented by the general formula (IX-alcohol):

[0311]

[0312] wherein R1", X, R4", R5" and R6" have the same meanings as defined herein for Formula (VI).

[0313] Alternatively, in a more preferred variant according to the first aspect of the present invention, the mycosporin-like amino acid compound (b) of the general formula (VI) is an acid compound represented by the general formula (IX-acid):

[0314]

[0315]

[0316] wherein R1", X, R4", R5" and R6" have the same meanings as defined herein for Formula (VI).

[0317] Alternatively, in a more preferred variant according to the first aspect of the present invention, the mycosporin-like amino acid compound (b) of the general formula (VI) is an ester compound represented by the general formula (VII-ester):

[0318]

[0319] wherein R1", X, R4", R5" and R6" have the same meanings as defined herein for Formula (VI).

[0320] Preferably, the alkyl residue in the general formula (VII-ester) is methyl or ethyl or propyl or isobutyl or butyl or isobutyl or tert-butyl, more preferably, the alkyl residue is methyl.

[0321] In an alternative more preferred variation according to the first aspect of the present invention, the mycosporin-like amino acid compound (b) of the general formula (VI) is an amide compound represented by the general formula (X):

[0322]

[0323] wherein R1", amide", X, R4, R5" and R6" have the same meanings as defined herein for formula (VI).

[0324] In a more preferred alternative variant according to the first aspect of the present invention, the mycosporin-like amino acid compound (b) of the general formula (VI) is an amide compound represented by the general formula (X-amide),

[0325]

[0326] wherein R1", X, R4", R5" and R6" have the same meanings as defined herein for formula (VI), and R11" and R12" are independently selected from the group consisting of H, OH and alkyl.

[0327] In a preferred variant according to the first aspect of the present invention, in the general formula (X-amide), R11″ and / or R12″ is H.

[0328] Preferably, R11"alkyl and R12"alkyl in the general formula (X-amide) are methyl or ethyl or propyl or isopropyl or butyl or isobutyl or tert-butyl.

[0329] Preferably, R11" and / or R12" in the general formula (X-amide) are each H or are each methyl.

[0330] In a still more preferred variation, the mycosporin-like amino acid compound (b) of formula (VI) is a Weinreb amide compound represented by the formula (X-Weinreb amide):

[0331]

[0332] wherein R1", X, R4", R5" and R6" have the same meanings as defined herein for Formula (VI).

[0333] In a preferred variant, the alkyl residue in the general formula (X-Weinreb amide) is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl, more preferably, the alkyl residue is methyl.

[0334] Alternatively, in a still more preferred variation, the mycosporin-like amino acid compound (b) of general formula (VI) is a hydroxamic acid compound represented by the general formula (X-hydroxamic acid derivative):

[0335]

[0336] wherein R1", X, R4", R5" and R6" have the same meanings as defined above for the general formula (VI).

[0337] Alternatively, in still another preferred variation, the mycosporin-like amino acid compound (b) of general formula (VI) is an alkylated hydroxamic acid compound represented by general formula (VIII-alkylated hydroxamic acid derivative)

[0338]

[0339] wherein R1", X, R4", R5" and R6" have the same meanings as defined herein for formula (VI).

[0340] In a preferred variant, the alkyl residue in the general formula (X-alkylated hydroxamic acid derivative) is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl, more preferably, the alkyl residue is methyl.

[0341] In the present invention, the same preferred variants as defined herein for the mycosporin-like amino acid compounds according to general formula (VI) analogously apply to the mycosporin-like amino acid compounds according to general formula (IX) or (X) and variants thereof.

[0342] In the following and throughout the specification, the term "according to the general formula YZ and variations thereof" includes any subformula (e) of said general formula as disclosed herein. Thus, variants of the general formulas (V) and (VI) as defined herein include formulas (VII), (VIII), (IX) and (X) as defined herein. Variants of the general formulas (VII) and (VIII) as defined herein include subformulas (VII-acid), (VII-ester), (VIII-amide), (VIII-Weinreb amide), (VIII-hydroxamic acid derivative) and (VIII-alkylated hydroxamic acid derivative) as defined herein. Variants of the general formulas (IX) and (X) as defined herein include formulas (IX-acid), (IX-ester), (X-amide), (X-Weinreb amide), (X-hydroxamic acid derivative) and (X-alkylated hydroxamic acid derivative) as defined herein.

[0343] In another preferred variant, in the general formula (VI), (IX), (X) and their variants, X is selected from the group consisting of: CH 2 , unsubstituted or substituted CH(alkyl), unsubstituted or substituted C(alkyl) 2 , unsubstituted or substituted CH(alkenyl), unsubstituted or substituted CH(alkynyl), unsubstituted or substituted CH(alkoxy), unsubstituted or substituted CH(alkylthio), unsubstituted or substituted CH(cycloalkyl), unsubstituted or substituted CH(aryl), unsubstituted or substituted CH(heterocycloalkyl), unsubstituted or substituted CH(heteroaryl), -CR7"R8", C=O, S, SO, SO 2 , NH, unsubstituted or substituted N(alkyl), unsubstituted or substituted N(alkenyl), unsubstituted or substituted N(alkynyl), unsubstituted or substituted N(alkoxy), unsubstituted or substituted N(alkylthio), unsubstituted or substituted N(cycloalkyl), unsubstituted or substituted N(aryl), unsubstituted or substituted N(heterocycloalkyl), unsubstituted or substituted N(heteroaryl), and unsubstituted or substituted C-spiro.

[0344] In another preferred variant according to the first aspect of the present invention, the mycosporin-like amino acid compound is a compound according to general formula (V), wherein

[0345] -Z is -O-R2' or amide'; and / or

[0346] -R1' is selected from the group consisting of: CH 2 、C(alkyl) 2 , O, S, SO, SO 2 , NH and N(alkyl); and / or

[0347] -R2' is selected from the group consisting of: H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, (2-ethyl-hexyl) and phenyl; or

[0348] -amide' is selected from the group consisting of: NH 2 、NH(alkyl), N(alkyl) 2 , -N(O-alkyl)(alkyl)(Weinreb amide) and -N(OH)(H)(hydroxamic acid); and / or

[0349] -R3' is selected from the group consisting of: H, methyl, ethyl, -O-methyl, -C(=O)-OH, -C(=O)-CH 3 , -C(=O)-C 3 H 7 and -C(=O)-O-methyl; and / or

[0350] - the substituents R4', R5' and R6' have the same meanings as defined for formula (V);

[0351] - wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0352] In another preferred variant according to the first aspect of the present invention, the mycosporin-like amino acid compound is a compound according to general formula (VII) or (VIII), wherein

[0353] -R1' is selected from the group consisting of: CH 2 、C(alkyl) 2 , O, S, SO, SO 2 , NH and N(alkyl); and / or

[0354] -R2' is selected from the group consisting of: H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, (2-ethyl-hexyl) and phenyl; or

[0355] -amide' is selected from the group consisting of: NH 2 、NH(alkyl), N(alkyl)2 , -N(O-alkyl)(alkyl)(Weinreb amide) and -N(OH)(H)(hydroxamic acid); and / or

[0356] -R3' is selected from the group consisting of: H, methyl, ethyl, -O-methyl, -C(=O)-OH, -C(=O)-CH 3 , -C(=O)-C 3 H 7 and -C(=O)-O-methyl; and / or

[0357] - the substituents R4', R5' and R6' have the same meanings as defined for formula (V);

[0358] - wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0359] In another preferred variant according to the first aspect of the present invention, the mycosporin-like amino acid compound is a compound according to general formula (VI), wherein

[0360] -R1" is selected from the group consisting of: CH 2 、C(alkyl) 2 , O, S, SO, SO 2 , NH and N(alkyl); and / or

[0361] -R2" is selected from the group consisting of: -CH 2 -OH, -C(=O)-OY and -C(=O)-amide"; and / or

[0362] -X is selected from the group consisting of: CH 2 、C=O、O、S、SO、SO 2 , NH and N(alkyl); and / or

[0363] -Y is selected from the group consisting of H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, (2-ethyl-hexyl) and phenyl; and / or

[0364] -amide" is selected from the group consisting of: NH 2 、NH(alkyl), N(alkyl) 2 , -N(O-alkyl)(alkyl)(Weinreb amide) and -N(OH)(H)(hydroxamic acid); and / or

[0365] - the substituents R4", R5" and R6" have the same meanings as defined for formula (VI);

[0366] - wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0367] In another preferred variant according to the first aspect of the present invention, the mycosporin-like amino acid compound is a compound according to general formula (V), wherein

[0368] -Z is -O-R2' or amide'; and / or

[0369] -R1' is selected from CH 2 and C(methyl) 2 a group of persons; and / or

[0370] -R2' is selected from the group consisting of: H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, (2-ethyl-hexyl) and phenyl; or

[0371] -amide' is selected from the group consisting of: NH 2 、NH(alkyl), N(alkyl) 2 , -N(O-alkyl)(alkyl)(Weinreb amide) and -N(OH)(H)(hydroxamic acid); and / or

[0372] -R3' is selected from the group consisting of: H, methyl, ethyl, -O-methyl, -C(=O)-OH, -C(=O)-CH 3 , -C(=O)-C 3 H 7 and -C(=O)-O-methyl; and / or

[0373] - the substituents R4', R5' and R6' have the same meanings as defined for formula (V);

[0374] - wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0375] In another preferred variant according to the first aspect of the present invention, the mycosporin-like amino acid compound is a compound according to general formula (VII) or (VIII), wherein

[0376] -R1' is selected from CH 2 and C(methyl) 2 a group of persons; and / or

[0377] -R2' is selected from the group consisting of: H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, (2-ethyl-hexyl) and phenyl; or

[0378] -amide' is selected from the group consisting of: NH 2 、NH(alkyl), N(alkyl) 2 , -N(O-alkyl)(alkyl)(Weinreb amide) and -N(OH)(H)(hydroxamic acid); and / or

[0379] -R3' is selected from the group consisting of: H, methyl, ethyl, -O-methyl, -C(=O)-OH, -C(=O)-CH 3 , -C(=O)-C 3 H 7 and -C(=O)-O-methyl; and / or

[0380] - the substituents R4', R5' and R6' have the same meanings as defined for formula (V);

[0381] - wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0382] In another preferred variant according to the first aspect of the present invention, the mycosporin-like amino acid compound is a compound according to general formula (VI), wherein

[0383] -R1" is selected from CH 2 and C(methyl) 2 a group of persons; and / or

[0384] -R2" is selected from the group consisting of: -CH 2 -OH, -C(=O)-OY and -C(=O)-amide"; and / or

[0385] -X is selected from the group consisting of: CH 2 、C=O、O、S、SO、SO 2 , NH and N(alkyl); and / or

[0386] -Y is selected from the group consisting of H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, (2-ethyl-hexyl) and phenyl; and / or

[0387] -amide" is selected from the group consisting of: NH 2 、NH(alkyl), N(alkyl) 2 , -N(O-alkyl)(alkyl)(Weinreb amide) and -N(OH)(H)(hydroxamic acid); and / or

[0388] - the substituents R4", R5" and R6" have the same meanings as defined for formula (VI);

[0389] - wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0390] In a still more preferred variant according to the invention, the sunscreen product, cosmetic or pharmaceutical preparation or home care product comprises at least one mycosporin-like amino acid compound selected from the group consisting of the following compounds I-1 to I-128 according to the general formula (V) and II-1 to II-192 according to the general formula (VI):

[0391] Table 1:

[0392]

[0393]

[0394]

[0395]

[0396]

[0397]

[0398]

[0399]

[0400] or tautomers or stereoisomers or salts of the above compounds or any mixtures of the above compounds.

[0401] In the mycosporin-like amino acid compounds of Table 1, the benzene ring may be unsubstituted or substituted. The substituents R4', R5', R6', R4", R5", R6", amide', Y, amide" and alkyl have the same meanings as previously defined for the mycosporin-like amino acid compounds according to general formula (V) or (VI).

[0402] Particularly preferred are those mycosporin-like amino acid compounds wherein in the general formula (V), R1' is CH 2 or C(methyl) 2 , or wherein in the general formula (VI), R1" is CH 2 or C(methyl) 2 :

[0403] Table 2:

[0404]

[0405]

[0406]

[0407] or tautomers or stereoisomers or salts of the above compounds or any mixtures of the above compounds.

[0408] In the mycosporin-like amino acid compounds of Table 2, the benzene ring may be unsubstituted or substituted. The substituents R4', R5', R6', R4", R5", R6", amide', Y, amide" and alkyl have the same meanings as previously defined for the mycosporin-like amino acid compounds according to general formula (V) or (VI).

[0409] Preferably, in the mycosporin-like amino acid compounds according to the general formula (V) and the general formula (VI) specified in Table 1 and Table 2

[0410] -R2' is selected from the group consisting of: H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, (2-ethylhexyl) and phenyl;

[0411] -amide' is selected from the group consisting of: NH 2 、NH(alkyl), N(alkyl) 2 , -N(O-alkyl)(alkyl)(Weinreb amide), and -N(OH)(H)(hydroxamic acid);

[0412] -Y is selected from the group consisting of H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, (2-ethylhexyl) and phenyl;

[0413] -amide" is selected from the group consisting of: NH 2 、NH(alkyl), N(alkyl) 2 , -N(O-alkyl)(alkyl)(Weinreb amide), and -N(OH)(H)(hydroxamic acid); and

[0414] - Alkyl is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0415] In the most preferred variant according to the first aspect of the present invention, the mycosporin amino acid compound is a compound according to the general formula (V) and its variants or a compound according to the formula (VI) and its variants, wherein R1' or R1" is CH 2 This mycosporin-like amino acid compound has particularly good water solubility.

[0416] In yet another preferred variant according to the first aspect of the present invention, the mycosporin amino acid compound is a compound according to the general formula (VI), (IX), (X) and their variants, wherein X is selected from S, SO and SO 2 The group composed of.

[0417] Such mycosporin-like amino acid compounds alter the UV absorption curve of sunscreen products or cosmetic or pharmaceutical preparations and broaden the UV absorption spectrum of the formulation across the entire UV radiation spectrum.

[0418] In still more preferred variants according to the first aspect of the invention, the mycosporin amino acid compound is a compound according to general formula (VI), (IX), (X) and variants thereof, wherein X is S. However, the S atom in said compound is susceptible to oxidation.

[0419] In a more preferred variant according to the first aspect of the present invention, the mycosporin amino acid compound is a compound according to formula (VI), (IX), (X) and their variants, wherein X is SO or SO 2 Such mycosporin-like amino acid compounds are particularly stable due to their oxidation state.

[0420] In yet another preferred variant according to the invention, in the general formulae (V) to (X) and their variants, n is 1.

[0421] In still more preferred variants according to the first aspect of the present invention, the mycosporin-like amino acid compound is a compound according to general formula (V), wherein

[0422] -Z is -O-R2' or amide'; and / or

[0423] -R1' is CH 2 or C(methyl) 2 ; and / or

[0424] - R2' is H or ethyl or isopropyl or 2-ethylhexyl or phenyl; or

[0425] -Amide' is NH 2 or N(methyl) 2 or N(ethyl) 2 or -N(O-alkyl)(alkyl)(Weinreb amide) or -N(OH)(H)(hydroxamic acid); and / or

[0426] -R3' is H or -O-methyl or -C(=O)-OH or -C(=O)-CH 3 or -C(=O)-O-methyl; and / or

[0427] - the substituents R4', R5' and R6' have the same meanings as defined for formula (V);

[0428] - wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0429] In a more preferred variant according to the first aspect of the present invention, the mycosporin-like amino acid compound is a compound according to general formula (VII) or (VIII), wherein

[0430] -R1' is CH 2 or C(methyl) 2 ; and / or

[0431] - R2' is H or ethyl or isopropyl or 2-ethylhexyl or phenyl; or

[0432] -Amide' is NH 2 or N(methyl) 2 or N(ethyl) 2 or -N(O-alkyl)(alkyl)(Weinreb amide) or -N(OH)(H)(hydroxamic acid); and / or

[0433] -R3' is H or -O-methyl or -C(=O)-OH or -C(=O)-CH 3 or -C(=O)-O-methyl; and / or

[0434] - the substituents R4', R5' and R6' have the same meanings as defined for formula (V);

[0435] - wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

[0436] In a more preferred variant according to the first aspect of the present invention, the mycosporin-like amino acid compound is a compound according to general formula (VI), wherein

[0437] -R1" is CH 2 or C(methyl) 2 ; and / or

[0438] -R2" is -C(=O)-OY or -C(=O)-amide"; and / or

[0439] -X is S, SO or SO 2 ; and / or

[0440] -Y is H or ethyl or isopropyl or 2-ethylhexyl or phenyl; or

[0441] -amide" is NH 2or N(methyl) 2 or N(ethyl) 2 or -N(O-alkyl)(alkyl)(Weinreb amide) or -N(OH)(H)(hydroxamic acid); and / or

[0442] - the substituents R4", R5" and R6" have the same meanings as defined for formula (VI);

[0443] - wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and butyl.

[0444] The benzene ring in the mycosporin-like amino acid compounds according to general formulae (V) to (X) and their variants may be unsubstituted or substituted.

[0445] In a preferred embodiment, the benzene ring in the mycosporin-like amino acid compounds according to the general formulae (V) to (X) is unsubstituted, i.e., the substituents R4′, R5′ and R6′ on the benzene ring in the general formula (V) are H; or the substituents R4″, R5″ and R6″ on the benzene ring in the general formula (VI) are H.

[0446] In another preferred variant, the benzene ring in the mycosporin-like amino acid compounds according to general formulae (V) to (X) and their variants is substituted.

[0447] Most preferably, the benzene ring in the mycosporin-like amino acid compounds according to formula (V), (VII), (VIII) and their variants is unsubstituted, i.e., the substituents R4', R5' and R6' are each H. Alternatively, most preferably, the benzene ring in the mycosporin-like amino acid compounds according to formula (VI), (IX), (X) and their variants is unsubstituted, i.e., the substituents R4", R5" and R6" are each H. The compounds have improved water solubility.

[0448] Preferably, the benzene ring in the mycosporin-like amino acid compounds according to general formulae (V) to (X) and their variants is mono-, di- or tri-substituted.

[0449] In still more preferred variants according to the first aspect of the invention, the mycosporin-like amino acid compound is a compound according to the general formula (V), (VII) and (VIII) and variants thereof, wherein the substituents R4', R5' and R6', which may be the same or different, are independently selected from the group consisting of: H, OH, alkyl, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl or tert-butyl, alkoxy, preferably O-methyl, O-ethyl or O-butyl, -S(=O) 2 OH and sulfonyl.

[0450] Still more preferably, the substituents R4', R5' and R6', which may be the same or different, in the general formula (V), (VII), (VIII) and their variants are independently selected from H, OH, methyl, O-methyl, -S(=O) 2 A group consisting of OH and sulfonyl.

[0451] Alternatively, the mycosporin-like amino acid compound is a mycosporin-like amino acid compound according to the general formula (VI), (IX) and (X) and their variants, wherein the substituents R4", R5" and R6", which may be the same or different, are independently selected from the group consisting of: H, OH, alkyl, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, alkoxy, preferably O-methyl, O-ethyl or O-butyl, -S(=O) 2 OH and sulfonyl.

[0452] Still more preferably, the substituents R4", R5" and R6" in the general formula (VI), (IX), (X) and their variants, which may be the same or different, are independently selected from the group consisting of H, OH, methyl, O-methyl, -S(=O) 2 A group consisting of OH and sulfonyl.

[0453] In the general formulae (V) to (X) and their variants, the following substitution patterns are particularly preferred:

[0454] R4′=H and R5′=H and R6′=H; or

[0455] R4′=H and R5′=H and R6′=OH; or

[0456] R4'=H and R5'=H and R6'=methyl; or

[0457] R4′=H and R5′=H and R6′=O-methyl; or

[0458] R4′=H and R5′=H and R6′=-S(=O) 2 OH; or

[0459] R4'=H and R5'=H and R6'=sulfonyl; or

[0460] R4′=H and R5′=OH and R6′=H; or

[0461] R4′=H and R5′=OH and R6′=OH; or

[0462] R4'=H and R5'=OH and R6'=methyl; or

[0463] R4'=H and R5'=OH and R6'=O-methyl; or

[0464] R4'=H and R5'=OH and R6'=-S(=O) 2 OH; or

[0465] R4'=H and R5'=OH and R6'=sulfonyl; or

[0466] R4'=H and R5'=methyl and R6'=H; or

[0467] R4'=H and R5'=methyl and R6'=OH; or

[0468] R4'=H and R5'=methyl and R6'=methyl; or

[0469] R4'=H and R5'=methyl and R6'=O-methyl; or

[0470] R4'=H and R5'=methyl and R6'=-S(=O) 2 OH; or

[0471] R4'=H and R5'=methyl and R6'=sulfonyl; or

[0472] R4'=H and R5'=O-methyl and R6'=H; or

[0473] R4'=H and R5'=O-methyl and R6'=OH; or

[0474] R4'=H and R5'=O-methyl and R6'=methyl; or

[0475] R4'=H and R5'=O-methyl and R6'=O-methyl; or

[0476] R4'=H and R5'=O-methyl and R6'=-S(=O) 2 OH; or

[0477] R4'=H and R5'=O-methyl and R6'=sulfonyl; or

[0478] R4'=H and R5'=-S(=O) 2 OH and R6′=H; or

[0479] R4'=H and R5'=-S(=O) 2 OH and R6′=OH; or

[0480] R4'=H and R5'=-S(=O) 2 OH and R6'=methyl; or

[0481] R4'=H and R5'=-S(=O) 2 OH and R6′=O-methyl; or

[0482] R4'=H and R5'=-S(=O) 2 OH and R6'=-S(=O) 2 OH; or

[0483] R4'=H and R5'=-S(=O) 2 OH and R6' = sulfonyl; or

[0484] R4'=H and R5'=sulfonyl and R6'=H; or

[0485] R4'=H and R5'=sulfonyl and R6'=OH; or

[0486] R4'=H and R5'=sulfonyl and R6'=methyl; or

[0487] R4'=H and R5'=sulfonyl and R6'=O-methyl; or

[0488] R4'=H and R5'=sulfonyl and R6'=-S(=O) 2 OH; or

[0489] R4'=H and R5'=sulfonyl and R6'=sulfonyl; or

[0490] R4′=OH and R5′=H and R6′=H; or

[0491] R4′=OH and R5′=H and R6′=OH; or

[0492] R4'=OH and R5'=H and R6'=methyl; or

[0493] R4'=OH and R5'=H and R6'=O-methyl; or

[0494] R4'=OH and R5'=H and R6'=-S(=O) 2 OH; or

[0495] R4'=OH and R5'=H and R6'=sulfonyl; or

[0496] R4′=OH and R5′=OH and R6′=H; or

[0497] R4′=OH and R5′=OH and R6′=OH; or

[0498] R4'=OH and R5'=OH and R6'=methyl; or

[0499] R4′=OH and R5′=OH and R6′=O-methyl; or

[0500] R4'=OH and R5'=OH and R6'=-S(=O) 2 OH; or

[0501] R4'=OH and R5'=OH and R6'=sulfonyl; or

[0502] R4'=OH and R5'=methyl and R6'=H; or

[0503] R4'=OH and R5'=methyl and R6'=OH; or

[0504] R4'=OH and R5'=methyl and R6'=methyl; or

[0505] R4′=OH and R5′=methyl and R6′=O-methyl; or

[0506] R4'=OH and R5'=methyl and R6'=-S(=O) 2 OH; or

[0507] R4'=OH and R5'=methyl and R6'=sulfonyl; or

[0508] R4'=OH and R5'=O-methyl and R6'=H; or

[0509] R4'=OH and R5'=O-methyl and R6'=OH; or

[0510] R4'=OH and R5'=O-methyl and R6'=methyl; or

[0511] R4′=OH and R5′=O-methyl and R6′=O-methyl; or

[0512] R4'=OH and R5'=O-methyl and R6'=-S(=O) 2 OH; or

[0513] R4'=OH and R5'=O-methyl and R6'=sulfonyl; or

[0514] R4'=OH and R5'=-S(=O) 2 OH and R6′=H; or

[0515] R4'=OH and R5'=-S(=O) 2OH and R6′=OH; or

[0516] R4'=OH and R5'=-S(=O)2OH and R6'=methyl; or

[0517] R4'=OH and R5'=-S(=O)2OH and R6'=O-methyl; or

[0518] R4'=OH and R5'=-S(=O) 2 OH and R6'=-S(=O) 2 OH; or

[0519] R4'=OH and R5'=-S(=O) 2 OH and R6' = sulfonyl; or

[0520] R4'=OH and R5'=sulfonyl and R6'=H; or

[0521] R4'=OH and R5'=sulfonyl and R6'=OH; or

[0522] R4'=OH and R5'=sulfonyl and R6'=methyl; or

[0523] R4'=OH and R5'=sulfonyl and R6'=O-methyl; or

[0524] R4'=OH and R5'=sulfonyl and R6'=-S(=O) 2 OH; or

[0525] R4'=OH and R5'=sulfonyl and R6'=sulfonyl; or

[0526] R4'=methyl and R5'=H and R6'=H; or

[0527] R4'=methyl and R5'=H and R6'=OH; or

[0528] R4'=methyl and R5'=H and R6'=methyl; or

[0529] R4'=methyl and R5'=H and R6'=O-methyl; or

[0530] R4'=methyl and R5'=H and R6'=-S(=O) 2 OH; or

[0531] R4'=methyl and R5'=H and R6'=sulfonyl; or

[0532] R4'=methyl and R5'=OH and R6'=H; or

[0533] R4'=methyl and R5'=OH and R6'=OH; or

[0534] R4'=methyl and R5'=OH and R6'=methyl; or

[0535] R4'=methyl and R5'=OH and R6'=O-methyl; or

[0536] R4'=methyl and R5'=OH and R6'=-S(=O) 2 OH; or

[0537] R4'=methyl and R5'=OH and R6'=sulfonyl; or

[0538] R4'=methyl and R5'=methyl and R6'=H; or

[0539] R4'=methyl and R5'=methyl and R6'=OH; or

[0540] R4'=methyl and R5'=methyl and R6'=methyl; or

[0541] R4'=methyl and R5'=methyl and R6'=O-methyl; or

[0542] R4'=methyl and R5'=methyl and R6'=-S(=O) 2 OH; or

[0543] R4'=methyl and R5'=methyl and R6'=sulfonyl; or

[0544] R4'=methyl and R5'=O-methyl and R6'=H; or

[0545] R4'=methyl and R5'=O-methyl and R6'=OH; or

[0546] R4'=methyl and R5'=O-methyl and R6'=methyl; or

[0547] R4'=methyl and R5'=O-methyl and R6'=O-methyl; or

[0548] R4'=methyl and R5'=O-methyl and R6'=-S(=O) 2 OH; or

[0549] R4'=methyl and R5'=O-methyl and R6'=sulfonyl; or

[0550] R4'=methyl and R5'=-S(=O) 2OH and R6′=H; or

[0551] R4'=methyl and R5'=-S(=O) 2 OH and R6′=OH; or

[0552] R4'=methyl and R5'=-S(=O)2OH and R6'=methyl; or

[0553] R4'=methyl and R5'=-S(=O)2OH and R6'=O-methyl; or

[0554] R4'=methyl and R5'=-S(=O) 2 OH and R6'=-S(=O) 2 OH; or

[0555] R4'=methyl and R5'=-S(=O) 2 OH and R6' = sulfonyl; or

[0556] R4'=methyl and R5'=sulfonyl and R6'=H; or

[0557] R4'=methyl and R5'=sulfonyl and R6'=OH; or

[0558] R4'=methyl and R5'=sulfonyl and R6'=methyl; or

[0559] R4'=methyl and R5'=sulfonyl and R6'=O-methyl; or

[0560] R4'=methyl and R5'=sulfonyl and R6'=-S(=O) 2 OH; or

[0561] R4'=methyl and R5'=sulfonyl and R6'=sulfonyl; or

[0562] R4'=O-methyl and R5'=H and R6'=H; or

[0563] R4'=O-methyl and R5'=H and R6'=OH; or

[0564] R4'=O-methyl and R5'=H and R6'=methyl; or

[0565] R4'=O-methyl and R5'=H and R6'=O-methyl; or

[0566] R4'=O-methyl and R5'=H and R6'=-S(=O) 2 OH; or

[0567] R4'=O-methyl and R5'=H and R6'=sulfonyl; or

[0568] R4'=O-methyl and R5'=OH and R6'=H; or

[0569] R4'=O-methyl and R5'=OH and R6'=OH; or

[0570] R4'=O-methyl and R5'=OH and R6'=methyl; or

[0571] R4'=O-methyl and R5'=OH and R6'=O-methyl; or

[0572] R4'=O-methyl and R5'=OH and R6'=-S(=O) 2 OH; or

[0573] R4'=O-methyl and R5'=OH and R6'=sulfonyl; or

[0574] R4'=O-methyl and R5'=methyl and R6'=H; or

[0575] R4'=O-methyl and R5'=methyl and R6'=OH; or

[0576] R4'=O-methyl and R5'=methyl and R6'=methyl; or

[0577] R4'=O-methyl and R5'=methyl and R6'=O-methyl; or

[0578] R4'=O-methyl and R5'=methyl and R6'=-S(=O) 2 OH; or

[0579] R4'=O-methyl and R5'=methyl and R6'=sulfonyl; or

[0580] R4'=O-methyl and R5'=O-methyl and R6'=H; or

[0581] R4'=O-methyl and R5'=O-methyl and R6'=OH; or

[0582] R4'=O-methyl and R5'=O-methyl and R6'=methyl; or

[0583] R4'=O-methyl and R5'=O-methyl and R6'=O-methyl; or

[0584] R4'=O-methyl and R5'=O-methyl and R6'=-S(=O) 2 OH; or

[0585] R4'=O-methyl and R5'=O-methyl and R6'=sulfonyl; or

[0586] R4'=O-methyl and R5'=-S(=O) 2 OH and R6′=H; or

[0587] R4'=O-methyl and R5'=-S(=O) 2 OH and R6′=OH; or

[0588] R4'=O-methyl and R5'=-S(=O)2OH and R6'=methyl; or

[0589] R4'=O-methyl and R5'=-S(=O)2OH and R6'=O-methyl; or

[0590] R4'=O-methyl and R5'=-S(=O) 2 OH and R6'=-S(=O) 2 OH; or

[0591] R4'=O-methyl and R5'=-S(=O) 2 OH and R6' = sulfonyl; or

[0592] R4'=O-methyl and R5'=sulfonyl and R6'=H; or

[0593] R4'=O-methyl and R5'=sulfonyl and R6'=OH; or

[0594] R4'=O-methyl and R5'=sulfonyl and R6'=methyl; or

[0595] R4'=O-methyl and R5'=sulfonyl and R6'=O-methyl; or

[0596] R4'=O-methyl and R5'=sulfonyl and R6'=-S(=O) 2 OH; or

[0597] R4'=O-methyl and R5'=sulfonyl and R6'=sulfonyl; or

[0598] R4'=-S(=O) 2 OH and R5′═H and R6′═H; or

[0599] R4'=-S(=O) 2 OH and R5′═H and R6′═OH; or

[0600] R4'=-S(=O)2 OH and R5'=H and R6'=methyl; or

[0601] R4'=-S(=O) 2 OH and R5′═H and R6′═O-methyl; or

[0602] R4'=-S(=O) 2 OH and R5'=H and R6'=-S(=O) 2 OH; or

[0603] R4'=-S(=O) 2 OH and R5'=H and R6'=sulfonyl; or

[0604] R4'=-S(=O) 2 OH and R5′=OH and R6′=H; or

[0605] R4'=-S(=O) 2 OH and R5′=OH and R6′=OH; or

[0606] R4'=-S(=O) 2 OH and R5'=OH and R6'=methyl; or

[0607] R4'=-S(=O) 2 OH and R5′=OH and R6′=O-methyl; or

[0608] R4'=-S(=O) 2 OH and R5'=OH and R6'=-S(=O) 2 OH; or

[0609] R4'=-S(=O) 2 OH and R5'=OH and R6'=sulfonyl; or

[0610] R4'=-S(=O) 2 OH and R5'=methyl and R6'=H; or

[0611] R4'=-S(=O) 2 OH and R5'=methyl and R6'=OH; or

[0612] R4'=-S(=O) 2 OH and R5'=methyl and R6'=methyl; or

[0613] R4'=-S(=O) 2 OH and R5'=methyl and R6'=O-methyl; or

[0614] R4'=-S(=O) 2 OH and R5'=methyl and R6'=-S(=O) 2 OH; or

[0615] R4'=-S(=O) 2 OH and R5'=methyl and R6'=sulfonyl; or

[0616] R4'=-S(=O) 2 OH and R5′═O-methyl and R6′═H; or

[0617] R4'=-S(=O) 2 OH and R5′=O-methyl and R6′=OH; or

[0618] R4'=-S(=O) 2 OH and R5′=O-methyl and R6′=methyl; or

[0619] R4'=-S(=O) 2 OH and R5′=O-methyl and R6′=O-methyl; or

[0620] R4'=-S(=O) 2 OH and R5'=O-methyl and R6'=-S(=O) 2 OH; or

[0621] R4'=-S(=O) 2 OH and R5'=O-methyl and R6'=sulfonyl; or

[0622] R4'=-S(=O) 2 OH and R5'=-S(=O) 2 OH= and R6′=H; or

[0623] R4'=-S(=O) 2 OH and R5'=-S(=O) 2 OH and R6′=OH; or

[0624] R4'=-S(=O) 2 OH and R5'=-S(=O) 2 OH and R6'=methyl; or

[0625] R4'=-S(=O) 2 OH and R5'=-S(=O) 2 OH and R6′=O-methyl; or

[0626] R4'=-S(=O) 2OH and R5'=sulfonyl and R6'=H; or

[0627] R4'=-S(=O) 2 OH and R5'=sulfonyl and R6'=OH; or

[0628] R4'=-S(=O) 2 OH and R5'=sulfonyl and R6'=methyl; or

[0629] R4'=-S(=O) 2 OH and R5'=sulfonyl and R6'=O-methyl; or

[0630] R4'=sulfonyl and R5'=H and R6'=H; or

[0631] R4'=sulfonyl and R5'=H and R6'=OH; or

[0632] R4'=sulfonyl and R5'=H and R6'=methyl; or

[0633] R4'=sulfonyl and R5'=H and R6'=O-methyl; or

[0634] R4'=sulfonyl and R5'=H and R6'=-S(=O) 2 OH; or

[0635] R4'=sulfonyl and R5'=H and R6'=sulfonyl; or

[0636] R4'=sulfonyl and R5'=OH and R6'=H; or

[0637] R4'=sulfonyl and R5'=OH and R6'=OH; or

[0638] R4'=sulfonyl and R5'=OH and R6'=methyl; or

[0639] R4'=sulfonyl and R5'=OH and R6'=O-methyl; or

[0640] R4'=sulfonyl and R5'=OH and R6'=-S(=O) 2 OH; or

[0641] R4'=sulfonyl and R5'=OH and R6'=sulfonyl; or

[0642] R4'=sulfonyl and R5'=methyl and R6'=H; or

[0643] R4'=sulfonyl and R5'=methyl and R6'=OH; or

[0644] R4'=sulfonyl and R5'=methyl and R6'=methyl; or

[0645] R4'=sulfonyl and R5'=methyl and R6'=O-methyl; or

[0646] R4'=sulfonyl and R5'=methyl and R6'=-S(=O) 2 OH; or

[0647] R4'=sulfonyl and R5'=methyl and R6'=sulfonyl; or

[0648] R4'=sulfonyl and R5'=O-methyl and R6'=H; or

[0649] R4'=sulfonyl and R5'=O-methyl and R6'=OH; or

[0650] R4'=sulfonyl and R5'=O-methyl and R6'=methyl; or

[0651] R4'=sulfonyl and R5'=O-methyl and R6'=O-methyl; or

[0652] R4'=sulfonyl and R5'=O-methyl and R6'=-S(=O) 2 OH; or

[0653] R4'=sulfonyl and R5'=O-methyl and R6'=sulfonyl; or

[0654] R4'=sulfonyl and R5'=-S(=O) 2 OH and R6′=H; or

[0655] R4'=sulfonyl and R5'=-S(=O) 2 OH and R6′=OH; or

[0656] R4'=sulfonyl and R5'=-S(=O) 2 OH and R6'=methyl; or

[0657] R4'=sulfonyl and R5'=-S(=O) 2 OH and R6′=O-methyl; or

[0658] R4'=sulfonyl and R5'=sulfonyl and R6'=H; or

[0659] R4'=sulfonyl and R5'=sulfonyl and R6'=OH; or

[0660] R4'=sulfonyl and R5'=sulfonyl and R6'=methyl; or

[0661] R4'=sulfonyl and R5'=sulfonyl and R6'=O-methyl; or

[0662] R4"=H and R5"=H and R6"=H; or

[0663] R4"=H and R5"=H and R6"=OH; or

[0664] R4"=H and R5"=H and R6"=methyl; or

[0665] R4"=H and R5"=H and R6"=O-methyl; or

[0666] R4"=H and R5"=H and R6"=-S(=O) 2 OH; or

[0667] R4"=H and R5"=H and R6"=sulfonyl; or

[0668] R4"=H and R5"=OH and R6"=H; or

[0669] R4"=H and R5"=OH and R6"=OH; or

[0670] R4"=H and R5"=OH and R6"=methyl; or

[0671] R4"=H and R5"=OH and R6"=O-methyl; or

[0672] R4"=H and R5"=OH and R6"=-S(=O) 2 OH; or

[0673] R4"=H and R5"=OH and R6"=sulfonyl; or

[0674] R4"=H and R5"=methyl and R6"=H; or

[0675] R4"=H and R5"=methyl and R6"=OH; or

[0676] R4"=H and R5"=methyl and R6"=methyl; or

[0677] R4" = H and R5" = methyl and R6" = O-methyl; or

[0678] R4"=H and R5"=methyl and R6"=-S(=O) 2 OH; or

[0679] R4" = H and R5" = methyl and R6" = sulfonyl; or

[0680] R4"=H and R5"=O-methyl and R6"=H; or

[0681] R4"=H and R5"=O-methyl and R6"=OH; or

[0682] R4" = H and R5" = O-methyl and R6" = methyl; or

[0683] R4"=H and R5"=O-methyl and R6"=O-methyl; or

[0684] R4"=H and R5"=O-methyl and R6"=-S(=O) 2 OH; or

[0685] R4" = H and R5" = O-methyl and R6" = sulfonyl; or

[0686] R4"=H and R5"=-S(=O) 2 OH and R6″=H; or

[0687] R4"=H and R5"=-S(=O) 2 OH and R6″=OH; or

[0688] R4"=H and R5"=-S(=O) 2 OH and R6″=methyl; or

[0689] R4"=H and R5"=-S(=O) 2 OH and R6″=O-methyl; or

[0690] R4"=H and R5"=-S(=O) 2 OH and R6"=-S(=O) 2 OH; or

[0691] R4"=H and R5"=-S(=O) 2 OH and R6″=sulfonyl; or

[0692] R4"=H and R5"=sulfonyl and R6"=H; or

[0693] R4"=H and R5"=sulfonyl and R6"=OH; or

[0694] R4" = H and R5" = sulfonyl and R6" = methyl; or

[0695] R4" = H and R5" = sulfonyl and R6" = O-methyl; or

[0696] R4"=H and R5"=sulfonyl and R6"=-S(=O) 2 OH; or

[0697] R4"=H and R5"=sulfonyl and R6"=sulfonyl; or

[0698] R4"=OH and R5"=H and R6"=H; or

[0699] R4"=OH and R5"=H and R6"=OH; or

[0700] R4" = OH and R5" = H and R6" = methyl; or

[0701] R4" = OH and R5" = H and R6" = O-methyl; or

[0702] R4"=OH and R5"=H and R6"=-S(=O) 2 OH; or

[0703] R4" = OH and R5" = H and R6" = sulfonyl; or

[0704] R4"=OH and R5"=OH and R6"=H; or

[0705] R4″=OH and R5″=OH and R6″=OH; or

[0706] R4"=OH and R5"=OH and R6"=methyl; or

[0707] R4"=OH and R5"=OH and R6"=O-methyl; or

[0708] R4"=OH and R5"=OH and R6"=-S(=O) 2 OH; or

[0709] R4"=OH and R5"=OH and R6"=sulfonyl; or

[0710] R4"=OH and R5"=methyl and R6"=H; or

[0711] R4"=OH and R5"=methyl and R6"=OH; or

[0712] R4" = OH and R5" = methyl and R6" = methyl; or

[0713] R4″=OH and R5″=methyl and R6″=O-methyl; or

[0714] R4"=OH and R5"=methyl and R6"=-S(=O) 2 OH; or

[0715] R4" = OH and R5" = methyl and R6" = sulfonyl; or

[0716] R4"=OH and R5"=O-methyl and R6"=H; or

[0717] R4"=OH and R5"=O-methyl and R6"=OH; or

[0718] R4″=OH and R5″=O-methyl and R6″=methyl; or

[0719] R4″=OH and R5″=O-methyl and R6″=O-methyl; or

[0720] R4"=OH and R5"=O-methyl and R6"=-S(=O) 2 OH; or

[0721] R4" = OH and R5" = O-methyl and R6" = sulfonyl; or

[0722] R4"=OH and R5"=-S(=O) 2 OH and R6″=H; or

[0723] R4"=OH and R5"=-S(=O) 2 OH and R6″=OH; or

[0724] R4"=OH and R5"=-S(=O) 2 OH and R6″=methyl; or

[0725] R4"=OH and R5"=-S(=O) 2 OH and R6″=O-methyl; or

[0726] R4"=OH and R5"=-S(=O) 2 OH and R6"=-S(=O) 2 OH; or

[0727] R4"=OH and R5"=-S(=O) 2 OH and R6″=sulfonyl; or

[0728] R4"=OH and R5"=sulfonyl and R6"=H; or

[0729] R4"=OH and R5"=sulfonyl and R6"=OH; or

[0730] R4" = OH and R5" = sulfonyl and R6" = methyl; or

[0731] R4" = OH and R5" = sulfonyl and R6" = O-methyl; or

[0732] R4"=OH and R5"=sulfonyl and R6"=-S(=O) 2 OH; or

[0733] R4"=OH and R5"=sulfonyl and R6"=sulfonyl; or

[0734] R4"=methyl and R5"=H and R6"=H; or

[0735] R4" = methyl and R5" = H and R6" = OH; or

[0736] R4" = methyl and R5" = H and R6" = methyl; or

[0737] R4" = methyl and R5" = H and R6" = O-methyl; or

[0738] R4"=methyl and R5"=H and R6"=-S(=O) 2 OH; or

[0739] R4" = methyl and R5" = H and R6" = sulfonyl; or

[0740] R4" = methyl and R5" = OH and R6" = H; or

[0741] R4"=methyl and R5"=OH and R6"=OH; or

[0742] R4" = methyl and R5" = OH and R6" = methyl; or

[0743] R4" = methyl and R5" = OH and R6" = O-methyl; or

[0744] R4"=methyl and R5"=OH and R6"=-S(=O) 2 OH; or

[0745] R4" = methyl and R5" = OH and R6" = sulfonyl; or

[0746] R4" = methyl and R5" = methyl and R6" = H; or

[0747] R4" = methyl and R5" = methyl and R6" = OH; or

[0748] R4" = methyl and R5" = methyl and R6" = methyl; or

[0749] R4" = methyl and R5" = methyl and R6" = O-methyl; or

[0750] R4"=methyl and R5"=methyl and R6"=-S(=O) 2 OH; or

[0751] R4" = methyl and R5" = methyl and R6" = sulfonyl; or

[0752] R4" = methyl and R5" = O-methyl and R6" = H; or

[0753] R4" = methyl and R5" = O-methyl and R6" = OH; or

[0754] R4" = methyl and R5" = O-methyl and R6" = methyl; or

[0755] R4" = methyl and R5" = O-methyl and R6" = O-methyl; or

[0756] R4"=methyl and R5"=O-methyl and R6"=-S(=O) 2 OH; or

[0757] R4" = methyl and R5" = O-methyl and R6" = sulfonyl; or

[0758] R4"=methyl and R5"=-S(=O) 2 OH and R6″=H; or

[0759] R4"=methyl and R5"=-S(=O) 2 OH and R6″=OH; or

[0760] R4"=methyl and R5"=-S(=O) 2 OH and R6″=methyl; or

[0761] R4"=methyl and R5"=-S(=O) 2 OH and R6″=O-methyl; or

[0762] R4"=methyl and R5"=-S(=O) 2 OH and R6"=-S(=O) 2 OH; or

[0763] R4"=methyl and R5"=-S(=O) 2 OH and R6″=sulfonyl; or

[0764] R4" = methyl and R5" = sulfonyl and R6" = H; or

[0765] R4" = methyl and R5" = sulfonyl and R6" = OH; or

[0766] R4" = methyl and R5" = sulfonyl and R6" = methyl; or

[0767] R4" = methyl and R5" = sulfonyl and R6" = O-methyl; or

[0768] R4" = methyl and R5" = sulfonyl and R6" = -S(=O) 2 OH; or

[0769] R4" = methyl and R5" = sulfonyl and R6" = sulfonyl; or

[0770] R4"=O-methyl and R5"=H and R6"=H; or

[0771] R4" = O-methyl and R5" = H and R6" = OH; or

[0772] R4" = O-methyl and R5" = H and R6" = methyl; or

[0773] R4" = O-methyl and R5" = H and R6" = O-methyl; or

[0774] R4"=O-methyl and R5"=H and R6"=-S(=O) 2 OH; or

[0775] R4" = O-methyl and R5" = H and R6" = sulfonyl; or

[0776] R4" = O-methyl and R5" = OH and R6" = H; or

[0777] R4"=O-methyl and R5"=OH and R6"=OH; or

[0778] R4" = O-methyl and R5" = OH and R6" = methyl; or

[0779] R4" = O-methyl and R5" = OH and R6" = O-methyl; or

[0780] R4"=O-methyl and R5"=OH and R6"=-S(=O) 2 OH; or

[0781] R4" = O-methyl and R5" = OH and R6" = sulfonyl; or

[0782] R4" = O-methyl and R5" = methyl and R6" = H; or

[0783] R4" = O-methyl and R5" = methyl and R6" = OH; or

[0784] R4" = O-methyl and R5" = methyl and R6" = methyl; or

[0785] R4" = O-methyl and R5" = methyl and R6" = O-methyl; or

[0786] R4"=O-methyl and R5"=methyl and R6"=-S(=O) 2 OH; or

[0787] R4" = O-methyl and R5" = methyl and R6" = sulfonyl; or

[0788] R4" = O-methyl and R5" = O-methyl and R6" = H; or

[0789] R4" = O-methyl and R5" = O-methyl and R6" = OH; or

[0790] R4" = O-methyl and R5" = O-methyl and R6" = methyl; or

[0791] R4" = O-methyl and R5" = O-methyl and R6" = O-methyl; or

[0792] R4"=O-methyl and R5"=O-methyl and R6"=-S(=O) 2 OH; or

[0793] R4" = O-methyl and R5" = O-methyl and R6" = sulfonyl; or

[0794] R4"=O-methyl and R5"=-S(=O) 2 OH and R6″=H; or

[0795] R4"=O-methyl and R5"=-S(=O) 2 OH and R6″=OH; or

[0796] R4"=O-methyl and R5"=-S(=O) 2 OH and R6″=methyl; or

[0797] R4"=O-methyl and R5"=-S(=O) 2 OH and R6″=O-methyl; or

[0798] R4"=O-methyl and R5"=-S(=O) 2 OH and R6"=-S(=O) 2 OH; or

[0799] R4"=O-methyl and R5"=-S(=O) 2 OH and R6″=sulfonyl; or

[0800] R4" = O-methyl and R5" = sulfonyl and R6" = H; or

[0801] R4" = O-methyl and R5" = sulfonyl and R6" = OH; or

[0802] R4" = O-methyl and R5" = sulfonyl and R6" = methyl; or

[0803] R4" = O-methyl and R5" = sulfonyl and R6" = O-methyl; or

[0804] R4" = O-methyl and R5" = sulfonyl and R6" = -S(=O) 2 OH; or

[0805] R4" = O-methyl and R5" = sulfonyl and R6" = sulfonyl; or

[0806] R4"=-S(=O) 2 OH and R5″=H and R6″=H; or

[0807] R4"=-S(=O) 2 OH and R5″=H and R6″=OH; or

[0808] R4"=-S(=O) 2 OH and R5″=H and R6″=methyl; or

[0809] R4"=-S(=O) 2 OH and R5″=H and R6″=O-methyl; or

[0810] R4"=-S(=O) 2 OH and R5"=H and R6"=-S(=O) 2 OH; or

[0811] R4"=-S(=O) 2 OH and R5″=H and R6″=sulfonyl; or

[0812] R4"=-S(=O) 2 OH and R5″=OH and R6″=H; or

[0813] R4"=-S(=O) 2 OH and R5″=OH and R6″=OH; or

[0814] R4"=-S(=O) 2 OH and R5″=OH and R6″=methyl; or

[0815] R4"=-S(=O) 2 OH and R5″=OH and R6″=O-methyl; or

[0816] R4"=-S(=O) 2 OH and R5"=OH and R6"=-S(=O) 2 OH; or

[0817] R4"=-S(=O) 2 OH and R5″=OH and R6″=sulfonyl; or

[0818] R4"=-S(=O) 2 OH and R5″=methyl and R6″=H; or

[0819] R4"=-S(=O) 2 OH and R5″=methyl and R6″=OH; or

[0820] R4"=-S(=O) 2 OH and R5″=methyl and R6″=methyl; or

[0821] R4"=-S(=O) 2 OH and R5″=methyl and R6″=O-methyl; or

[0822] R4"=-S(=O) 2 OH and R5"=methyl and R6"=-S(=O) 2 OH; or

[0823] R4"=-S(=O) 2 OH and R5″=methyl and R6″=sulfonyl; or

[0824] R4"=-S(=O) 2 OH and R5″=O-methyl and R6″=H; or

[0825] R4"=-S(=O) 2OH and R5″=O-methyl and R6″=OH; or

[0826] R4"=-S(=O) 2 OH and R5″=O-methyl and R6″=methyl; or

[0827] R4"=-S(=O) 2 OH and R5″=O-methyl and R6″=O-methyl; or

[0828] R4"=-S(=O) 2 OH and R5"=O-methyl and R6"=-S(=O) 2 OH; or

[0829] R4"=-S(=O) 2 OH and R5″=O-methyl and R6″=sulfonyl; or

[0830] R4"=-S(=O) 2 OH and R5"=-S(=O) 2 OH=and R6″=H; or

[0831] R4"=-S(=O) 2 OH and R5"=-S(=O) 2 OH and R6″=OH; or

[0832] R4"=-S(=O) 2 OH and R5"=-S(=O) 2 OH and R6″=methyl; or

[0833] R4"=-S(=O) 2 OH and R5"=-S(=O) 2 OH and R6″=O-methyl; or

[0834] R4"=-S(=O) 2 OH and R5"=sulfonyl= and R6"=H; or

[0835] R4"=-S(=O) 2 OH and R5″=sulfonyl and R6″=OH; or

[0836] R4"=-S(=O) 2 OH and R5″=sulfonyl and R6″=methyl; or

[0837] R4"=-S(=O) 2 OH and R5″=sulfonyl and R6″=O-methyl; or

[0838] R4"=sulfonyl and R5"=H and R6"=H; or

[0839] R4"=sulfonyl and R5"=H and R6"=OH; or

[0840] R4" = sulfonyl and R5" = H and R6" = methyl; or

[0841] R4" = sulfonyl and R5" = H and R6" = O-methyl; or

[0842] R4"=sulfonyl and R5"=H and R6"=-S(=O) 2 OH; or

[0843] R4" = sulfonyl and R5" = H and R6" = sulfonyl; or

[0844] R4" = sulfonyl and R5" = OH and R6" = H; or

[0845] R4"=sulfonyl and R5"=OH and R6"=OH; or

[0846] R4" = sulfonyl and R5" = OH and R6" = methyl; or

[0847] R4" = sulfonyl and R5" = OH and R6" = O-methyl; or

[0848] R4"=sulfonyl and R5"=OH and R6"=-S(=O) 2 OH; or

[0849] R4" = sulfonyl and R5" = OH and R6" = sulfonyl; or

[0850] R4" = sulfonyl and R5" = methyl and R6" = H; or

[0851] R4" = sulfonyl and R5" = methyl and R6" = OH; or

[0852] R4" = sulfonyl and R5" = methyl and R6" = methyl; or

[0853] R4" = sulfonyl and R5" = methyl and R6" = O-methyl; or

[0854] R4" = sulfonyl and R5" = methyl and R6" = -S(=O) 2 OH; or

[0855] R4" = sulfonyl and R5" = methyl and R6" = sulfonyl; or

[0856] R4" = sulfonyl and R5" = O-methyl and R6" = H; or

[0857] R4" = sulfonyl and R5" = O-methyl and R6" = OH; or

[0858] R4" = sulfonyl and R5" = O-methyl and R6" = methyl; or

[0859] R4" = sulfonyl and R5" = O-methyl and R6" = O-methyl; or

[0860] R4" = sulfonyl and R5" = O-methyl and R6" = -S(=O) 2 OH; or

[0861] R4" = sulfonyl and R5" = O-methyl and R6" = sulfonyl; or

[0862] R4"=sulfonyl and R5"=-S(=O) 2 OH and R6″=H; or

[0863] R4"=sulfonyl and R5"=-S(=O) 2 OH and R6″=OH; or

[0864] R4"=sulfonyl and R5"=-S(=O) 2 OH and R6″=methyl; or

[0865] R4"=sulfonyl and R5"=-S(=O) 2 OH and R6″=O-methyl; or

[0866] R4" = sulfonyl and R5" = sulfonyl and R6" = H; or

[0867] R4"=sulfonyl and R5"=sulfonyl and R6"=OH; or

[0868] R4" = sulfonyl and R5" = sulfonyl and R6" = methyl; or

[0869] R4" = sulfonyl and R5" = sulfonyl and R6" = O-methyl.

[0870] In the general formulae (V), (VI), (VII), (VIII), (IX), (X) and their variants, the substituted benzene ring bonded to the imino functional group is preferably selected from the group consisting of:

[0871]

[0872] The dotted line indicates the binding site to the cyclohexene imine ring.

[0873] In still more preferred variants according to the first aspect of the invention, in the general formulae (V), (VII), (VIII) and their variants, the substituents R4', R5' and R6', which may be identical or different, are independently selected from the group consisting of: H; OH; alkyl, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl or tert-butyl; alkoxy, preferably O-methyl, O-ethyl or O-butyl; -S(=O) 2 OH; and sulfonyl; provided that if the substituted benzene ring is monosubstituted, the substituent is located in the ortho- or meta-position rather than in the para-position to the imino function of the general formulae (V), (VI) and (VIII).

[0874] In still more preferred variants according to the first aspect of the invention, in the general formula (VI), (IX), (X) and variants thereof, the substituents R4", R5" and R6", which may be identical or different, are independently selected from the group consisting of: H, OH, alkyl, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl or tert-butyl, alkoxy, preferably O-methyl, O-ethyl or O-butyl, -S(=O) 2 OH and sulfonyl; provided that if the substituted benzene ring is monosubstituted, the substituent is located in the ortho- or meta-position to the imino function of the general formula (VI), (IX), (X) and not in the para-position to the imino function.

[0875] According to the first aspect of the present invention, still more preferably, the sunscreen product, cosmetic or pharmaceutical preparation or home care product comprises at least one mycosporin-like amino acid compound selected from the group consisting of:

[0876] Table 3:

[0877]

[0878]

[0879]

[0880]

[0881]

[0882] or tautomers or stereoisomers or salts of the above compounds or any mixtures of the above compounds.

[0883] Among the mycosporin-like amino acid compounds specified above, compounds MAA-1 and MAA-13 are particularly preferred because they have significant SPF performance and UVA light protection improvement effects. Most preferred are acid compounds MAA-20, MAA-21, MAA-22, MAA-23, MAA-24, MAA-24, MAA-26, MAA-27, MAA-28, MAA-29, MAA-30, MAA-31 and amide compounds MAA-32, MAA-33, MAA-34, MAA-35, MAA-36, MAA-37, MAA-38 and MAA-39. The compounds having acid or amide functional groups are light-stable and temperature-stable, and show stability in pH solutions or in oil-in-water emulsions and do not degrade compared to the corresponding ester analogs. Particularly preferred are the acid compounds MAA-20, MAA-21, MAA-22, MAA-23, MAA-24, MAA-24, MAA-26, MAA-27, MAA-28, MAA-29, MAA-30 and MAA-31 due to their stability and their enhanced solubility in water.

[0884] In particular, the mycosporin-like amino acid compounds MAA-20, MAA-21, MAA-22, MAA-23, MAA-24, MAA-24, MAA-26, MAA-27, MAA-28, MAA-29, MAA-30 and MAA-31 have better stability over a wider pH range, compared to their respective ester compounds which hydrolyze and are therefore unstable in alkaline solutions / formulations above pH 9.

[0885] Due to their better solubility in water, the mycosporin-like amino acid compounds can be incorporated into the aqueous phase of emulsions at higher concentrations, resulting in an improved SPF performance boost and resulting in improved UVA photoprotection in sunscreen products, cosmetic or pharmaceutical preparations or home care products.

[0886] According to the first aspect of the present invention, still more preferably, the sunscreen product, cosmetic or pharmaceutical preparation or home care product comprises at least one mycosporin-like amino acid compound selected from the group consisting of:

[0887] MAA-A:

[0888]

[0889] MAA-B:

[0890] and

[0891] MAA-C:

[0892]

[0893] or its tautomer or stereoisomer or salt, or any mixture of the aforementioned compounds, wherein the alkyl group is preferably methyl or ethyl or propyl or isopropyl or butyl or isobutyl or tert-butyl, most preferably methyl.

[0894] The mycosporin-like amino acid compounds according to the invention and as defined herein are used as the sole substance or in a mixture with one, two or more different mycosporin-like amino acid compounds as defined herein.

[0895] Particularly preferred is a mixture of two mycosporin-like amino acid compounds according to the invention and defined herein. As demonstrated in the following examples, such a mixture shows particularly excellent SPF performance and UVA photoprotection boosting effect.

[0896] The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the first aspect of the present invention is further characterized in that it does not contain one or more of the following mycosporin-like amino acid compounds:

[0897] Compound 1:

[0898]

[0899] Compound 2:

[0900]

[0901] Compound 3:

[0902]

[0903] Compound 4:

[0904]

[0905] Compound 5:

[0906]

[0907] Compound 6:

[0908]

[0909] Compound 7:

[0910]

[0911] Compound 8:

[0912]

[0913] Compound 9:

[0914]

[0915] and

[0916] Compound 10:

[0917]

[0918] As described herein, various mycosporin amino acid compounds (b) contain one or more chiral centers and may therefore exist as racemic mixtures of enantiomers, mixtures of diastereomers, or enantiomerically or optically pure compounds. It should also be noted that the compounds of the present invention include E and Z isomers or mixtures thereof, as well as cis and trans isomers or mixtures thereof.

[0919] Therefore, the chemical structures of formulae (V) to (X) and variations thereof and compounds expressly disclosed herein include all possible enantiomers and diastereomers or stereoisomers.

[0920] In certain embodiments, the mycosporin-like amino acid compound (b) used according to the present invention is isolated as an E or Z isomer. In other embodiments, the compound of the present invention is a mixture of E and Z isomers.

[0921] Alternatively, stereoisomerically pure compounds are used in sunscreen products, cosmetics or pharmaceutical preparations or home care products according to the present invention. As used herein and unless otherwise indicated, the term "stereoisomerically pure" means that a stereoisomer of a compound is substantially free of other stereoisomers of the compound, or a geometric isomer (e.g., about one double bond) is substantially free of other geometric isomers. For example, the stereoisomerically pure compound of the present invention with a chiral center will be substantially free of the opposite enantiomer of the compound. The stereoisomerically pure compound of the present invention with two chiral centers or its composition will be substantially free of other diastereomers of the compound. The stereoisomerically pure compound of the present invention with a double bond capable of E / Z isomerization or its composition will be substantially free of an isomer in the E / Z isomer.

[0922] Typical stereomerically pure compounds include greater than about 80% of one stereoisomer or E / Z isomer by weight of the compound and less than about 20% of other stereoisomers or E / Z isomers by weight of the compound, more preferably greater than about 90% of one stereoisomer or E / Z isomer by weight of the compound and less than about 10% of other stereoisomers or E / Z isomers by weight of the compound, even more preferably greater than about 95% of one stereoisomer or E / Z isomer by weight of the compound and less than about 5% of other stereoisomers or E / Z isomers by weight of the compound, and most preferably greater than about 97% of one stereoisomer or E / Z isomer by weight of the compound and less than about 3% of other stereoisomers or E / Z isomers by weight of the compound.

[0923] As used herein and unless otherwise indicated, the term "stereoisomerically enriched" means a compound of the invention, or composition thereof, which contains greater than about 60% of one stereoisomer or E / Z isomer by weight of the compound of the invention, preferably greater than about 70% by weight, more preferably greater than about 80% of one stereoisomer or E / Z isomer by weight of the compound of the invention.

[0924] Therefore, it should be noted that, unless otherwise indicated, the term "mycosporine-like amino acid compound" according to general formula (V) to (X) and their variations, as well as the individual mycosporine-like amino acid compounds specified herein, are to be interpreted as covering racemic mixtures of enantiomers, mixtures of diastereomers or enantiomerically or optically pure compounds.

[0925] Due to their amino-cyclohexene-imine structures and their electron delocalization capabilities, the mycosporin-like amino acid compounds according to the general formulae (V) to (X) and their variants are in equilibrium with their tautomeric structures, in which the hydrogen of the amino group changes its position with the double bond of the cyclohexene ring.

[0926] Tautomerism is defined as each of two or more isomers of a compound that coexist in equilibrium and readily interchange by migration of atoms or groups within the molecule. Over time, a tautomerically pure or enriched system will readily interchange into an equilibrium state.

[0927] The tautomers of the general formula (V) are represented by the general formula (V-τ):

[0928]

[0929] The tautomers of the general formula (VI) are represented by the general formula (VI-τ):

[0930]

[0931] The above principles of tautomerism and redispersion explained based on the mycosporin-like amino acid compounds according to general formula (V) and (VI) are equally applicable to any of the mycosporin-like amino acid compounds defined by general formula (VII), (VIII), (IX), (X) and variations thereof, or to any individual mycosporin-like amino acid compound specified herein.

[0932] Therefore, hereinafter and throughout the specification, references to a mycosporin-like amino acid compound represented by any of the general formulae (V) to (X) and variations thereof, or to an individual mycosporin-like amino acid compound specified herein, also encompass tautomeric isomers thereof.

[0933] According to the first aspect of the present invention, the mycosporin-like amino acid compounds according to the general formula (V) to (X) and their variants as well as the individual mycosporin-like amino acid compounds specified herein are used in neutral (i.e. uncharged form) or in the form of their salts (such as acid addition salts with inorganic or organic acids).

[0934] The term "salt" in the context of the present invention refers to a salt of a compound having the desired effect or pharmacological activity of the parent compound. Such salts include:

[0935] (1) an acid addition salt formed with an inorganic acid or with an organic acid (preferably a monovalent or polyvalent carboxylic acid); or

[0936] (2) A salt formed when an acidic proton present in the starting compound is replaced by a metal ion (eg, an alkali metal ion, an alkaline earth metal ion, or an aluminum ion); or a salt formed when coordinated with an organic base.

[0937] Among these salts, acid addition salts are also particularly preferred because the mycosporin-like amino acid compounds according to general formulae (V) to (X) and their variants or the mycosporin-like amino acid compounds specified herein include a protonatable N atom.

[0938] The inorganic acid that forms an acid addition salt with the mycosporin-like amino acid compound is preferably selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc. Particularly preferred are hydrochloride, sulfate or phosphate.

[0939] Even more preferred are acid addition salts with organic mono- or polycarboxylic acids. Further preferred are acid addition salts with organic mono- or polycarboxylic acids, wherein the carboxylic acid is selected from the group consisting of saturated or monounsaturated or polyunsaturated C1 to C30 monocarboxylic acids, saturated or monounsaturated or polyunsaturated C3 to 10 dicarboxylic acids or tricarboxylic acids. The carboxylic acids may be mono- or polysubstituted by hydroxyl groups, preferably α-hydroxycarboxylic acids, wherein the hydroxyl groups are located on carbon atoms adjacent to the carboxyl groups. Many representatives occur naturally in the form of so-called fruit acids. Preferred α-hydroxycarboxylic acids are: malic acid, citric acid, 2-hydroxy-4-methylmercaptobutyric acid, glycolic acid, isocitric acid, mandelic acid, lactic acid, tartronic acid or tartaric acid.

[0940] The organic acid that forms an acid addition salt with the mycosporin-like amino acid compound is preferably selected from the group consisting of amino acids, acetic acid, trifluoroacetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, oxalic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, 4-hydroxybutyric acid, and the like.

[0941] Suitable anionic counterions are in particular chloride, bromide, hydrogensulfate, sulfate, dihydrogenphosphate, hydrogenphosphate, phosphate, nitrate, hydrogencarbonate, carbonate, hexafluorosilicate, hexafluorophosphate, benzoate and anions of C1 to C4-alkanoic acids, preferably formate, acetate, trifluoroacetate, propionate and butyrate, furthermore lactate, gluconate and anions of polyacids such as succinate, oxalate, maleate, fumarate, malate, tartrate and citrate, furthermore sulfonate anions such as benzenesulfonate (benzenesulfonate), toluenesulfonate (p-toluenesulfonate), naphthenesulfonate (naphthalene-2-sulfonate), methanesulfonate (mesylate), ethanesulfonate (ethanesulfonate) and edisulphonate. They can be formed by reacting the compounds according to the invention having basic functional groups with acids of the corresponding anions. Preferred salts of the compounds of formulae (I) to (III) and the individual mycosporin-like amino acid compounds specified herein are chloride salts.

[0942] The metal ion for salt formation which replaces the acidic protons present in the starting compound is selected from the group consisting of alkali metal ions (preferably Na+, K+ or Li+), alkaline earth metal ions (preferably Ca++ or Mg++), aluminum+++ or NH4+.

[0943] The coordinating organic base used for salt formation is selected from the group consisting of ethanolamine, diethanolamine, triethanolamine, N-methylglucamine, triethylamine and the like.

[0944] In the following description and claims, unless otherwise indicated, the term "mycosporine-like amino acid compound" includes neutral, uncharged forms of the compound / molecule, as well as salt forms of the compound.

[0945] The salt form of mycosporin-like amino acid compounds results in lower logP OW , and thus make the compound more hydrophilic, which leads to better water solubility. In particular, the cationic salts of mycosporin-like amino acid compounds support the emulsification process in emulsions due to their surface activity (i.e. co-emulsifying properties). In addition, the cationic salt forms of mycosporin-like compounds show excellent substantivity behavior on skin and hair: most conditioning active substances are cationic; the conditioning effect leads to a softer skin feel, which makes the final product more acceptable to consumers. In addition, mycosporin-like amino acid compounds in cationic salt form show antimicrobial activity.

[0946] In a particularly advantageous variant, the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the first aspect of the invention comprises one of the following combinations of components (a) and (b):

[0947] ■At least one inorganic UV filter: titanium dioxide (TiO 2 ) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al 2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3 ), all of the above inorganic UV filters in non-nanopigment, nanopigment, treated non-nanopigment and treated nanopigment form, in combination with at least one compound according to formula (V) as defined herein; or

[0948] ■At least one inorganic UV filter: titanium dioxide (TiO 2 ) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al 2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3 ), all of the above inorganic UV filters in non-nanopigment, nanopigment, treated non-nanopigment and treated nanopigment form, in combination with at least one compound according to formula (VI) as defined herein.

[0949] Such combinations of inorganic UV filters and mycosporin-like amino acid compounds show synergistic SPF performance and UVA photoprotection improvement of sunscreen products, cosmetic or pharmaceutical preparations or home care products.

[0950] In the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the first aspect of the present invention, a more preferred combination of components (a) and (b) is:

[0951] ■At least one inorganic UV filter: titanium dioxide (TiO 2 ) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al 2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3 ), all of the above inorganic UV filters in the form of non-nanopigments, nanopigments, treated non-nanopigments and treated nanopigments, in combination with MAA-1; or

[0952] ■At least one inorganic UV filter: titanium dioxide (TiO 2 ) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2) and / or manganese oxide (e.g., MnO), aluminum oxide (Al 2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3 ), all of the above inorganic UV filters in the form of non-nanopigments, nanopigments, treated non-nanopigments and treated nanopigments, in combination with MAA-2; or

[0953] ■At least one inorganic UV filter: titanium dioxide (TiO 2 ) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al 2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3 ), all of the above inorganic UV filters in the form of non-nanopigments, nanopigments, treated non-nanopigments and treated nanopigments, in combination with MAA-3; or

[0954] ■At least one inorganic UV filter: titanium dioxide (TiO 2 ) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al 2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3 ), all of the above inorganic UV filters in non-nanopigment, nanopigment, treated non-nanopigment and treated nanopigment form, in combination with MAA-4; or

[0955] ■At least one inorganic UV filter: titanium dioxide (TiO 2) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al 2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3 ), all of the above inorganic UV filters in the form of non-nanopigments, nanopigments, treated non-nanopigments and treated nanopigments, in combination with MAA-5; or

[0956] ■At least one inorganic UV filter: titanium dioxide (TiO 2 ) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al 2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3 ), all of the above inorganic UV filters in non-nanopigment, nanopigment, treated non-nanopigment and treated nanopigment form, in combination with MAA-6; or

[0957] ■At least one inorganic UV filter: titanium dioxide (TiO 2 ) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al 2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3), all of the above inorganic UV filters in non-nanopigment, nanopigment, treated non-nanopigment and treated nanopigment form, in combination with MAA-7; or

[0958] ■At least one inorganic UV filter: titanium dioxide (TiO 2 ) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al 2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3 ), all of the above inorganic UV filters in non-nanopigment, nanopigment, treated non-nanopigment and treated nanopigment form, in combination with MAA-8; or

[0959] ■At least one inorganic UV filter: titanium dioxide (TiO 2 ) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al 2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3 ), all of the above inorganic UV filters in non-nanopigment, nanopigment, treated non-nanopigment and treated nanopigment form, in combination with MAA-9; or

[0960] ■At least one inorganic UV filter: titanium dioxide (TiO 2 ) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3 ), all of the above inorganic UV filters in the form of non-nanopigments, nanopigments, treated non-nanopigments and treated nanopigments, in combination with MAA-11; or

[0961] ■At least one inorganic UV filter: titanium dioxide (TiO 2 ) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al 2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3 ), all of the above inorganic UV filters in non-nanopigment, nanopigment, treated non-nanopigment and treated nanopigment form, in combination with MAA-12; or

[0962] ■At least one inorganic UV filter: titanium dioxide (TiO 2 ) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al 2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3 ), all of the above inorganic UV filters in non-nanopigment, nanopigment, treated non-nanopigment and treated nanopigment form, in combination with MAA-13; or

[0963] ■At least one inorganic UV filter: titanium dioxide (TiO 2) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al 2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3 ), all of the above inorganic UV filters in non-nanopigment, nanopigment, treated non-nanopigment and treated nanopigment form, in combination with MAA-14; or

[0964] ■At least one inorganic UV filter: titanium dioxide (TiO 2 ) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al 2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3 ), all of the above inorganic UV filters in non-nanopigment, nanopigment, treated non-nanopigment and treated nanopigment form, in combination with MAA-16; or

[0965] ■At least one inorganic UV filter: titanium dioxide (TiO 2 ) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al 2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3), all of the above inorganic UV filters in non-nanopigment, nanopigment, treated non-nanopigment and treated nanopigment form, in combination with MAA-17; or

[0966] ■At least one inorganic UV filter: titanium dioxide (TiO 2 ) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al 2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3 ), all of the above inorganic UV filters in the form of non-nanopigments, nanopigments, treated non-nanopigments and treated nanopigments, in combination with MAA-20; or

[0967] ■At least one inorganic UV filter: titanium dioxide (TiO 2 ) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al 2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3 ), all of the above inorganic UV filters in the form of non-nanopigments, nanopigments, treated non-nanopigments and treated nanopigments, in combination with MAA-21; or

[0968] ■At least one inorganic UV filter: titanium dioxide (TiO 2 ) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3 ), all of the above inorganic UV filters in non-nanopigment, nanopigment, treated non-nanopigment and treated nanopigment form, in combination with MAA-22; or

[0969] ■At least one inorganic UV filter: titanium dioxide (TiO 2 ) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al 2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3 ), all of the above inorganic UV filters in non-nanopigment, nanopigment, treated non-nanopigment and treated nanopigment form, in combination with MAA-23; or

[0970] ■At least one inorganic UV filter: titanium dioxide (TiO 2 ) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al 2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3 ), all of the above inorganic UV filters in non-nanopigment, nanopigment, treated non-nanopigment and treated nanopigment form, in combination with MAA-24; or

[0971] ■At least one inorganic UV filter: titanium dioxide (TiO 2) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al 2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3 ), all of the above inorganic UV filters in the form of non-nanopigments, nanopigments, treated non-nanopigments and treated nanopigments, in combination with MAA-25; or

[0972] ■At least one inorganic UV filter: titanium dioxide (TiO 2 ) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al 2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3 ), all of the above inorganic UV filters in non-nanopigment, nanopigment, treated non-nanopigment and treated nanopigment form, in combination with MAA-26; or

[0973] ■At least one inorganic UV filter: titanium dioxide (TiO 2 ) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al 2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3), all of the above inorganic UV filters in non-nanopigment, nanopigment, treated non-nanopigment and treated nanopigment form, in combination with MAA-27; or

[0974] ■At least one inorganic UV filter: titanium dioxide (TiO 2 ) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al 2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3 ), all of the above inorganic UV filters in non-nanopigment, nanopigment, treated non-nanopigment and treated nanopigment form, in combination with MAA-28; or

[0975] ■At least one inorganic UV filter: titanium dioxide (TiO 2 ) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al 2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3 ), all of the above inorganic UV filters in non-nanopigment, nanopigment, treated non-nanopigment and treated nanopigment form, in combination with MAA-29; or

[0976] ■At least one inorganic UV filter: titanium dioxide (TiO 2 ) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3 ), all of the above inorganic UV filters in the form of non-nanopigments, nanopigments, treated non-nanopigments and treated nanopigments, in combination with MAA-30; or

[0977] ■At least one inorganic UV filter: titanium dioxide (TiO 2 ) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al 2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3 ), all of the above inorganic UV filters in non-nanopigment, nanopigment, treated non-nanopigment and treated nanopigment form, in combination with MAA-31; or

[0978] ■At least one inorganic UV filter: titanium dioxide (TiO 2 ) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al 2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3 ), all of the above inorganic UV filters in non-nanopigment, nanopigment, treated non-nanopigment and treated nanopigment form, in combination with MAA-32; or

[0979] ■At least one inorganic UV filter: titanium dioxide (TiO 2) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al 2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3 ), all of the above inorganic UV filters in non-nanopigment, nanopigment, treated non-nanopigment and treated nanopigment form, in combination with MAA-33; or

[0980] ■At least one inorganic UV filter: titanium dioxide (TiO 2 ) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al 2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3 ), all of the above inorganic UV filters in non-nanopigment, nanopigment, treated non-nanopigment and treated nanopigment form, in combination with MAA-34; or

[0981] ■At least one inorganic UV filter: titanium dioxide (TiO 2 ) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al 2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3), all of the above inorganic UV filters in the form of non-nanopigments, nanopigments, treated non-nanopigments and treated nanopigments, in combination with MAA-35; or

[0982] ■At least one inorganic UV filter: titanium dioxide (TiO 2 ) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al 2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3 ), all of the above inorganic UV filters in non-nanopigment, nanopigment, treated non-nanopigment and treated nanopigment form, in combination with MAA-36; or

[0983] ■At least one inorganic UV filter: titanium dioxide (TiO 2 ) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al 2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3 ), all of the above inorganic UV filters in non-nanopigment, nanopigment, treated non-nanopigment and treated nanopigment form, in combination with MAA-37; or

[0984] ■At least one inorganic UV filter: titanium dioxide (TiO 2 ) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3 ), all of the above inorganic UV filters in non-nanopigment, nanopigment, treated non-nanopigment and treated nanopigment form, in combination with MAA-38; or

[0985] ■At least one inorganic UV filter: titanium dioxide (TiO 2 ) (amorphous or crystalline, rutile and / or anatase form) and / or zinc oxide (ZnO) and / or iron oxide (Fe 2 O 3 ) and / or zirconium oxide (ZrO 2 ) and / or silicon dioxide (SiO 2 ) and / or manganese oxide (e.g., MnO), aluminum oxide (Al 2 O 3 ) and / or cerium oxide (Ce 2 O 3 ) and / or barium carbonate (BaCO 3 ) and / or calcium carbonate (CaCO 3 ), all of the above inorganic UV filters in the form of non-nanopigments, nanopigments, treated non-nanopigments and treated nanopigments, in combination with MAA-39;

[0986] In particular, the combination with mycosporin-like amino acid compounds and inorganic UV filters shows a synergistic SPF performance and UVA photoprotection improvement effect. This SPF performance and UVA photoprotection improvement effect can be particularly observed when the mycosporin-like amino acid is in its acid form or its salt form, i.e., its cationic form. The synergistic SPF performance and UVA photoprotection improvement effect is particularly pronounced for mycosporin-like amino acid compounds MAA-1 or MAA-13 and MAA-20 to MAA-39 when combined with any of the inorganic UV filters.

[0987] In the preparation of sunscreen products, cosmetic or pharmaceutical preparations or home care products according to the invention, the compounds defined herein can be used in combination with further UV absorbers different from the at least one inorganic UV filter (a) in order to further optimize the SPF, i.e. to obtain a high SPF in the range of 6 to 100, preferably in the range of 6 to 70, and to cover a wide UVA and UVB range.

[0988] Thus, at least the inorganic UV filter (a) in the sunscreen product, cosmetic or pharmaceutical preparation or home care product as defined herein is advantageously combined with at least one primary organic UV filter and / or with at least one secondary sunscreen ingredient or secondary sunscreen UV filter.

[0989] Therefore, the sunscreen products, cosmetic or pharmaceutical preparations or home care products according to the invention advantageously contain at least one further primary organic UVA filter and / or UVB filter and / or broadband filter for their use in blocking UV radiation.

[0990] Non-limiting examples of such primary organic UV filters include:

[0991] (i) Slightly soluble UV filters (not appreciably soluble in water or oil), such as methylenebis-benzotriazolyltetramethylbutylphenol, tris-biphenyltriazine, ketone, 1,1'-(1,4-piperazinediyl)diol

[0992] [1-[2-[4-(diethylamino)-2-hydroxybenzoyl-]phenyl];

[0993] (ii) oil-soluble organic UV filters (at least partially soluble in oil or organic solvents), such as bis-ethylhexyloxyphenol methoxyphenyl triazine, butyl methoxydibenzoylmethane (BMBM), oxybenzone, sulisobenzone, diethylhexyl butyramido triazone (DBT), drometrizole trisiloxane, ethylhexyl methoxycinnamate (EHMC), ethylhexyl salicylate (EHS), ethylhexyl triazone (EHT), homosalate, isoamyl p-methoxycinnamate, 4-methylbenzylidene camphor, octocrylene (OCR), polysilicone-15 and diethylaminohydroxybenzoyl hexyl benzoate (DHHB); and

[0994] (iii) water-soluble UV filters such as phenylbenzimidazole sulfonic acid (PBSA), sulfisobenzone-sodium salt, benzadiene camphor sulfonic acid, camphor benzalkonium methyl sulfate, cinoxate, disodium phenyldibenzylimidazole tetrasulfonate, terephthalylidene dicamphor sulfonic acid, PABA and PEG-25PAB; and any mixtures thereof.

[0995] According to the invention, many different organic compounds can be used as UV filters. They are divided into several structural classes:

[0996] (1) Benzophenone

[0997] a. Benzophenone-3 (BP3)

[0998] b. Benzophenone-4 (BP4)

[0999] (3) Salicylate

[1000] a. Homosalate (HMS)

[1001] b.2-Ethylhexyl salicylate (EHS)

[1002] (4) p-Aminobenzoic acid and its derivatives

[1003] a. Dimethyl PABA ethylhexyl ester (OD-PABA)

[1004] b.4-para-aminobenzoic acid (PABA)

[1005] (5) Benzimidazole derivatives

[1006] a. Phenylbenzimidazole sulfonic acid (PMDSA)

[1007] b. Disodium phenyl dibenzimidazole tetrasulfonate (Disodium bispyribacinidinium tetrasulfonate)

[1008] (6) Triazine

[1009] a. Ethylhexyl triazone (OT)

[1010] b. Diethylhexyl butyramido triazone (DBT)

[1011] c. Bis-ethylhexyloxyphenol methoxyphenyl triazine (EMT)

[1012] (7) Benzotriazole

[1013] a. Dromtriazole trisiloxane (DRT)

[1014] b. Methylene bis-benzotriazolyl tetramethylbutylphenol (MBP, biscotrizole)

[1015] (8) Dibenzoylmethane derivatives

[1016] a.4-tert-Butyl-4'-methoxydibenzoylmethane (BM-DBM, avobenzone)

[1017] (9) Cinnamate

[1018] a. Ethylhexyl methoxycinnamate (OMC)

[1019] b. Isoamyl methoxycinnamate (IMC, amitraz)

[1020] (10) Camphor derivatives

[1021] a. Terephthalidene dicamphor sulfonic acid (PDSA)

[1022] b.3-Methylbenzylidene camphor (3BC)

[1023] c. Benzylidene camphorsulfonic acid (BCSA)

[1024] d.4-Methylbenzylidene camphor (4-MBC)

[1025] e. Polyacrylamide methylbenzylidene camphor (PBC)

[1026] (11)Camphor benzalkonium methylsulfate (CBM)

[1027] In some cases, the UV filter is one or more of a p-aminobenzoic acid derivative, a salicylic acid derivative, a cinnamic acid derivative, a benzophenone or an aminobenzophenone, an anthranilic acid derivative, a b,b-diphenylacrylate derivative, a benzylidene camphor derivative, a phenylbenzimidazole derivative, a benzotriazole derivative, a triazine derivative, a bisresorcinol-based triazine, an imidazoline derivative, a benzylidene malonate derivative, a 4,4-diarylbutadiene derivative, a benzoxazole derivative, a merocyanine, a malononitrile or malonate diphenylbutadiene derivative, a chalcone, and any mixture thereof.

[1028] The at least one primary organic UV filter is preferably selected from the group consisting of: camphor benzalkonium methylsulfate, homosalate, benzophenone-3, phenylbenzimidazole sulfonic acid, terephthalylidene dicamphor sulfonic acid, butyl methoxydibenzoylmethane, benzylidene camphor sulfonic acid, octocrylene, polyacrylamidomethylbenzylidene camphor, ethylhexyl methoxycinnamate, PEG-25 PABA, isopentyl p-methoxycinnamate, ethylhexyl triazone, drometrizole trisiloxane, diethylhexyl butamido triazone, 4-methylbenzylidene camphor, ethylhexyl salicylate, ethylhexyl dimethyl PABA, benzophenone -4, benzophenone-5, methylene bis-benzotriazolyl tetramethylbutylphenol (nano), disodium phenyl dibenzimidazole tetrasulfonate, bis-ethylhexyloxyphenol methoxyphenyl triazine, polysilicone-15, diethylamino hydroxybenzoyl hexyl benzoate, tris-biphenyl triazine (nano), phenylene bis-diphenyl triazine, methoxypropylaminocyclohexenylene ethoxyethyl cyanoacetate, bis-(diethylamino hydroxybenzoyl benzoyl) piperazine, TEA-salicylate, benzophenone-8, PABA, dimethyl PABA ethylhexyl ester, anthranilate, and any mixture thereof.

[1029] More preferably, the at least one primary organic UV filter is selected from the group consisting of camphor benzalkonium methylsulfate, benzophenone-3, terephthalylidene dicamphor sulfonic acid, benzylidene camphor sulfonic acid, polyacrylamide methyl benzylidene camphor, PEG-25 PABA, drometrizole trisiloxane, dimethyl PABA ethylhexyl ester, benzophenone-4, benzophenone-5, methylene bis-benzotriazolyl tetramethylbutylphenol, polysilicone-15, titanium dioxide (nano), tris-biphenyl triazine (nano), phenylene bis-diphenyl triazine, methoxypropylaminocyclohexenylene ethoxyethyl cyanoacetate, bis-(diethylaminohydroxybenzoylbenzoyl)piperazine, benzophenone-8, dimethyl PAB A ethylhexyl ester, homosalate, phenylbenzimidazole sulfonic acid, butyl methoxydibenzoylmethane, octocrylene, ethylhexyl methoxycinnamate, isoamyl p-methoxycinnamate, ethylhexyl triazone, diethylhexyl butyramido triazone, 4-methylbenzylidene camphor, ethylhexyl salicylate, disodium phenyl dibenzimidazole tetrasulfonate, bis-ethylhexyloxyphenol methoxyphenyl triazine, diethylaminohydroxybenzoyl hexyl benzoate, menthyl anthranilate, and any mixture thereof.

[1030] Most preferably, the at least one primary organic UV filter is selected from the group consisting of homosalate, phenylbenzimidazole sulfonic acid, butyl methoxydibenzoylmethane, octocrylene, ethylhexyl methoxycinnamate, isoamyl p-methoxycinnamate, ethylhexyl triazone, diethylhexyl butamido triazone, 4-methylbenzylidene camphor, ethylhexyl salicylate, disodium phenyl dibenzimidazole tetrasulfonate, bis-ethylhexyloxyphenol methoxyphenyl triazine, diethylaminohydroxybenzoyl hexyl benzoate, menthyl anthranilate, and any mixtures thereof.

[1031] Advantageously, the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the invention comprises at least one UVA filter and at least one UVB filter. Such a sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the invention provides broad-spectrum protection against light, i.e. against both UVA and UVB.

[1032] In another preferred variant, the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the invention comprises a combination with one or more broadband filters selected from the group consisting of 2-ethylhexyl-2-cyano-3,3-diphenylacrylate, ethyl-2-cyano-3,3'-diphenylacrylate, dihydroxy-4-methoxybenzophenone, 2,4-dihydroxybenzophenone, tetrahydroxybenzophenone, 2,2'-dihydroxy-4,4'-dimethoxybenzophenone, 2-hydroxy-4-n-octyloxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, sodium hydroxymethoxybenzophenone sulfonate, disodium 2,2'-dihydroxy-4,4'-dimethoxy-5,5'-dimethoxybenzophenone. -Disulfobenzophenone, phenol, 2-(2H-benzotriazol-2-yl)-4-methyl-6-(2-methyl-3(1,3,3,3-tetramethyl-1-(trimethylsilyl)oxy)disiloxy)propyl), 2,2'-methylene-bis-(6-(2H-benzotriazol-2-yl)-4-1,1,3,3-tetramethylbutyl)phenol)(methylene-bis-benzotriazolyltetramethylbutylphenol), 2,4-bis-[4-(2-ethylhexyloxy)-2-hydroxyphenyl]-1,3,5-triazine, 2,4-bis-[{(4-(2-ethylhexyloxy)-2-hydroxy}phenyl]-6-(4-methoxyphenyl)-1,3,5-triazine (INCI: anise triazine) ), 2,4-bis-[{(4-(3-sulfonate)-2-hydroxypropoxy)-2-hydroxy}phenyl]-6-(4-methoxyphenyl)-1,3,5-triazine sodium salt, 2,4-bis-[{(3-(2-propoxy)-2-hydroxypropoxy)-2-hydroxy}phenyl]-6-(4-methoxyphenyl)-1,3,5-triazine, 2,4-bis-[{4-(2-ethylhexyloxy)-2-hydroxy}phenyl]-6-[4-(2-methoxyethylcarbonyl)phenylamino]-1,3,5-triazine, 2,4-bis-[{4-(3-(2-propoxy)-2-hydroxypropoxy)-2-hydroxy}phenyl]-6-[4-(2-ethylcarboxyl)phenylamino]-1,3,5- triazine, 2,4-bis-[{4-(2-ethylhexyloxy)-2-hydroxy}phenyl]-6-(1-methylpyrrol-2-yl)-1,3,5-triazine, 2,4-bis-[{4-tris-(trimethylsiloxysilyloxy)-2-hydroxy}phenyl]-6-(4-methoxyphenyl)-1,3,5-triazine, 2,4-bis-[{4-(2"-methylpropenyloxy)-2-hydroxy}phenyl]-6-(4-methoxyphenyl)-1,3,5-triazine, 2,4-bis-[{4-(1',1',1',3',5',5'-heptamethylsilyloxy-2"-methylpropoxy)-2-hydroxy}phenyl]-6-(4-methoxyphenyl)-1,3,5-triazine, dioctylbutylamide triazone (INCI: dioctylbutylamide triazone), 2,4-bis-[5-1(dimethylpropyl)benzoxazol-2-yl-(4-phenyl)-imino]-6-(2-ethylhexyl)-imino-1,3,5-triazine, 4,4',4"-(1,3,5-triazine-2,4,6-triimino)tris-benzoic acid-tri(2-ethyl-hexyl)ester (also: 2,4,6-tris[anilino(p-carbon-2'-ethyl-1'-hexyloxy)]-1,3,5-triazine (INCI: octyl triazone), 2,4,6-terphenyl-4 -1,3,5-triazine, 2-ethylhexyl 4-methoxycinnamate (ethylhexyl methoxycinnamate), benzoic acid, 2-hydroxy-, 3,3,5-trimethylcyclohexyl ester (homosalate), 2-ethylhexyl salicylate (ethylhexyl salicylate), 2-ethylhexyl 4-(dimethylamino)benzoate (dimethyl PABA ethylhexyl ester), N,N,N-trimethyl-4-(2-oxoboron-3-ylmethylene), aniline methylsulfate (camphor benzalkonium methylsulfate), dimethyl dimethyl diethyl benzomalonate (polysilicone-15) and any mixture thereof. ,

[1033] The aforementioned primary organic UV filters which can be used in the context of the present invention are preferred but are naturally not restrictive.

[1034] The above-mentioned primary organic UV filters are used as a single component in sunscreens or cosmetic or pharmaceutical preparations or comprise at least two, more preferably at least three, most preferably at least four or even more different UV filters.

[1035] The combination of different classes of effective sunscreen UV filters such as UVA filters, UVB, broadband filters, inorganic pigments etc. provides reliable protection against different UV rays in the wavelength range from 290 nm to 400 nm.

[1036] In a further preferred variant, the sunscreen products, cosmetic or pharmaceutical preparations or home care products according to the invention comprise primary organic and / or inorganic UV filters in such a total amount that the products or preparations according to the invention have a sun protection factor SPF of 6 to 100, preferably 6 to 70. Such compositions according to the invention are particularly suitable for protecting the skin, hair and nails.

[1037] Besides the abovementioned group of primary inorganic and organic sunscreen UV filters, secondary sunscreen ingredients of the antioxidant type can also advantageously be used in the sunscreen products, cosmetic or pharmaceutical preparations or home care products according to the invention in order to further optimize the UV protection.

[1038] Antioxidant-type secondary sunscreen ingredients interrupt the chain of photochemical reactions that are initiated when UV rays penetrate the skin.

[1039] Typical examples of secondary sunscreen ingredients are amino acids (e.g. arginine, lysine, glycine, histidine, tyrosine, tryptophan) and their derivatives in very low compatible doses, imidazoles (e.g. urocanic acid) and their derivatives, peptides such as D,L-carnosine, D-carnosine, L-carnosine and their derivatives (e.g. anserine), carotenoids, carotenes (e.g. α-carotene, β-carotene, lycopene) and their derivatives, chlorogenic acid and its derivatives, lipoic acid and its derivatives (e.g. dihydrolipoic acid), aurothiocan, propylthiouracil and other thiols (e.g. thioredoxin, glutathione, cysteine) and their derivatives. thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and its derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) and sulfoxide amine compounds (e.g. buthionine sulfoxide amine, homocysteine ​​sulfoxide amine, buthionine sulfoxide ether sulfone, penta-, hexa- and heptathionine sulfoxide amine), and also (metal) chelators (e.g. α-hydroxy fatty acids, palmitic acid, phytic acid, lactic acid ferritin), α-hydroxy acids (e.g. citric acid, lactic acid, malic acid), humic acid, bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and their derivatives, unsaturated fatty acids and their derivatives (e.g. linoleic acid, oleic acid), folic acid and its derivatives, ubiquinone and ubiquinol and their derivatives, vitamin C and its derivatives (e.g. ascorbyl palmitate, magnesium ascorbyl phosphate, ascorbyl acetate), tocopherol and its derivatives (e.g. vitamin E acetate), vitamin A and its derivatives (vitamin A palmitate) and coniferyl benzoate of benzoin resin, rutinic acid and its derivatives Derivatives, glycosyl rutin, ferulic acid, furfurylidene glucitol, carnosine, butylated hydroxytoluene, butylated hydroxyanisole, nordihydroguaiaretic acid, nordihydroguaiaretic acid, trihydroxybutylpropionic acid, uric acid and its derivatives, mannose and its derivatives, superoxide dismutase, sinapinic acid, sinapinic acid malate, sinapinic acid ester derivatives, selenium and its derivatives (e.g. selenomethionine), stilbene and its derivatives (e.g. stilbene oxide, trans-stilbene oxide) and derivatives (salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids) of these active substances suitable for the purposes of the present invention.

[1040] This group of secondary sunscreen ingredients also encompasses plant-based extracts which have antioxidant and generally photoprotective properties and interrupt the photochemical reaction chain initiated when UV rays penetrate into the skin, thus effectively preventing skin aging. The plant extract with UV protection properties is selected from the group consisting of lignin / cellulose, lignin, hydrolyzed lignin, propolis and green propolis, galangal extract, macroalgae and microalgae (porphyra, red algae (Porphyra Umbilicalis, Palmaria palmata, Saccharina latissima, Corallina pilulifera, Eckloina cava, Sargassum sagamianum, Porphyra rosengurttii, Sargassum siliquastrum, Thalassiosira weissflogii), green microalgae (e.g., Interfilum and Klebsormidium), seaweed (e.g., Padina australis), Eucheuma cottonii), Pongamia Glabra seed oil, Karanja oil (Millettiapinnata), Rhatania Extrakt (Krameria lappacea), Lichen, Soybean, Capparis spinosa, Bamboo, Green Coffee Oil, Buriti Oil (Mauritiaflexuosa), Black Sea Cucumber (Holothuria atra), Cyanobacteria, Polypodiumleucotomos, Green Tea, Black Tea (Camellia sinensis), Aloe, Walnut, Borage Oil, Evening Primrose Oil, Avocado Oil, Tea Tree Oil, Red Clover (Trifolium pratense L.), Soybean (Glycine max L.), Capparis spinosa, Apricot, Flame Tree (Spathodea campanulata), milk thistle (Silybum marianum L.), cashew nut shells, grapes, blood oranges, pomegranates (Punica granatu), blueberries (Vaccinium myrtillus L.), blueberries (Vaccinium uliginosum L.), Strawberry (Fragaria ananassa), Polygonum multiflorum Thunb, Turmeric (Curcuma longa L.), Ginseng (Panax ginseng), Ivy (Hederahelix), Broccoli (Brassica oleracea var italica), Tamarind (Tamarindus indica), Prickly pear cactus, Coffee, Basil (Ocimum basilicum, Linn.), Pomegranate seed oil (Punica granatum), Wheat germ oil (Triticum vulgare), Blackcurrant seed oil (Ribes nigrum), Sesame oil (Sesamum indicum), Carrot (Daucuscarota sativa), Raspberry (Rubus idaeus), Traditional medicinal plants from Sri Lanka (Aporosalindleyana (Euphorbiaceae), Atalantia ceylanica (Rutaceae), Hibiscus furcatus (Malvaceae), Olax zeylanica (Araceae), Ophiorrhiza mungos (Rubiaceae), Argyreia populifolia (Convolvulaceae), Ipomoea mauritiana (Convolvulaceae), Lasia spinosa (Araceae), Leucas zeylanica (Lamiaceae), Plectranthus zeylanicus (Lamiaceae)), and traditional medicinal plants from Brazil (D. gardneriana seeds, L. microphylla leaves, Amburanacearensis, Aspidosperma cuspa, Aspidospermapyrifolium, Croton sonderianus, Curatella americana, Dimophandragardneriana, Lippia microphylla, Luehea paniculata, Sida galheirensis), and any mixtures thereof.

[1041] Preferably, the plant extract having UV protective properties is selected from the group consisting of lignin / cellulose, lignin, hydrolyzed lignin, galangal extract, laver, red algae (Porphyra), green microalgae (e.g., Endothella and Creatia), seaweed (e.g., Padina australis, Eucheuma), Pongamia seed oil, Karanja oil (Erythrina pinnatifida oil), Dracaena extract (Dracaena lappa extract), soy, bamboo, Buriti oil (Mauritian palm oil), cyanobacteria, Phenoxylum bungeana (Polypoda alba), green tea, black tea (Camellia sinensis), aloe vera, evening primrose oil, cashew nut shell, pomegranate (Punica granatum) and any mixture thereof.

[1042] Advantageously, the amount of secondary sunscreen substances in the sunscreen products, cosmetic or pharmaceutical preparations or home care products according to the invention is advantageously from 0.005% to 5.0% by weight, preferably from 0.01% to 4.0% by weight and most preferably from 0.05% to 3.0% by weight, based on the total weight of the ready-to-use formulation.

[1043] The UV filters are incorporated into the aqueous part or the lipophilic part of the sunscreen products, cosmetic or pharmaceutical preparations or home care products, depending on whether they are water or oil (fat) soluble / miscible UV filters, or can even be added to the final product by standard methods known to those skilled in the art.

[1044] At least one inorganic UV filter (a) according to the first aspect of the invention is present in the sunscreen product, cosmetic or pharmaceutical preparation or home care product in an amount of 0.5% to 60.0% by weight, based on the total weight of the final formulation. In a preferred variant, the sunscreen product, cosmetic or pharmaceutical preparation or home care product comprises the inorganic UV filter (a) in an amount of 0.3% to 55.0% by weight, based on the total weight of the final formulation. In a more preferred variant, the inorganic UV filter (a) is advantageously used in an amount of 0.1% to 50.0% by weight, based on the total weight of the final formulation in the sunscreen product, cosmetic or pharmaceutical preparation or home care product. In a most preferred variant, the inorganic UV filter is advantageously used in an amount of 1.0% to 45.0% by weight, based on the total weight of the final formulation in the sunscreen product, cosmetic or pharmaceutical preparation or home care product.

[1045] For mixtures of inorganic UV filters, the above amounts relate to the total content of inorganic UV filters in the mixture, ie the amount is the sum of the contents of all inorganic UV filters in the mixture.

[1046] The inorganic UV filter (a) and further UV protection components such as primary organic UV filters and secondary sunscreen ingredients as defined herein (i.e. the total amount of all UV filters) are present in the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the invention in an amount of 0.1% to 85.0% by weight, based on the total weight of the final formulation. In a preferred variant, the sunscreen product, cosmetic or pharmaceutical preparation or home care product comprises the inorganic UV filter (a) and further primary and secondary UV protection components as defined herein in an amount of 0.3% to 80.0% by weight, based on the total weight of the final formulation. In a more preferred variant, the inorganic UV filter (a) and further primary and secondary UV protection components as defined herein are advantageously used in the sunscreen product, cosmetic or pharmaceutical preparation or home care product in an amount of 0.5% to 75.0% by weight, based on the total weight of the final formulation. The above amounts therefore relate to the sum of the contents of all UV filters / UV protection components present in the sunscreen or cosmetic, pharmaceutical or home care preparation.

[1047] At least one mycosporin-like amino acid compound (b) according to the first aspect of the present invention is present in a sunscreen product, a cosmetic or pharmaceutical preparation or a home care product in an amount of 0.001% to 15.0% by weight, based on the total weight of the final formulation. In a preferred variant, the sunscreen product, the cosmetic or pharmaceutical preparation or the home care product comprises at least one mycosporin-like amino acid compound (b) in an amount of 0.01% to 10.0% by weight, based on the total weight of the final formulation. In a more preferred variant, at least one mycosporin-like amino acid compound (b) is advantageously used in a sunscreen product, a cosmetic or pharmaceutical preparation or a home care product in an amount of 0.05% to 7.5% by weight, based on the total weight of the final formulation. In a most preferred variant, at least one mycosporin-like amino acid compound (b) is advantageously used in a sunscreen product, a cosmetic or pharmaceutical preparation or a home care product in an amount of 0.1% to 5.0% by weight, based on the total weight of the final formulation.

[1048] For a mixture of mycosporine-like amino acid compounds (b), the above amount relates to the total content of mycosporine-like amino acid compounds in the mixture, ie the amount is the sum of the contents of all mycosporine-like amino acid compounds (b) in the mixture.

[1049] Advantageously, the sunscreen product according to the first aspect of the present invention comprises

[1050] (i) 0.5 to 60.0% by weight of at least one inorganic UV filter; and

[1051] (ii) 0.001% to 15.0% by weight of at least one mycosporin-like amino acid compound as defined herein;

[1052] Based on the total weight of the final formulation.

[1053] In a preferred variant, the cosmetic or pharmaceutical preparation according to the first aspect of the invention comprises

[1054] (iii) 1.0 to 45.0 wt. % of at least one inorganic UV filter; and

[1055] (iv) 0.1% to 5.0% by weight of at least one mycosporin-like amino acid compound as defined herein;

[1056] Based on the total weight of the final formulation.

[1057] The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the invention provides broad spectrum photoprotection to the skin and therefore provides protection against both UVA and UVB radiation. The sun protection factor (SPF) is a measure of UVB protection, as described above. Typically, the composition of the invention has an SPF of at least 6. However, the SPF may vary as desired. The type and amount of UVA and UVB filters may vary to obtain a desired SPF level.

[1058] Preferably, the SPF (UVB) of the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the invention is at least 6, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80 or even higher.

[1059] Furthermore, the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the invention has an SPF (UVA) or UVA SP of 1 to 50, preferably at least 10, and most preferably greater than 2.

[1060] In the context of the present invention, it is also possible and in some cases advantageous to combine the sunscreen product, cosmetic or pharmaceutical preparation or household care product according to the first aspect of the invention with other conventional active substances, adjuvants or additives conventionally used in sunscreen products, cosmetic or pharmaceutical compositions or household care products as further described below, in order to obtain a ready-to-use preparation or formulation.

[1061] Other active agents and / or adjuvants and / or additives or auxiliaries are, for example, abrasives, anti-acne agents, anti-skin aging agents, anti-cellulitis agents, anti-dandruff agents, anti-inflammatory agents, anti-irritants, irritation inhibitors, antioxidants, alkanediols, astringents, odor absorbers, antiperspirants, preservatives, antistatic agents, antibacterial agents, adhesives, buffers, carrier materials, oil components, chelating agents, cell stimulants, cleaning agents, depilatories, surfactants, deodorants, antiperspirants, softeners, emulsifiers, enzymes, enzyme inhibitors, Essential oils, fibers, film formers, water resistance improvers, fixatives, foaming agents, foam stabilizers, anti-foaming substances, foam enhancers, gelling agents, gel forming agents, hair care products, hair setting agents, hair straightening agents, moisture supply agents, moisturizing substances, water retaining substances, bleaching agents, enhancers, detergents, fluorescent whitening agents, impregnants, stain repellents, dyes, friction reducers, lubricants, moisturizing creams, ointments, sunscreens, plasticizers, covering agents, polishing agents, preservatives, glossing agents, green and synthetic polymers, powders, proteins, re oiling agents, abrasives, silicones, skin soothing agents, skin cleansers, skin care agents, skin healing agents, skin lightening agents, skin protectants, skin softeners, hair promoters, cooling agents, skin cooling agents, warming agents, skin warming agents, stabilizers, surfactants, antimicrobial agents, detergents / surfactants, fabric conditioners, suspending agents, skin tanning agents, active substances that regulate skin or hair pigmentation, matrix metalloproteinase inhibitors, skin moisturizers, glycosaminoglycan stimulators, TRPV1 antagonists, desquamation agents, anti-cellulite agents or fat enhancing agents, hair growth activators or inhibitors, thickeners, rheological additives, vitamins, oils, waxes, pearlescent waxes, fats, phospholipids, saturated fatty acids, mono- or polyunsaturated fatty acids, alpha-hydroxy acids, polyhydroxy fatty acids, liquefiers, dyes, color fixatives, pigments, preservatives, fragrance or perfume oils, fragrances, flavoring substances, odoriferous substances, polyols, electrolytes, organic solvents and mixtures of two or more of the above substances, as further described below.

[1062] The above-mentioned cosmetic or pharmaceutical excipients and / or active substances and / or additives and / or auxiliary carriers, oil components, rheological additives, hydrotropes, solubilizers, powders, film formers, water resistance improvers, skin moisturizing and / or water retention substances, soothing substances, physiological cooling agents, alkanediols, antioxidants, anti-skin aging agents, matrix metalloproteinase inhibitors (MMPI), anti-inflammatory agents, TRPV1 antagonists, emulsifiers, antimicrobial agents, preservatives, antibacterial or antifungal active substances, chelating agents, surfactants, fragrances / fragrance oils or perfume oils, and any mixtures of two or more of the above-mentioned substances are particularly preferred in the preparation of sunscreen products, cosmetic and pharmaceutical preparations or home care products.

[1063] Carrier: sunscreen products, cosmetics or medicines in the form of ointments, pastes, creams and gels as defined herein, particularly dermatological preparations or home care products are preferably based on carriers. The most common acceptable carrier is water. Acceptable carriers other than water include glycerol, C1-4 alcohols, organic solvents, fatty alcohols, fatty ethers, fatty esters, polyols, ethylene glycol, vegetable oils, mineral oils, liposomes, lamellar lipid materials, water or mixtures thereof. Non-limiting examples of organic solvents include monoalcohols and polyols, such as ethanol, isopropanol, propanol, benzyl alcohol and phenylethyl alcohol, or ethylene glycol or glycol ethers, such as monomethyl, monoethyl and monobutyl ethers of ethylene glycol, propylene glycol or their ethers, such as monomethyl ethers of propylene glycol, butylene glycol, hexylene glycol, dipropylene glycol and alkyl ethers of diethylene glycol, such as monoethyl ether or monobutyl ethers of diethylene glycol. Examples of other suitable organic solvents are ethylene glycol, propylene glycol, butylene glycol, hexylene glycol, propylene glycol and glycerol. The organic solvent may be a volatile or non-volatile compound.The total amount of carrier in the composition may vary but is typically from 40% to 90% by weight based on the total weight of the composition.

[1064] Compositions of the present invention may include at least one water-soluble or organic solvent. Non-limiting examples of organic solvents include monoalcohols and polyols, such as ethanol, isopropanol, propanol, benzyl alcohol and phenylethyl alcohol, or ethylene glycol or glycol ethers, such as monomethyl, monoethyl and monobutyl ethers of ethylene glycol, propylene glycol or their ethers, such as monomethyl ether of propylene glycol, butylene glycol, hexylene glycol, dipropylene glycol and alkyl ethers of diethylene glycol, such as monoethyl ether or monobutyl ether of diethylene glycol. The example of other suitable organic solvents is ethylene glycol, propylene glycol, butylene glycol, hexylene glycol, propylene glycol and glycerine. The organic solvent can be a volatile or non-volatile compound.

[1065] Additional non-limiting examples of water-soluble solvents include alkanols (polyols such as ethylene glycol and polyols) such as glycerol, 1,2,6-hexanetriol, trimethylolpropane, ethylene glycol, propylene glycol, diethylene glycol, butylene glycol, hexylene glycol, triethylene glycol, tetraethylene glycol, pentaethylene glycol, dipropylene glycol, 1,3-butylene glycol, 2,3-butylene glycol, 1,4-butylene glycol, 3-methyl-1,3-butylene glycol, 1,5-pentanediol, tetraethylene glycol, 1 ,6-hexanediol, 2-methyl-2,4-pentanediol, polyethylene glycol, 1,2,4-butanetriol, 1,2,6-hexanetriol, 2-butene-1,4-diol, 2-ethyl-1,3-hexanediol, 2-methyl-2,4-pentanediol, 1,2-pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol, 1,2-decanediol and 4-methyl-1,2-pentanediol; alkyl alcohols having 1 to 4 carbon atoms, Such as ethanol, methanol, butanol, propanol and isopropanol; glycol ethers such as ethylene glycol monomethyl ether, ethylene glycol monoethyl ether, ethylene glycol monobutyl ether, ethylene glycol monomethyl ether acetate, diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, diethylene glycol mono-n-propyl ether, ethylene glycol monoisopropyl ether, diethylene glycol monoisopropyl ether, ethylene glycol mono-n-butyl ether, ethylene glycol mono-tert-butyl ether, diethylene glycol mono-tert-butyl ether, 1-methyl-1-methoxybutanol, propylene glycol monomethyl ether, propylene glycol monoethyl ether , propylene glycol mono-tert-butyl ether, propylene glycol mono-n-propyl ether, propylene glycol mono-isopropyl ether, dipropylene glycol mono-methyl ether, dipropylene glycol mono-ethyl ether, dipropylene glycol mono-n-propyl ether and dipropylene glycol mono-isopropyl ether; 2-pyrrolidone, N-methyl-2-pyrrolidone, 1,3-dimethyl-2-imidazolidinone, formamide, acetamide, dimethyl sulfoxide, sorbitol, sorbitan, acetin, diacetin, triacetin, sulfolane and any mixture thereof. The total amount of water-soluble solvent or organic solvent in the composition according to the present invention may vary, but is generally 0.1% to 50% by weight based on the total weight of the composition.

[1066] Solubilizer: The composition of the present invention may include at least one solubilizer. A solubilizer is a compound that aids in the dissolution of the UV filters and / or other components in the composition. A particularly useful but non-limiting example of a solubilizer is a hydrotrope. Hydrotropes (or hydrotropic agents) are a diverse class of typically water-soluble compounds that may be characterized by an amphiphilic molecular structure and the ability to significantly increase the solubility of poorly soluble organic molecules in water. Non-limiting examples of hydrotropes include sodium 1,3-benzenedisulfonate, sodium benzoate, sodium 4-pyridinecarboxylate, sodium salicylate, sodium benzenesulfonate, caffeine, sodium p-toluenesulfonate, sodium butyl monoglycol sulfate, 4-aminobenzoic acid HCl, sodium cumenesulfonate, N,N-diethylnicotinamide, N-pyridylmethylnicotinamide, N-allylnicotinamide, 2-methacryloyloxyethylphosphorylcholine, resorcinol, butyl urea, pyrogallol, N-methylpyridineacetamide 3.5, procaine HCl, proline HCl, nicotinamide, pyridine, 3-methylpyridinamine, sodium ibuprofen, sodium xylenesulfonate, ethyl carbamate, pyridoxal hydrochloride, sodium benzoate, 2-pyrrolidone, ethyl urea, N,N-dimethylacetamide, N-methylacetamide and isoniazid, and any mixtures thereof. In some cases, particularly useful hydrotropes include nicotinamide (nicotinamide), caffeine, sodium PCA, sodium salicylate, urea and hydroxyethyl urea, in particular nicotinamide (nicotinamide) and / or caffeine. Combinations of two or more, three or more or four or more hydrotropes may also be used in the composition according to the invention. The total amount of solubilizer in the composition of the invention may vary, but is typically in an amount of 0.01% to 20% by weight based on the total weight of the composition.

[1067] Oil component: Sunscreen products, cosmetic or pharmaceutical preparations or home care products may include at least one oil phase or at least one oil component, wax, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silicon dioxide, talc and zinc oxide or any mixture thereof. Powders include carriers such as lactose, talc, silicon dioxide, aluminum hydroxide, calcium silicate and polyamide powders or any mixture thereof. Solutions and emulsions include carriers such as solvents such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, propylene glycol, etc. or any mixture thereof. However, formulations based only on water are also possible. Oil, oil-in-water and water-in-oil emulsions, etc. are preferred.

[1068] Possibly suitable oily phases or oil components in the sunscreen products, cosmetics, pharmaceutical preparations or home care products according to the invention are, for example, vegetable oils, hydrocarbons, fatty alcohols, fatty acid esters or mixtures of two or more of the aforementioned oil components.

[1069] The oil phase or oil component in sunscreen products, cosmetics, pharmaceutical preparations is preferably a vegetable oil, and even more preferably a liquid vegetable oil. It can also advantageously be a mixture of two or more vegetable oil components, especially a liquid vegetable oil mixture.

[1070] Vegetable oils or vegetable oils are oils extracted from seeds, or less commonly, from other parts of fruit. Like animal fats, vegetable oils are mixtures of triglycerides. Soybean oil, rapeseed oil, and cocoa butter are examples of vegetable oils from seeds. Olive oil, palm oil, and rice bran oil are examples of oils from other parts of fruit. In common usage, vegetable oil or vegetable oil may refer specifically to vegetable fats that are liquid at room temperature or at skin temperature of 35°C to 37°C. Vegetable oils are usually edible.

[1071] The term "vegetable oil" also includes unsaturated vegetable oils. Unsaturated oils or vegetable oils can be converted into oils with higher melting points by partial or complete "hydrogenation". The hydrogenation process involves "spraying" the oil with hydrogen gas at high temperature and pressure in the presence of a catalyst (usually a powdered nickel compound). When each carbon-carbon double bond is chemically reduced to a single bond, the two hydrogen atoms each form a single bond with two carbon atoms. The process of eliminating double bonds by adding hydrogen atoms is called saturation; as the degree of saturation increases, the oil is gradually fully hydrogenated. Oils can be hydrogenated to increase resistance to rancidity (oxidation) or to change their physical properties. As the degree of saturation increases, the viscosity and melting point of the oil increase.

[1072] In a preferred variant, the vegetable oil is selected from the group consisting of: Avocado (Avocado Tree Oil), White Fir Seed Oil, Victoria Acacia Seed Oil, Kiwi (Kiwi) Seed Oil, Amaranth Seed Oil, Arachis (Peanut) Oil, Murumuru Seed Butter, Tukuma Seed Butter, Tukuma Seed Oil, Common Star Fruit Oil, Common Star Fruit Kernel Oil, Oat Bran Meal (Avena Sativa) Kernel Oil, White Mustard Seed Oil, Brassica (Rapeseed) Seed Oil, Butyrospermum Parkii (Shea) Butter, Butyrospermum Parkii (Shea) Butter, Calendula Officinalis Seed Oil, Tung Oil, Takamahaka Seed Oil, Camellia Japonica Seed Oil, Camellia Reticulata Seed Oil, Tea Seed Oil, Hemp Seed Oil, Hemp Seed / Stem Oil, Rapeseed Oil, Carthamus Tinctorius (Safflower Dye) Seed Oil, Chlorella Vulgaris Oil, Cucurbitaceae Citrus Grandis (Watermelon) Seed Oil, Citrus Limon (Lime) Seed Oil, Citrus Aurantium Dulcis (Orange) Seed Oil, Citrus Grandis (Grapefruit) Seed Oil, Cocos Nucifera (Coconut) Oil, Copaiba (Coconut) Seed Butter, Coffea Canina (Coffee) Seed Oil, Chlorella Vulgaris Oil (Biotech), Corylus Avellana (Hazelnut) Seed Oil, Corylus Avellana (Hazelnut) Seed Oil, Corylus Avellana (Hazelnut) Seed Oil, Cucumis Sativus (Melon) Seed Oil, Cucumis Cucumis (Cucumber) Seed Oil, Cucumis Pepo (Pumpkin) Seed Oil, Elaeis Guineensis (Palm) Oil, Elaeis Guineensis (Palm) Oil ) fruit oil, soybean (soybean) oil, cotton (cotton) seed oil, cotton (cotton) seed oil, sunflower (sunflower) seed oil, macadamia seed oil, macadamia nut seed oil, mango (mango) seed butter, mango (mango) seed oil, lemon balm seed oil, microalgae oil, moringa seed oil, moringa seed oil, evening primrose (evening primrose) oil, olive (olive) fruit oil, rice (rice) bran / germ oil, rice (rice) bran oil, rice (rice) germ oil, rice (rice) lipids, rice (rice) seed oil, poppy seed oil, passionflower seed oil, avocado Persea gratissima (avocado) butter, persea gratissima (allergen) oil, prunus amygdalus dulcis (sweet almond) oil, prunus armeniaca (apricot) kernel oil, persica (peach) kernel oil, punica granatum seed oil, malus domestica (apple) seed oil, castor / caproic / caprylic / capric triglycerides, ricinus communis (castor) seed oil, rosa canina fruit oil, rosa odorifera seed oil, rubus idaeus (raspberry) seed oil, sesamum indica (sesame) seed butter, soy bean glycerides, theobroma cacao (cocoa) seed butter, theobroma grandiflorum seed butter, triticum vulgare (wheat) bran, triticum vulgare (wheat) germ oil, vitis vinifera (grape) seed oil, zea mays (corn) germ oil, and zea mays (corn) oil.

[1073] The vegetable oils specified above are the most common natural lipid components used as base substances for the manufacture of cosmetic or pharmaceutical formulations.

[1074] Hydrocarbons (mineral oils) are generally organic compounds composed entirely of hydrogen and carbon. As defined by IUPAC nomenclature or organic chemistry, hydrocarbons are classified as follows:

[1075] 1. Saturated hydrocarbons are the simplest hydrocarbon substances. They are composed entirely of single bonds and are saturated with hydrogen. The formula for acyclic saturated hydrocarbons (i.e., alkanes) is C n H 2n+2 The most common form of saturated hydrocarbons is Cn H 2n+2(1-r) , where r is the number of rings. Hydrocarbons with exactly one ring are cycloalkanes. Saturated hydrocarbons are the basis of petroleum fuels and are found with straight or branched chains.

[1076] 2. Unsaturated hydrocarbons have one or more double or triple bonds between carbon atoms. Hydrocarbons with double bonds are called olefins. Hydrocarbons with one double bond have the formula C n H 2n (Assuming a non-cyclic structure). Hydrocarbons containing a triple bond are called alkynes. A hydrocarbon with one triple bond has the formula C n H 2n-2 .

[1077] 3. Aromatic hydrocarbons (also called arenes) are hydrocarbons with at least one aromatic ring.

[1078] Hydrocarbons can be liquids (e.g., hexane and benzene), waxes or low melting point solids (e.g., paraffin and naphthalene) in particular. The term "aliphatic" refers to non-aromatic hydrocarbons. Saturated aliphatic hydrocarbons are sometimes referred to as "paraffins". Mineral oils and waxes are mixtures of mainly saturated hydrocarbons consisting of straight, branched and cyclic structures with carbon chain lengths greater than C14. Mineral oils and waxes are chemical substances other than naturally occurring crude oil. They are mainly composed of mineral oil saturated hydrocarbons (MOSH) and mineral oil aromatic hydrocarbons (MOAH). For decades, hydrocarbons have been used in skin and lip care cosmetic products because of their excellent skin tolerance, high protection and cleaning properties and a wide range of viscosity options. Unlike vegetable oils, mineral oils do not cause allergies because they are highly stable and not easily oxidized or rancid.

[1079] Fatty alcohols (or long-chain alcohols) are usually high molecular weight, straight-chain primary alcohols derived from natural fats and oils, but can range from as few as 4 to 6 carbons to as many as 22 to 26 carbons. The exact chain length varies depending on the source. Some commercially important fatty alcohols are lauryl alcohol, stearyl alcohol, and oleyl alcohol. They are colorless oily liquids (for smaller carbon numbers) or waxy solids, but impure samples may appear yellow. Fatty alcohols usually have an even number of carbon atoms and a single alcohol group (-OH) attached to the terminal carbon. Some fatty alcohols are unsaturated, and some fatty alcohols are branched. It is found that most fatty alcohols in nature are waxes, which are esters of fatty acids and fatty alcohols. The traditional sources of fatty alcohols are mostly various vegetable oils, and these are still large-scale raw materials. Alcohols are obtained from triglycerides (triglycerides of fatty acids), which are the main components of oils. The process involves transesterification of triglycerides to obtain methyl esters, which are then hydrogenated to obtain fatty alcohols. Fatty alcohols can also be prepared from petrochemical sources. In the Ziegler process, ethylene is oligomerized using triethylaluminum, followed by air oxidation. Alternatively, ethylene can be oligomerized to give a mixture of olefins, which is hydroformylated, a process that gives odd-numbered aldehydes, which are subsequently hydrogenated. Fatty alcohols are primarily used in the production of detergents and surfactants. They are also a component of cosmetic solvents. They are used in cosmetics as co-emulsifiers, emollients, and thickeners.

[1080] In a preferred variant, the fatty alcohol is selected from the group consisting of phenyl propanol, dimethylphenyl butanol, hexyldecanol, octyldodecanol, octyldodecanol, tridecanol, isostearyl alcohol, phenyl isohexanol, phenyl propanol, trimethylphenyl propanol, isopentanol, isostearyl alcohol and isotridecanol. In a more preferred variant, the fatty alcohol is selected from the group consisting of hexyldecanol, octyldodecanol, phenylpropanol, isopentanol and a mixture of two or more of the above fatty alcohols. The fatty alcohol can be used as a single component or mixed with one or more further different fatty alcohols as specified above.

[1081] Fatty acid esters are a type of ester produced by a combination of fatty acids and alcohols. When the alcohol component is glycerol, the fatty acid ester produced can be a monoglyceride, a diglyceride, or a triglyceride. Fatty acid esters have a conditioning effect that softens the skin to produce a smooth feel. They are also added to cosmetics to dissolve highly polar active ingredients and UV absorbers. Esters of straight-chain fatty acids and lower alcohols are effective for dissolving slightly soluble ingredients in oils with a light touch during application. Isostearic acid and other liquid oils with branched fatty acids and unsaturated fatty acids are commonly used as emollients. Esters of higher fatty acids and higher alcohols with relatively high melting points are added to skin creams to adjust the feel of application.

[1082] Oil bodies and emollients: Sunscreen products, cosmetic or pharmaceutical preparations or home care products according to the invention advantageously include one or more oil bodies or emollients. Emollients are oily or oily substances which contribute to smoothing and softening the skin and which may also reduce skin roughness, cracking or irritation. In particular, in sunscreen products, emollients keep crystalline and oil-soluble organic and inorganic UV filters in a dissolved state and prevent them from recrystallizing. In addition, emollients act as wetting agents for inorganic UV filters in order to disperse them evenly in the formulation. Suitable oil bodies are, for example, Guerbet alcohols based on fatty alcohols having 6 to 18, preferably 8 to 10, carbon atoms, linear C 6 -C 22 -Fatty acids with straight or branched chain C 6 -C 22 - esters of fatty alcohols, or branched C 6 -C 13 -Carboxylic acid with straight or branched C 6 -C 22 - esters of fatty alcohols, such as, for example, myristyl myristate, myristyl palmitate, myristyl stearate, myristyl isostearate, myristyl oleate, myristyl behenate, myristyl erucate, cetyl myristate, cetyl palmitate, cetyl stearate, cetyl isostearate, cetyl oleate, cetyl behenate, cetyl erucate, myristyl stearate, palmitostearate, stearyl stearate, isostearyl stearate, oleyl stearate, behenyl stearate, erucyl stearate, myristyl isostearate, palmitostearate, stearyl stearate, Isostearic acid ester, isostearic acid isostearic acid ester, oleic acid isostearic acid ester, behenic acid isostearic acid ester, oleic acid isostearic acid ester, myristic acid oleic acid ester, palmitic acid oleic acid ester, stearic acid oleic acid ester, isostearic acid oleic acid ester, oleic acid oleic acid ester, behenic acid oleic acid ester, erucic acid oleic acid ester, myristic acid behenic acid ester, palmitic acid behenic acid ester, stearic acid behenic acid ester, isostearic acid behenic acid ester, oleic acid behenic acid ester, behenic acid behenic acid ester, behenic acid erucic acid ester, myristic acid sinapic acid ester, palmitic acid sinapic acid ester, stearic acid sinapic acid ester, isostearic acid sinapic acid ester, oleic acid sinapic acid ester, behenic acid sinapic acid ester and erucic acid ester. Also suitable are straight chain C 6 -C 22 - Esters of fatty acids with branched alcohols, especially 2-ethylhexanol, C 18 -C 38 -Alkyl hydroxycarboxylic acid with straight or branched C 6 -C 22 - esters of fatty alcohols, in particular dioctyl malate, esters of linear and / or branched fatty acids with polyols (such as, for example, propylene glycol, dimer or trimer) and / or Guerbet alcohols, based on C 6 -C 10 Triglycerides of fatty acids, based on C 6 -C 18-Liquid mono- / di- / triglyceride mixture of fatty acids, C 6 -C 22 - esters of fatty alcohols and / or Guerbet alcohols with aromatic carboxylic acids, in particular benzoic acid, C 2 -C 12 - esters of dicarboxylic acids with straight-chain or branched alcohols having 1 to 22 carbon atoms or polyols having 2 to 10 carbon atoms and 2 to 6 hydroxyl groups, vegetable oils, branched primary alcohols, substituted cyclohexanes, straight-chain and branched C 6 -C 22 - fatty alcohol carbonates such as, for example, dicaprylyl carbonate ( CC), Guerbet carbonates based on fatty alcohols having 6 to 18, preferably 8 to 10, carbon atoms, having linear and / or branched C 6 -C 22 -Alcohol benzoate (e.g. TN), a linear or branched, symmetrical or asymmetrical dialkyl ether having 6 to 22 carbon atoms in each alkyl group, such as, for example, dioctyl ether ( OE), ring-opening products of epoxidized fatty acid esters with polyols, silicone oils (cyclomethicone, siloxane methicone grade, etc.) and / or aliphatic or cycloalkane such as, for example, squalane, squalene or dialkylcyclohexanes, and any mixtures thereof.

[1083] Powder: The composition as defined herein may optionally comprise a powder. The optional powder provides a formulation that makes the skin smoother and softer. Representative powders include talc, mica, magnesium carbonate, calcium carbonate, magnesium silicate, magnesium aluminum silicate, silicon dioxide, titanium dioxide, zinc oxide, red iron oxide, yellow iron oxide, black iron oxide, polyethylene powder, methacrylate powder, polystyrene powder, silk powder, which can be a component of the composition according to the present invention. Preferred solid powder materials are hydrocolloids such as starch, degraded starch, chemically or physically modified starch, dextrin, (powdered) maltodextrin (preferably with a dextrose equivalent value of 5 to 25, preferably 10-20), lactose, silicon dioxide, glucose, modified cellulose, gum arabic, gum ghatti, tragacanth, karaya gum, carrageenan, pullulan, curdlan, xanthan gum, gellan gum, guar flour, carob flour, alginates, agar, pectin, inulin and mixtures of two or more of these solids (preferably with a dextrose equivalent value of 15-20), lactose, silicon dioxide and / or glucose.

[1084] Rheology modifier: The sunscreen product, cosmetic or pharmaceutical formulation or home care product according to the present invention advantageously includes one or more thickeners and / or rheology modifiers. The rheology modifier is present in an amount to prevent significant dripping or pooling of the composition after application to the skin or surface. Preferably, the rheology modifier is a carbomer. In some embodiments, the rheology modifier is selected from stearic acid, palmitic acid, stearyl alcohol, hexadecanol, behenyl alcohol, stearic acid, palmitic acid, polyethylene glycol ethers of stearyl alcohol having an average of about 1 to about 21 ethylene oxide units, polyethylene glycol ethers of hexadecanol having an average of about 1 to about 5 ethylene oxide units, and mixtures thereof.

[1085] Other examples of rheology modifiers include thickeners or gelling agents, including materials that can increase the viscosity of the composition. Thickeners include those that can increase the viscosity of the composition without substantially changing the efficacy of the active ingredient in the formulation. Thickeners can also increase the stability of the formulation of the present application. In certain aspects of the present application, thickeners include hydrogenated polyisobutylene or trihydroxystearin, or a mixture of the two. Other non-limiting examples of other thickeners that can be used in the context of the present application include carboxylic acid polymers, cross-linked polyacrylate polymers, polyacrylamide polymers, polysaccharides and gums. Examples of carboxylic acid polymers include cross-linked compounds containing one or more monomers derived from acrylic acid, substituted acrylic acid, and salts and esters of these acrylic acid and substituted acrylic acid, wherein the cross-linking agent contains two or more carbon-carbon double bonds, and is derived from polyols (see CTFA International Cosmetic Ingredient Dictionary, Fourth Edition, 1991, pages 12 and 80). Examples of commercially available carboxylic acid polymers include carbomers, which are homopolymers of acrylic acid crosslinked with allyl ethers of sucrose or pentaerythritol (e.g., Carbopol from BF Goodrich). TM 900 Series). Non-limiting examples of cross-linked polyacrylate polymers include cationic and nonionic polymers.

[1086] Non-limiting examples of polyacrylamide polymers (including nonionic polyacrylamide polymers, including substituted branched or unbranched polymers) include polyacrylamide, isoparaffin and laureth-7, multi-block copolymers of acrylamide and substituted acrylamides with acrylic acid and substituted acrylic acid.

[1087] Non-limiting examples of polysaccharides include cellulose, carboxymethyl hydroxyethyl cellulose, cellulose acetate propionate carboxylate, hydroxyethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, methyl hydroxyethyl cellulose, microcrystalline cellulose, sodium cellulose sulfate, and mixtures thereof. Another example is alkyl-substituted cellulose, in which the hydroxyl groups of the cellulose polymer are hydroxyalkylated (preferably hydroxyethylated or hydroxypropylated) to form hydroxyalkylated cellulose, which is then further modified with a C10-C30 straight or branched chain alkyl group via an ether linkage. Typically, these polymers are ethers of a C10-C30 straight or branched chain alcohol and a hydroxyalkyl cellulose. Other useful polysaccharides include scleroglucan, which includes a linear chain of (1 to 3) linked glucose units, with one (1 to 6) linked glucose per three units.

[1088] Non-limiting examples of gums that can be used with the compositions of the present invention include gum arabic, agar, alginates, alginic acid, ammonium alginate, pullulan, calcium alginate, calcium carrageenan, carnitine, carrageenan, dextrin, gelatin, gellan gum, guar gum, guar hydroxypropyltrimonium chloride, hectorite, hyaluronic acid, hydrated silica, hydroxypropyl chitosan, hydroxypropyl guar gum, karaya gum, kelp, locust bean gum, natto gum, potassium alginate, potassium carrageenan, propylene glycol alginate, sclerotium gum, sodium carboxymethyl dextran, sodium carrageenan, tragacanth gum, xanthan gum, and mixtures thereof. In one embodiment, the thickener is an extract of chondrus crispus (carrageenan).

[1089] Film formers: The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the invention may advantageously comprise one or more film formers or film-forming agents. Film formers are hydrophobic materials which impart water resistance and film-forming properties to the sunscreen product, cosmetic or pharmaceutical preparation or home care product. Standard film formers are preferably chitosan, microcrystalline chitosan, quaternized chitosan, polyvinylpyrrolidone, vinylpyrrolidone / vinyl acetate copolymers, polymers of the acrylic acid series, quaternary cellulose derivatives, collagen, hyaluronic acid and their salts and similar compounds. Preferred film formers for improving the water resistance of the composition are selected from the group consisting of polyamide-8 (such as Oleocraft LP20 PA (MV)), polyamide-3 (such as Oleocraft MP 32 PA (MV)), trimethylpentanediol / adipic acid / glycerin crosspolymer (such as WetFilm), octyldodecyl citrate crosspolymer (such as CosmoSurf CE 100), polyglyceryl-3 methylglucose distearate (such as TegoCare 450), C28-52 olefin / undecenoic acid copolymer (such as Performa V6112), hydrolyzed jojoba esters, jojoba esters, water agents (such as Floraester Jojoba K100), cyclopentasiloxane acrylate / dimethicone copolymer (such as KP545), acrylates / beheneth-25 methacrylate copolymer (such as Volarest), styrene / acrylates copolymer (such as Dermacryl E polymer), polyurethanes (such as Baycusan C1001), polyurethane-2 and polymethyl methacrylate (such as Hybridur 875 polymer), acrylates / octylacrylamide copolymer (such as Dermacryl 2.0 polymer), beeswax (Cera alba) (and) sodium stearoyl lactylate (such as SymEffect Sun), pullulan, xanthan gum, hydrogenated palm oil, sugar cane extract (SymEffect TM UV), microcrystalline cellulose (and) Sphingomonas ferment extract (and) cellulose gum (such as PemuPur TM START polymers), gum arabic and xanthan gum (such as SOLAGUA™ AX), microcrystalline cellulose (and) cellulose gum (such as SOLAGUM TM AX), microcrystalline cellulose (and) cellulose gum (such as Natpure Cellgum Plus), sodium stearoyl glutamate (such as HS-11P), hydrogenated polycyclopentadiene (and) caprylic / capric triglyceride (such as 5400CCT), Hydrogenated Rosin Glycerides (and) Caprylic / Capric Triglycerides (and) Tocopherol (such as NATURAL 2063-CCT), galactoarabinan (such as A 200), C26-28 alkyl dimethicone (such as Wacker CDM 3526VP), caprylyl methicone (such as Silsoft 034), stearyl dimethicone (and) octadecene (such as Dowsil 2503 Cosmetic Wax), VP / hexadecene copolymer (such as Antaron TM V 216), triacontanyl PVP (such as Antaron TM WP-660), caprylylglycerol / sebacic acid copolymer (such as LexFilm TM SunNatural MB), poly C10-30 alkyl acrylate (such as Tego SP 13 Sun Up), microcrystalline cellulose (such as Sunspheres TM BIO SPF Booster) and any mixtures thereof. The aforementioned film formers are used as a single component or preferably mixed with two or more of the film formers as specified above in sunscreens, cosmetic or pharmaceutical preparations or home care products. The film former is used in an effective amount that allows the final formulation to remain on the skin or surface after exposure to circulating water for at least 40 minutes, preferably 80 minutes. The film former is present in the sunscreen product, cosmetic or pharmaceutical preparation or home care product in an amount of 0.01 to 10.0 wt. %, preferably 0.05 to 8.0 wt. %, based on the total weight of the final formulation.

[1090] Water resistance improver: Sunscreen products, cosmetic or pharmaceutical preparations or home care products according to the present invention may advantageously include one or more agents for improving water resistance. Agents for improving water resistance are hydrophobic materials that impart film-forming properties and water resistance properties to the emulsion. Typical suitable water resistance improvers include copolymers derived from the polymerization of octadecene-1 and maleic anhydride. Preferred water resistance improvers are polyanhydride resins. Another preferred water resistance improver is a copolymer of vinyl pyrrolidone and eicosene monomers. The water resistance improver is used in an amount that effectively allows the final formulation to remain on the skin or surface after being exposed to circulating water for at least 40 minutes, preferably 80 minutes. Based on the total weight of the final formulation, one or more water resistance improvers may optionally be included in the final formulation in an amount ranging from 0.01% to 10.0% by weight, preferably from 0.05% to 8.0% by weight, and more preferably from 0.1% to 5.0% by weight.

[1091] Silicones: In order to impart a silky, spreadable and luxurious texture and to make the skin look and feel smoother, and also to improve processability (defoaming), the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the invention preferably comprises one or more silicones or silicone derivatives. The total amount of silicone compounds in the composition according to the invention may occur, but is generally from 0.1% to 35.0% by weight, based on the total weight of the composition.

[1092] Dry feel modifier: The sunscreen product or cosmetic or pharmaceutical formulation according to the present invention is preferably combined with a dry feel modifier. A dry feel modifier is an agent that, when incorporated into an emulsion, imparts a "dry feel" to the skin when the emulsion dries. Dry feel modifiers may also reduce the migration of sunscreens on the skin. Dry feel modifiers may include starch, talc, kaolin, chalk, zinc oxide, hydroxyapatite (such as Tinomax CC), silicone fluids, inorganic salts (such as barium sulfate and sodium chloride), C6 to C12 alcohols (such as octanol); sulfonated oils; surface treated silica, precipitated silica, fumed silica, such as those available from Degussa Inc., New York, USA or mixtures thereof; dimethicone, a mixture of a mixture of methylated linear siloxane polymers, available as DC200 fluid under the trade name Dow Corning, Midland, Mich. USA. One or more dry feel modifiers may optionally be included in the sunscreen in an amount ranging from 0.01 wt % to 20 wt %, more preferably from 0.1 wt % to 10.0 wt %.

[1093] Soothing substances: The sunscreen product or cosmetic or pharmaceutical preparation according to the invention may also advantageously contain one or more soothing substances, wherein any soothing substance suitable or commonly used in cosmetic or pharmaceutical applications may be used, such as α-bisabolol, azulene, guaiacene, 18-β-glycyrrhetinic acid, allantoin, aloe vera juice or gel, Hamamelis Virginiana (Witch Hazel), Echinacea, Centella Asiatica, Chamomile, Arnica, Licorice, algae, seaweed and calendula extracts and vegetable oils (such as sweet almond oil, baobab oil), olive oil and panthenol, Laureth-9, Trideceth-9 and 4-tert-butylcyclohexanol.

[1094] Physiological cooling agents: The sunscreen products or cosmetic or pharmaceutical preparations according to the invention can be combined with one or more physiological cooling agents with particular advantage. The use of cooling agents can relieve itching. Preferred individual cooling agents for use within the scope of the present invention are listed below. A person skilled in the art can add many other cooling agents to this list; the cooling agents listed can also be used in combination with one another, and these cooling agents are preferably selected from the following list: menthol and menthol derivatives (e.g. L-menthol, D-menthol, racemic menthol, isomenthol, neoisomenthol), menthyl ethers (e.g. (I-menthoxy)-1,2-propanediol, (L-menthoxy)-2-methyl-1,2-propanediol, l-menthyl-methyl ether), menthone glycerol acetal, menthone glycerol ketal or a mixture of the two, menthyl esters (e.g. menthyl formate, menthyl acetate, menthyl isobutyrate, menthyl hydroxyisobutyrate, menthyl lactate, L-menthyl acetate, menthyl acetate, menthyl isobutyrate, menthyl hydroxyisobutyrate, menthyl lactate, L-menthyl acetate, menthyl acetate, menthyl hydroxyisobutyrate, menthyl lactate, L-menth ... Menthyl-L-lactate, L-menthyl-D-lactate, menthyl-(2-methoxy-)acetate, menthyl-(2-methoxyethoxy)acetate, menthyl pyroglutamate), menthyl carbonates (e.g. menthyl propylene glycol carbonate, menthyl ethylene glycol carbonate, menthyl glycerol carbonate or mixtures thereof), half esters of menthol with dicarboxylic acids or their derivatives (e.g. monomenthyl succinate, monomenthyl glutarate, monomenthyl malonate, O-menthyl succinate-N,N-(dimethyl)amide, O-menthyl succinate amide), menthanecarboxylic acid amides (in this case preferably menthanecarboxylic acid-N-acetamide [WS3] or N-(menthyl) succinate-N-acetamide [WS4] or N-(menthyl) succinate-N-acetamide [WS5] or N-(menthyl) succinate-N-acetamide [WS6] or N-(menthyl) succinate-N-acetamide [WS7] or N-(menthyl) succinate-N-acetamide [WS8] or N-(menthyl) succinate-N-acetamide [WS9] or N-(menthyl) succinate-N-acetamide [WS3] αWS5], menthanecarboxylic acid-N-(4-cyanophenyl)amide or menthanecarboxylic acid-N-(-4-cyanomethylphenyl)amide, menthanecarboxylic acid-N-(alkoxyalkyl)amide), menthone and menthone derivatives (e.g. L-menthone glycerol ketal), 2,3-dimethyl-2-(2-propyl)-butyric acid derivatives (e.g. 2,3-dimethyl-2-(2-propyl)-butyric acid-N-methylamide [WS23]), isopulegol or its esters (1-(-)-isopulegol, 1-(-)-isopulegol acetate), menthane derivatives (e.g. p-menthane-3,8-diol), cubebol or synthetic or natural mixtures containing cubebol, pyrrolidone derivatives of cycloalkyldione derivatives (e.g. 3-methyl-2(1-pyrrolidinyl)-2-cyclopenten-1-one) or tetrahydropyrimidin-2-one (e.g. WO iciline or related compounds as described in 2004 / 026840), other carboxamides (e.g. N-(2-(pyridin-2-yl)ethyl)-3-p-menthanecarboxamide or related compounds), (1R,2S,5R)-N-(4-methoxyphenyl)-5-methyl-2-(1-isopropyl)cyclohexanecarboxamide [WS12], oxalates and [(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl]2-(ethylamino)-2-oxo-acetate (Xcool). Preferred coolants due to their special synergistic effects are l-menthol, d-menthol, racemic menthol, menthone glycerol acetal (trade name: MGA), menthyl lactate (preferably l-menthyl lactate, especially l-menthyl lactate (trade name: ML)), substituted menthyl-3-carboxamides (such as menthyl-3-carboxylic acid N-ethylamide), 2-isopropyl-N-2,3-trimethylbutyramide, substituted cyclohexanecarboxamides, 3-menthoxypropane-1,2-diol, 2-hydroxyethyl menthyl carbonate, 2-hydroxypropyl menthyl carbonate and isopulegol. Particularly preferred cooling agents are l-menthol, racemic menthol, menthone glycerol acetal (trade name: MGA), menthyl lactate (preferably l-menthyl lactate, especially l-menthyl lactate (trade name: ML)), 3-menthoxypropane-1,2-diol, 2-hydroxyethyl menthyl carbonate and 2-hydroxypropyl menthyl carbonate. Very particularly preferred cooling agents are l-menthol, menthone glycerol acetal (trade name: MGA) and menthyl lactate (preferably l-menthyl lactate, especially l-menthyl lactate (trade name: ML)).

[1095] Alkanediols: In another preferred variant, the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the invention comprises one or more linear alkanediols having a carbon chain of 5 to 12 carbon atoms. Preferably, the one or more linear alkanediols are selected from the group consisting of 1,2-alkanediol, 2,3-alkanediol, 3,4-alkanediol and 1,3-alkanediol, more preferably 2,3-alkanediol and 1,3-alkanediol. Most preferably, the linear alkanediol is selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol, 1,2-nonanediol, 1,2-decanediol, 1,2-undecanediol, 1,2-dodecanediol, 2,3-pentanediol, 2,3-hexanediol, 2,3-heptanediol, 2,3-octanediol, 2,3-nonanediol, 2,3-decanediol, 2,3-undecanediol and 2,3-dodecanediol.

[1096] Initial observations by the inventors surprisingly showed that compositions according to the invention comprising one or more linear alkanediols having a carbon chain of 5 to 12 carbon atoms (preferably as defined herein) show particularly advantageous emulsifying properties. In particular, it was surprisingly found that one or more of said linear alkanediols (in the case of not being an emulsion itself) support the formation of water or oil droplets having a particularly small average size in the emulsion or (in the case of an emulsion itself) contain water or liquid droplets having a particularly small average size.

[1097] In addition, it has been found that the presence of an alkanediol, in particular 1,2-alkanediol or 2,3-alkanediol, increases the solubility of the oil component, such as one or more oil bodies or waxes, in the sunscreen product, cosmetic or pharmaceutical formulation or home care product according to the invention. Preferably, the oil body or wax is selected from the group consisting of natural fats and oils, fatty alcohols and alcohols, glycerides and derivatives thereof, esters, ethers, silicones and silanes, waxes and cycloalkanes, preferably from the group consisting of squalene, dialkylcyclohexanes, tetradecane, isohexadecane, dodecane, docosane, paraffin and mineral oil, and is further described below.

[1098] The combination of one or more of the alkanediols and 4-hydroxyacetophenone generally in an amount of 0.1 to 2 wt. %, more preferably 0.1 to 1 wt. %, increases the solubility of the oil component even in a synergistic manner.

[1099] Preferably, the composition comprises 0.01% to 10% by weight, more preferably 0.1% to 5% by weight, still more preferably 0.3% to 3% by weight, most preferably 0.5% to 1% by weight of said linear alkanediol having a carbon chain of 5 to 12 carbon atoms and as defined herein, based on the total weight of the composition.

[1100] Antioxidants: Sunscreen products, cosmetic or pharmaceutical preparations or home care products according to the invention advantageously include one or more antioxidants. Suitable antioxidants include amino acids (preferably glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (preferably urocanic acid) and their derivatives, peptides (preferably D,L-carnosine, D-carnosine, L-carnosine) and their derivatives (preferably anserine), carnitine, creatine, matrikine peptides (preferably lysyl-threonyl-threonyl-lysylserine) and palmitoylated pentapeptides, carotenoids, carotenes (preferably α-carotene, β-carotene, lycopene) and their derivatives, lipoic acid and its derivatives (preferably dihydrolipoic acid) in very small tolerated doses (e.g. pmol to μmol / kg). , aurothioglucose, propylthiouracil and other thiols (preferably thioredoxin, glutathione, cysteine, cystine, cystamine and glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, γ-linoleyl, cholesteryl, glyceryl and oligoglycerols thereof) and their salts, dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and its derivatives (preferably esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) and sulfoxide amine compounds (preferably buthionine sulfoxide amine, homocysteine ​​sulfoxide amine, buthionine sulfoxide ether sulfone, penta-, hexa- and heptathionine sulfoxide amine), also (metal) chelators (preferably α-hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin, α-hydroxy acids (preferably citric acid, lactic acid, malic acid), humic acid, bile acid, bile extract, tannic acid, bilirubin, biliverdin, EDTA, EGTA and derivatives thereof), unsaturated fatty acids and derivatives thereof (preferably γ-linoleic acid, linoleic acid, oleic acid), folic acid and derivatives thereof, ubiquinone and derivatives thereof, vitamin C and derivatives (preferably ascorbyl palmitate, magnesium ascorbyl phosphate, ascorbyl acetate, ascorbyl glucoside), tocopherol and derivatives (preferably vitamin E acetate), vitamin A and derivatives (vitamin A palmitate) and benzoin resin coniferyl benzoate, rutinic acid and its derivatives, flavonoids and their glycosylated precursors, in particular quercetin and its derivatives, preferably α-glucosylrutin, rosmarinic acid, carnosin, carnosic acid, resveratrol, caffeic acid and its derivatives, sinapinic acid and its derivatives, ferulic acid and its derivatives, curcumin, chlorogenic acid and its derivatives, retinoids, preferably retinyl palmitate, retinol or retinoic acid, ursolic acid, levulinic acid, butylated hydroxytoluene, butylated hydroxyanisole, dehydroguaiac acid, nordihydroguaiaretic acid, trihydroxybutyrophenone, uric acid and its derivatives, mannose and its derivatives, zinc and its derivatives (preferably ZnO, ZnSO 4), selenium and its derivatives (preferably selenomethionine), superoxide dismutase, stilbene and its derivatives (preferably stilbene oxide, trans-stilbene oxide), and derivatives (salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids) of these cited active ingredients, as well as extracts or fractions of plants having an antioxidant effect, preferably green tea, rooibos, honeybush, grape, rosemary, sage, lemon balm, thyme, lavender, olive, oat, cocoa, ginkgo, ginseng, liquorice, honeysuckle, sophora japonica, kudzu root, pine, citrus, emblica or St. John's wort, grape seed, wheat germ, emblica, coenzyme, preferably coenzyme Q10, plastoquinone and menaquinone. Preferred antioxidants are selected from the group consisting of vitamin A and derivatives, vitamin C and derivatives, tocopherol and derivatives, preferably tocopherol acetate and ubiquinone.

[1101] Emulsifier: Furthermore, the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the invention may advantageously contain one or more emulsifiers. Emulsifiers include amphoteric, anionic, cationic or nonionic emulsifiers which can be used alone or in mixture. The emulsifier is selected in a suitable manner depending on the emulsion to be obtained. Preferred examples include:

[1102] - Add 2 mol to 30 mol of ethylene oxide and / or 0 mol to 5 mol of propylene oxide to the linear C 8-22 Fatty alcohol, C 12-22 Products of fatty acids and alkylphenols containing 8 to 15 carbon atoms in the alkyl group;

[1103] - C of the product of adding 1 mol to 30 mol of ethylene oxide to glycerol 12 / 18 Fatty acid monoesters and diesters;

[1104] - mono- and di-glycerides, mono- and di-sorbitol esters and ethylene oxide addition products thereof of saturated and unsaturated fatty acids containing from 6 to 22 carbon atoms;

[1105] - products of the addition of 15 to 60 mol of ethylene oxide onto castor oil and / or hydrogenated castor oil;

[1106] - polyol esters, and in particular polyglycerol esters, such as, for example, polyglycerol polyricinoleate, polyglycerol poly-12-hydroxystearate or polyglycerol dimethyl isostearate. Mixtures of compounds from several of these classes are also suitable;

[1107] - products of the addition of 2 to 15 mol of ethylene oxide onto castor oil and / or hydrogenated castor oil;

[1108] - Based on straight chain, branched, unsaturated or saturated C 6 / 22Fatty acids, ricinoleic acid and 12-hydroxystearic acid and glycerol, polyglycerol, pentaerythritol, dipentaerythritol, sugar alcohols (e.g. sorbitol), alkyl glucosides (e.g. methyl glucoside, butyl glucoside, lauryl glucoside) and polyglucosides (e.g. cellulose);

[1109] - mono-, di- and tri-alkyl phosphates and mono-, di- and / or tri-PEG-alkyl phosphates and their salts;

[1110] -Wool wax alcohol;

[1111] - polysiloxane / polyalkyl polyether copolymers and corresponding derivatives;

[1112] - pentaerythritol, fatty acids, citric acid and fatty alcohols and / or C 6-22 Mixed esters of fatty acids, methyl glucose and polyols, preferably glycerol or polyglycerol,

[1113] -polyalkylene glycol and

[1114] -Glyceryl carbonate.

[1115] Products of the addition of ethylene oxide and / or propylene oxide to fatty alcohols, fatty acids, alkylphenols, glycerol monoesters and diesters and sorbitan monoesters and diesters of fatty acids or to castor oil are known products which are commercially available. They are homologous mixtures whose average degree of alkoxylation corresponds to the ratio between the amount of ethylene oxide and / or propylene oxide and the amount of substrate subjected to the addition reaction. The C of the addition products of ethylene oxide onto glycerol is 12 / 18 Fatty acid monoesters and diesters are known as lipid layer enhancers for cosmetic formulations. Preferred emulsifiers are described in more detail below:

[1116] Partial glycerides: Typical examples of suitable partial glycerides are hydroxystearic acid monoglyceride, hydroxystearic acid diglyceride, isostearic acid monoglyceride, isostearic acid diglyceride, oleic acid monoglyceride, oleic acid diglyceride, ricinoleic acid monoglyceride, ricinoleic acid diglyceride, linoleic acid monoglyceride, linoleic acid diglyceride, linolenic acid monoglyceride, linolenic acid diglyceride, erucic acid monoglyceride, erucic acid diglyceride, tartaric acid monoglyceride, tartaric acid diglyceride, citric acid monoglyceride, citric acid diglyceride, malic acid monoglyceride, malic acid diglyceride and technical mixtures thereof, which may still contain small amounts of triglycerides from the production process. Also suitable are products of the addition of 1 to 30 and preferably 5 to 10 mol of ethylene oxide to the partial glycerides mentioned.

[1117] Sorbitan esters: Suitable sorbitan esters are sorbitan monoisostearate, sorbitan sesquiisostearate, sorbitan diisostearate, sorbitan triisostearate, sorbitan monooleate, sorbitan sesquioleate, sorbitan dioleate, sorbitan trioleate, sorbitan monoerucate, sorbitan hemierucate, sorbitan glycerol dierucate, sorbitan monoricinoleate, sorbitan sesquiricinoleate, sorbitan diricinoleate, sorbitan triricinoleate, sorbitan monooleate, sorbitan sesquioleate, sorbitan dioleate, sorbitan trioleate, sorbitan monoerucate, sorbitan hemierucate, sorbitan glycerol dierucate, sorbitan monoricinoleate, sorbitan sesquiricinoleate, sorbitan diricinoleate, sorbitan triricinoleate, sorbitan monooleate, sorbitan sesquioleate, sorbitan dioleate, sorbitan trioleate, sorbitan monoerucate, sorbitan Sugar alcohol monohydroxystearate, sorbitan sesquihydroxystearate, sorbitan dihydroxystearate, sorbitan trihydroxystearate, sorbitan monotartrate, sorbitan sesquitartrate, sorbitan ditartrate, sorbitan tritartrate, sorbitan monocitrate, sorbitan sesquicitrate, sorbitan dicitrate, sorbitan tricitrate, sorbitan monomaleate, sorbitan sesquimaleate, sorbitan dimaleate, sorbitan trimalate and technical mixtures thereof. Also suitable are products of the addition of 1 to 30 and preferably 5 to 10 mol of ethylene oxide to the sorbitan esters mentioned.

[1118] Polyglycerol esters: A typical example of a suitable polyglycerol ester is polyglyceryl-2 dipolyhydroxystearate ( PGPH), Polyglyceryl-3 Diisostearate ( TGI), polyglyceryl-4 isostearate ( GI 34), Polyglyceryl-3 Oleate, Polyglyceryl-3 Diisostearate ( PDI), polyglyceryl-3 methyl glucose distearate (Tego 450), Polyglyceryl-3 Beeswax (Cera )、Polyglyceryl-4 Caprate (Polyglyceryl Caprate T2010 / 90), Polyglyceryl-3 Cetyl Ether ( NL), polyglyceryl-3 distearate ( GS 32) and polyglyceryl polyricinoleate ( WOL 1403), polyglyceryl dimethyl ether isostearate and mixtures thereof. Other examples of suitable polyol esters are monoesters, diesters and triesters of trimethylolpropane or pentaerythritol with lauric acid, coconut fatty acid, tallow fatty acid, palmitic acid, stearic acid, oleic acid, behenic acid and the like, optionally reacted with 1 mol to 30 mol of ethylene oxide.

[1119] Anionic emulsifiers: Typical anionic emulsifiers are aliphatic C12-C22 fatty acids, such as palmitic acid, stearic acid or behenic acid, and C12-C22 dicarboxylic acids, such as azelaic acid or sebacic acid, for example potassium cetyl phosphate, and hydrogenated palm glycerides (Emulsiphos / Emulsiphos F).

[1120] Amphoteric emulsifiers: Other suitable emulsifiers are amphoteric or zwitterionic surfactants. Zwitterionic surfactants are surface-active compounds which contain at least one quaternary ammonium group and at least one carboxylate and one sulfonate group in the molecule. Particularly suitable zwitterionic surfactants are the so-called betaines, such as N-alkyl-N,N-dimethylammonium glycinates, for example cocoalkyldimethylammonium glycinate, N-amidopropyl-N,N-dimethylammonium glycinates, for example cocoamidopropyldimethylammonium glycinate and 2-alkyl-3-carboxymethyl-3-hydroxyethylimidazolines and cocoamidoethylhydroxyethylcarboxymethylglycinate containing 8 to 18 carbon atoms in the alkyl or acyl group. Particularly preferred are the fatty acid amide derivatives known under the CTFA name cocamidopropyl betaine. Amphoteric surfactants are also suitable emulsifiers. Amphoteric surfactants are, in addition to C 8 / 18 In addition to an alkyl or acyl group, the molecule also contains at least one free amino group and at least one -COOH- or -SO 3 H-group and capable of forming internal salts. Examples of suitable amphoteric surfactants are N-alkyl glycines, N-alkyl propionic acids, N-alkyl aminobutyric acids, N-alkyl iminodipropionic acids, N-hydroxyethyl-N-alkylaminopropyl glycine, N-alkyl taurine, N-alkyl sarcosine, 2-alkyl aminopropionic acids and alkyl aminoacetic acids, which contain about 8 to 18 carbon atoms in the alkyl group. Particularly preferred amphoteric surfactants are N-cocoalkyl aminopropionate, cocoacyl aminoethyl aminopropionate and C12 / 18 acyl sarcosine.

[1121] Anti-aging active substances: The composition according to the invention is preferably combined with one or more anti-aging active substances. In the context of the present invention, anti-aging agents or biogenic agents are, for example, antioxidants, matrix metalloproteinase inhibitors (MMPIs), skin moisturizers, glycosaminoglycan stimulators, anti-inflammatory agents, TRPV1 antagonists and plant extracts.

[1122] Matrix metalloproteinase inhibitors (MMPI): The composition according to the invention is preferably combined with one or more matrix metalloproteinase inhibitors, especially those inhibitors that inhibit the enzymatic cleavage of collagen by matrix metalloproteinases, which inhibitors are selected from the group consisting of ursolic acid, retinyl palmitate, propyl gallate, prosole, 6-hydroxy-7-methoxy-2,2-dimethyl-1(2H)-benzopyran, 3,4-dihydro-6-hydroxy-7-methoxy-2,2-dimethyl-1(2H)-benzopyran, benzamidine hydrochloride, cysteine ​​protease inhibitor N-ethyl Serine protease inhibitors of phenylmethylsulfonyl fluoride, collhibin (Pentapharm; INCI: hydrolyzed rice protein), oenotherol (Soliance; INCI: propylene glycol, water, evening primrose root extract, ellagic acid and ellagitannins, e.g. from pomegranate), phosphamidone hinokitiol, EDTA, MGDA (trisodium dicarboxymethyl alanine), galardin, EquiStat (Collaborative Group company; apple fruit extract, soybean seed extract, ursolic acid, soy isoflavones and soy protein), sage extract, MDI (Atrium company; INCI: glycosaminoglycans), fermiskin (Silab / Mawi company; INCI: water and shiitake mushroom extract), actimp 1.9.3 (Expanscience / Rahn company; INCI: hydrolyzed lupine protein), soy isoflavones (Mibelle company; INCI: ethanol, polysorbate 80, lecithin and soy isoflavones), green and black tea extracts and other plant extracts, proteins or glycoproteins from soy, hydrolyzed proteins from rice, pea or lupine, plant extracts that inhibit MMP, preferably from shiitake mushrooms, extracts from leaves of the Rosaceae subfamily, in particular from blackberry leaves, such as, for example, SymMatrix (Symrise company, INCI: maltodextrin, cranberry (blackberry) leaf extract). Preferred active ingredients are selected from the group consisting of retinyl palmitate, ursolic acid, Rosaceae Rosaceae leaf extract, genistein and soy flavonoids.

[1123] Skin moisturizing and / or water-retaining substances: Sunscreen products or cosmetic or pharmaceutical preparations according to the present invention advantageously include one or more skin moisturizing and / or water-retaining substances. Preferred skin moisturizing and / or water-retaining substances are selected from alkanediols or alkanetriols comprising 3 to 12 carbon atoms, preferably C 3 -C 10 -Alkanediol and C 3 -C 10More preferably, the skin moisturizer is selected from the group consisting of glycerol, 1,2-propylene glycol, 1,2-butylene glycol, 1,3-butylene glycol, 1,2-pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol and 1,2-decanediol. Other skin moisturizing and / or water-retaining substances include sodium lactate, urea, urea derivatives, alcohols, glycerol, glycols such as propylene glycol, hexylene glycol, collagen, elastin or hyaluronic acid, diacyl adipate, petrolatum, urocanic acid, lecithin, panthenol, phytantriol, lycopene, (pseudo)ceramides, glycosphingolipids, cholesterol, phytosterols, chitosan, chondroitin sulfate, lanolin, lanolin esters, amino acids, α-hydroxy acids (such as citric acid, lactic acid, malic acid) and their derivatives, monosaccharides, disaccharides and oligosaccharides such as glucose, galactose, fructose, mannose, fructose and lactose, polysaccharides such as R-glucans, in particular 1,3-1,4-β-glucans from oats, α-hydroxy fatty acids, triterpene acids such as betulinic acid or ursolic acid, and algae extracts.

[1124] Glycosaminoglycan stimulators: Preferred compositions according to the invention comprise one or more substances stimulating the synthesis of glycosaminoglycans selected from the group consisting of: hyaluronic acid and its derivatives or salts, Subliskin (Sederma, INCI: Sinorhizobium meliloti ferment filtrate, cetyl hydroxyethylcellulose, lecithin), Hyalufix (BASF, INCI: water, butylene glycol, Alpinia galanga leaf extract, xanthan gum, caprylic / capric triglyceride), Stimulhyal (Soliance, INCI: calcium ketogluconate), Syn-Glycan (DSM, INCI: tetradecylaminobutyryl valyl aminobutyric acid urea trifluoroacetate, glycerin, magnesium chloride), Kalpariane (Biotech Marine), DC Upregulex (Distinctive Cosmetic Ingredients). Ingredients), INCI: water, butylene glycol, phospholipids, hydrolyzed sericin), glucosamine, N-acetyl glucosamine, retinoids, preferably retinol and vitamin A, burdock fruit extract, loquat extract, genkwain, N-methyl-L-serine, (-)-α-bisabolol or synthetic α-bisabolol, such as, for example, Dragosantol and Dragosantol 100 from Symrise, oat glucan, echinacea extract and soy protein hydrolysate. Preferred active substances are selected from the group consisting of hyaluronic acid and its derivatives or salts, (-)-α-bisabolol or synthetic α-bisabolol, such as, for example, Dragosantol and Dragosantol 100 from Symrise, oat glucan, Echinacea extract, Sinorhizobium meliloti ferment filtrate, calcium ketogluconate, Alpinia galanga leaf extract and tetradecylaminobutyryl valylaminobutyric acid urea trifluoroacetate.

[1125] Anti-inflammatory agents: The composition according to the present invention is preferably combined with anti-inflammatory and / or redness and / or itching improving ingredients, in particular, steroid substances selected from the group consisting of hydrocortisone, dexamethasone, dexamethasone phosphate, methylprednisolone or cortisone are advantageously used as anti-inflammatory active ingredients or active ingredients for reducing redness and itching, and its list can be expanded by adding other steroidal anti-inflammatory drugs. Non-steroidal anti-inflammatory drugs can also be used. More specifically:

[1126] (i) steroidal anti-inflammatory substances of the corticosteroid type, in particular hydrocortisone, hydrocortisone derivatives such as hydrocortisone 17-butyrate, dexamethasone, dexamethasone phosphate, methylprednisolone or cortisone,

[1127] (ii) non-steroidal anti-inflammatory substances, in particular oxicams such as piroxicam or tenoxicam; salicylates such as aspirin, disalicylate, solprin or fendosal; acetic acid derivatives such as diclofenac, fenclofenac, indomethacin, sulindac, tolmetin or clindanac; fenamate esters such as mefenamic acid, meclofenamic acid, flufenamic acid or niflumic acid; propionic acid derivatives such as ibuprofen, naproxen or benoxaprofen; pyrazoles such as phenylbutazone, oxyphenylbutazone, feprazone or azapropazone,

[1128] (iii) natural or naturally occurring anti-inflammatory substances or substances which relieve redness and / or itching, in particular extracts or fractions from chamomile, aloe vera, myrrh substances, madder substances, willow, willow herb, oats, calendula, arnica, St John's wort, honeysuckle, rosemary, passion flower, witch hazel, ginger or echinacea, or their single active compounds,

[1129] (iv) histamine receptor antagonists, serine protease inhibitors (e.g., soybean extracts), TRPV1 antagonists (e.g., 4-tert-butylcyclohexanol), NK1 antagonists (e.g., aprepitant, hydroxyphenylpropionamide benzoic acid), cannabinoid receptor agonists (e.g., palmitoylethanolamine), and TRPV3 antagonists.

[1130] Examples that may be cited here are oxicams, such as piroxicam or tenoxicam; salicylates, such as aspirin, disalicylic acid, solprin or fendosal; acetic acid derivatives, such as diclofenac, fenclofenac, indomethacin, sulindac, tolmetin or clindamycin; fenamates, such as mefenam, meclofenam, flufenam or niflumic acid; propionic acid derivatives, such as ibuprofen, naproxen or benoxaprofen; or pyrazoles, such as phenylbutazone, oxyphenylbutazone, feprazone or azapropazone. Anthranilic acid derivatives are preferred antipruritic ingredients in the composition according to the invention.

[1131] Also useful are mixtures of natural or naturally occurring anti-inflammatory substances or mixtures of substances that relieve redness and / or itching, in particular extracts or fractions from chamomile, aloe, Commiphora species, Rubia species, willow, willowherb, oats, calendula, arnica, St. John's wort, honeysuckle, rosemary, passion flower, witch hazel, ginger or echinacea; preferably selected from the group consisting of extracts or fractions from chamomile, aloe, oats, calendula, arnica, honeysuckle, rosemary, witch hazel, ginger or echinacea; and / or pure substances, preferably alpha-bisabolol, apigenin, apigenin-7 -glucoside, gingerol, shogaol, dehydrogingerdione, gingerol; natural or naturally occurring avenanthramide, preferably tranilast, avenanthramide A, avenanthramide B, avenanthramide C; non-natural or non-naturally occurring avenanthramide, preferably dihydroavenanthramide D, dihydroavenanthramide E, avenanthramide D, avenanthramide E, avenanthramide F, boswellic acid, phytosterols, glycyrrhizin, glabridin and licoricechalcone A; preferably selected from the group consisting of α-bisabolol, natural avenanthramide, non-natural avenanthramide, preferably dihydroavenanthramide D (such as WO 2004 047833 A1), boswellic acid, phytosterols, glycyrrhizin and licoricechalcone A and / or allantoin, panthenol, lanolin, (pseudo)ceramides [preferably ceramide 2, hydroxypropyl bispalmitamide MEA, hexadecanoyl glyceryl methoxypropyl myristamide, N-(1-hexadecanoyl)-4-hydroxy-L-proline (1-hexadecanoyl) ester, hydroxyethyl palmitoyl hydroxypropyl palmitamide], glycosphingolipids, phytosterols, chitosan, mannose, lactose and -glucans, in particular 1,3->1,4-β-glucans from oats.

[1132] TRPV1 antagonists: Preferred compositions according to the invention comprise one or more TRPV1 antagonists. Suitable compounds that reduce skin nerve hypersensitivity based on their action as TRPV1 antagonists include, for example, trans-4-tert-butylcyclohexanol, or compounds that indirectly modulate TRPV1 by activating μ-receptors (e.g., acetyl tetrapeptide-15) are preferred.

[1133] Antimicrobial agents: Sunscreen products, cosmetic or pharmaceutical preparations or home care products according to the invention can advantageously be combined with an antimicrobial agent, which acts primarily against microorganisms, in particular bacteria, yeasts and / or fungi, and includes one or more antimicrobial agents such as caprylylhydroxamic acid, o-cymen-5-ol, propylparaben, capryloylglycine, phenylpropanol, tropone, PCA ethylcocoyl arginate, 2-methyl 5-cyclohexylpentanol, phenoxyethanol, disodium EDTA, paraben. Methyl ester and its salts, sodium benzoate, benzyl alcohol, potassium sorbate, benzyl salicylate, propylparaben, sodium methylparaben, methylisothiazolinone, methylisothiazolinone, ethylhexylglycerin, butylparaben, ethylparaben, sodium propylparaben, DMDM ​​hydantoin, dehydroacetic acid, salicylic acid, chlorpheniramine, isobutylparaben, sodium ethylparaben, diazolidinyl urea, diazolidinyl urea, farnesol, bisabolol, caprylic acid glyceryl, sodium phytate or sodium phytate, sodium levulinate or levulinic acid and their esters and / or ketals, chloramine Hexidine, lauric acid glyceryl, anisic acid and its salts, chlorhexidine digluconate, TEA-salicylate, phenethyl alcohol, caprylic glyceryl, sorbitan caprylate, tetrasodium glutamate diacetate, trisodium ethylenediamine disuccinate, hydroxyethoxyphenyl butanone, hydroxyethoxyphenyl butanol, itaconic acid, octopirox, propylene glycol caprylate, clombazole, undecylenyl glycine, thymol, 4-hydroxyacetophenone, lactic acid, sodium lactate, trisodium dicarboxymethyl alanine, fabinone, dimethyl caprylate, 3-hydroxypropyl benzoate, anisole 3-Hydroxypropyl benzoate, 3-hydroxypropyl 2-hydroxybenzoate, 1,3-propylene glycol, 1,2-pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol, 1,2-nonanediol, 1,2-decanediol, 1,2-undecanediol, 1,2-dodecanediol, 2,3-pentanediol, 2,3-hexanediol, 2,3-heptanediol, 2,3-octanediol, 2,3-nonanediol, 2,3-decanediol, 2,3-undecanediol, 2,3-dodecanediol, and any mixture thereof.

[1134] Preferably, the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the invention comprises one or more antimicrobial agents selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol, 1,2-nonanediol, 1,2-decanediol, 1,2-undecanediol, 1,2-dodecanediol, 2,3-pentanediol, 2,3-hexanediol, 2,3-heptanediol, 2,3-octanediol, 2,3-nonanediol, 2,3-decanediol, 2,3-undecanediol, 2,3-dodecanediol, 2-benzylheptanol, 2-hydroxyacetophenone, 2-methyl 5-cyclohexylpentanol, 3-hydroxypropyl 2-hydroxybenzoate, 4-hydroxyacetophenone and any mixtures thereof. More preferably, the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the invention comprises one or more antimicrobial agents selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol, 1,2-nonanediol, 1,2-decanediol, 1,2-undecanediol, 1,2-dodecanediol, 1,2-tridecanediol, 4-hydroxyacetophenone and any mixture thereof.

[1135] In order to further enhance antimicrobial efficacy, sunscreen products, cosmetics or pharmaceutical preparations or household care products as defined herein are advantageously combined with at least one another antimicrobial agent that is different from the antimicrobial agent specified above. The combination with another antimicrobial agent provides reliable protection of microbial degradation and deterioration of preparation, particularly during storage. In addition, another different antimicrobial agent provides reliable protection for other microorganisms as described above, such as Corynebacterium, Anaerococcus, Fingoldia, Moraxella, Porphyromonas, Fusobacterium, Malassezia, Dyspepsia, Streptococcus, Lactobacillus, Gardnerella, Vansella, Epidermophyton, Trichophyton, Dermatobacterium. Therefore, the combination with another different antimicrobial agent allows antimicrobial protection for different microbial groups, and therefore allows antimicrobial protection for a wider range of microorganisms. Another different antimicrobial agent in the context of the present invention is preferably selected from the group consisting of: 2-benzylheptanol, alkyl (C12-C22) trimethylammonium bromide and chloride, ascorbic acid and its salts, benzalkonium bromide, benzalkonium chloride, benzalkonium, benzethonium chloride, benzoic acid, camphor, cetylpyridinium chloride, chlorhexidine diacetate, chlorhexidine dihydrochloride, chlorocresol, chloroxylenol, cyclohexylglycerol, dimethylphenylbutanol, dimethylphenylpropanol, ethanol, ethyl lauroyl arginate HCl, ethyl lauroyl arginate laurate, eucalyptol, gluconic acid and its salts, glycerol, hexaamidine, hexaamidine diisothiocyanate, hexylglycerin, iodopropynyl butylcarbamate, jasmone, lauryl alcohol, levulinic acid and its esters and / or ketals, mannitol, menthol, methyl salicylate, octenidine HCl, polyarginine, polyglyceryl-10 laurate, polyglyceryl-2 caprate, polyglyceryl-3 caprylate, polylysine, clary sage oil, silver chloride, silver citrate, sodium caproyl lactylate, sodium caproyl / lauroyl lactylate, sodium lauroyl lactylate, sorbic acid, sorbitol, phytomyces extract, triclocarban, triclosan, triethyl citrate, dimethyl sesquioctanoate, zinc citrate, zinc pyrithione, zinc ricinoleate, and any mixture thereof.

[1136] The aforementioned antimicrobial agents are used in sunscreen products, cosmetic or pharmaceutical preparations or home care products as a single component or preferably in a mixture with two or more of said antimicrobial agents as specified above.

[1137] The antimicrobial agent is present in the sunscreen product, cosmetic or pharmaceutical preparation or home care product in an amount of 0.01 wt% to 25.0 wt%, preferably 0.02 wt% to 15.0 wt%, most preferably 0.05 wt% to 6.0 wt%, based on the total weight of the final formulation.

[1138] Advantageously, at least one antimicrobial alkanediol is present in the sunscreen product, cosmetic or pharmaceutical preparation or home care product in an amount of 0.1% to 5% by weight, based on the total weight of the final formulation and / or 4-hydroxyacetophenone is present in the sunscreen product, cosmetic or pharmaceutical preparation or home care product in an amount of 0.01% to 2% by weight, based on the total weight of the final formulation.

[1139] Preservatives: For preservation purposes, the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the present invention preferably comprises one or more preservatives suitable for or commonly used in sunscreen products, cosmetic or pharmaceutical preparations or home care products. Suitable and advantageous preservatives are, for example, benzoic acid, sodium benzoate, ammonium benzoate, butyl benzoate, calcium benzoate, ethyl benzoate, isobutyl benzoate, isopropyl benzoate, magnesium benzoate, mea benzoate, methyl benzoate, phenyl benzoate, potassium benzoate, propyl benzoate, propionic acid, ammonium propionate, calcium propionate, magnesium propionate, potassium propionate, sodium propionate, salicylic acid, calcium salicylate, magnesium salicylate, mea salicylate, sodium salicylate, potassium salicylate, tea salicylate, sorbic acid, calcium sorbate, sodium sorbate, potassium sorbate, o-phenylphenol, sodium sulfite, ammonium bisulfite, ammonium sulfite, potassium sulfite, potassium bisulfite, sodium bisulfite, metabisulfite, Sodium bisulfite, potassium metabisulfite, chlorobutanol, 4-hydroxybenzoic acid, methylparaben, potassium ethylparaben, potassium paraben, sodium methylparaben, sodium ethylparaben, ethylparaben, sodium paraben, potassium methylparaben, calcium paraben, butylparaben, propylparaben, sodium propylparaben, sodium butylparaben, potassium butylparaben, potassium propylparaben, dehydroacetic acid, sodium dehydroacetate, formic acid, sodium formate, dibromohexamidine isethionate, thimerosal, phenylmercuric acetate, phenylmercuric benzoate, undecylenic acid, potassium undecylenate, sodium undecylenate, calcium undecylenate, mea undecylenate, tea undecylenate, hexamidine, 5-bromo-5-nitro 1,3-dioxane, 2-bromo-2-nitropropane-1,3-diol, dichlorobenzyl alcohol, triclocarban, para-chloro-meta-cresol, triclosan, chloroxylenol, imidazolidinyl urea, polyaminopropyl biguanide, phenoxyethanol, hexamethylenetetramine, chloroimidazole, DMDM ​​hydantoin, benzyl alcohol, 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2-pyridone, piroctone olamine, bromochlorobenzene, o-cymene-5-ol, methylchloroisothiazolinone and methylisothiazolinone, chlorhexidine, chlorhexidine diacetate, chlorhexidine digluconate, chlorhexidine dihydrochloride, phenoxyisopropyl alcohol, scopolamine chloride (1), cypermethrin trimethoate, ...

[1140] Medicaments: The sunscreen product or cosmetic or pharmaceutical preparation according to the present invention is preferably combined with one or more medicaments. In certain such embodiments, the pharmaceutically active agent is selected from anti-acne agents, agents for treating rosacea, analgesics, anesthetics, anorectal agents, antihistamines, anti-inflammatory agents including non-steroidal anti-inflammatory drugs, antibiotics, antifungals, antivirals, antimicrobials, anticancer active substances, scabicides, pedicicides, antitumor agents, antiperspirants, antipruritics, antipsoriatic agents, antisebum agents, biologically active proteins and peptides, burn treatment agents, cautery agents, depigmentation agents, depilatory agents. agents, diaper rash treatments, enzymes, hair growth stimulants, hair growth retardants, including eflornithine and its salts and analogs, hemostatics, corneal solutions, mouth ulcer treatments, cold sore treatments, dental and periodontal treatments, photosensitizing actives, skin protectants / barrier agents, steroids including hormones and corticosteroids, sunburn treatments, sunscreens, transdermal actives, nasal actives, vaginal actives, wart treatments, wound treatments, wound healing agents, etc.

[1141] Particularly useful are mixtures of natural or naturally occurring anti-inflammatory substances or mixtures of substances which relieve redness and / or itching, in particular extracts or fractions from chamomile, aloe, myrrh species, madder species, willow, willowherb, oats, calendula, arnica, St. John's wort, honeysuckle, rosemary, passionflower, witch hazel, ginger or echinacea; preferably selected from the group consisting of extracts or fractions of chamomile, aloe, oats, calendula, arnica, honeysuckle, rosemary, witch hazel, ginger or echinacea, and / or pure substances, preferably alpha-bisabolol, apigenin, apigenin-7-glucoside, gingerol, shogaol, gingerdiol, dehydrogingerdione, shogaol, natural or naturally occurring avenant alkaloids, preferably tranilast, avenant alkaloid A, avenant alkaloid B, avenant alkaloid C, non-natural or non-naturally occurring avenant alkaloids, preferably dihydroavenant alkaloids D, dihydroavenous alkaloid E, avenous alkaloid D, avenous alkaloid E, avenous alkaloid F, boswellic acid, phytosterols, glycyrrhizin, glabridin and licoricechalcone A; preferably selected from the group consisting of α-bisabolol, natural avenous alkaloids, unnatural avenous alkaloids, preferably dihydroavenous alkaloid D, boswellic acid, phytosterols, glycyrrhizin and licoricechalcone A, and / or allantoin, panthenol, lanolin, (pseudo)ceramides [preferably ceramide 2, hydroxypropyl bispalmitamide MEA, hexadecyloxypropyl glyceryl methoxypropyl myristamide, N-(1-hexadecyl)-4-hydroxy-L-proline (1-hexadecyl) ester, hydroxyethyl palmityloxyhydroxypropyl palmitamide], glycosphingolipids, phytosterols, chitosan, mannose, lactose and β-glucans, in particular 1,3->1,4-β-glucans from oats.

[1142] Besides the substances mentioned above, it is also possible to use further ingredients customary in sunscreen products, cosmetic or pharmaceutical preparations or household care products which are suitable or customary for the compositions according to the invention.

[1143] The sunscreen product or cosmetic or pharmaceutical (particularly dermatological) preparation according to the first aspect of the invention is intended for topical application. The term "topical" is understood to mean external application on the skin or mucous membranes of mammals, in particular for the protection, treatment, care and cleaning of the skin, scalp, eyelashes, eyebrows, nails, mucous membranes and hair. The mammal is preferably a human being.

[1144] For topical application, the cosmetic or pharmaceutical formulations may be rinse-off or leave-on formulations.

[1145] Sunscreen products according to the present invention may be in the form of aqueous solutions, dispersions, hydroalcoholic vehicles, sticks, ointments, gels, aerosols (foams, sprays, propellant pumps), and the like.

[1146] The sunscreen product, cosmetic or pharmaceutical (especially dermatological) preparation or home care product according to the first aspect of the invention can be present in different forms, for example in the form of a dispersion, in the form of anhydrous formulations, or in the form of solutions based on water, water / alcohol, especially water / ethanol, water / glycol or alcohol / glycol, especially ethanol / glycol.

[1147] In a preferred variant, the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the first aspect of the invention is a dispersion. The term "dispersion" in the context of the present invention means that the sunscreen product, cosmetic or pharmaceutical preparation or home care product is a dispersed two-phase system consisting of colloidal particles (dispersed phase) and a medium (dispersion medium) in which they are suspended. The two phases are immiscible with each other and can only be miscible with an emulsifier. Such a dispersion (e.g., an emulsion) comprises preferably an amount of ≥1% by weight, more preferably an amount of ≥3% by weight, of at least one oil component (without UV filters).

[1148] Preferably, the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the first aspect of the invention is in various forms, such as emulsions, in particular O / W emulsions, W / O emulsions, multiple emulsions, water-dispersible gels, balms, water-in-oil (W / O / WO) or oil-in-water (O / W / O) multiple emulsions, PIT emulsions, Pickering emulsions, microemulsions, liquids, lotions, suspensions, milks, ointments, pastes, gels, cream-based, oil-based or liposome-based formulations or aerosols, such as foams and sprays, including all types of silicone-based emulsions.

[1149] In a most preferred variant, the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the invention is in the form of an emulsion as defined herein, advantageously in the form of an oil-in-water (O / W) emulsion comprising an oily phase dispersed in an aqueous phase in the presence of an O / W or polymeric emulsifier.

[1150] If the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the invention is a dispersion, preferably an emulsion, the oil component (without UV filters) is present in the cosmetic or pharmaceutical preparation in an amount of 0.01% by weight to 50.0% by weight, based on the total weight of the composition. In a preferred variant, the cosmetic or pharmaceutical preparation comprises an amount of 0.1% by weight to 45.0% by weight of the oil component, based on the total weight of the composition. In a particularly preferred variant, the oil component is advantageously used in the cosmetic or pharmaceutical preparation in an amount of 1.0% by weight to 40% by weight, based on the total weight of the composition.

[1151] In another variant, the sunscreen product, cosmetic or pharmaceutical (preferably dermatological) preparation or home care product according to the first one of the present invention is an anhydrous formulation, ie an oil formulation.

[1152] If the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the invention is an anhydrous formulation, i.e. an oil formulation, the oil component is present in the cosmetic or pharmaceutical preparation in an amount of ≥ 60 wt.-%, preferably ≥ 75 wt.-%, more preferably ≥ 90 wt.-%, based on the total weight of the composition.

[1153] Such anhydrous formulations include, for example, oils, skin creams, powders, lipsticks, antiperspirants / deoxidizers, and decorative cosmetics.

[1154] Additionally, other anhydrous formulations are also ethanol / diol / triol / glycol based formulations such as sprays or gels.

[1155] Alternatively, the sunscreen product, cosmetic or pharmaceutical preparation or home care product as disclosed herein is based on water or water / alcohol, preferably water / ethanol, water / glycol, or alcohol / glycol, preferably ethanol / glycol solution. Typically, this can be a composition of glycerol in water or alcohol. The solution is a homogeneous single-phase system of water / alcohol / ethylene glycol and other components. Based on the total weight of the solution, the solution based on water / alcohol or water / glycol or alcohol / glycol includes an amount of 0.1 wt % to 70.0 wt %, preferably 0.5 wt % to 60.0 wt %, more preferably 1.0 wt % to 50.0 wt % of fatty alcohol or ethylene glycol. Fatty alcohol is preferably selected from the group consisting of ethanol, isopropanol, and n-propanol. Ethylene glycol is preferably selected from the group consisting of glycerol, propylene glycol, 1,3-propylene glycol, 1,2-propylene glycol, 1,2-C5 to C10 alkanediol, butylene glycol or dipropylene glycol.

[1156] Preferably, the total water content in the final water-based solution may be ≥ 30 wt%, more preferably ≥ 40 wt%, most preferably ≥ 50 wt%.

[1157] Such water or water / alcohol or water / glycol or alcohol / glycol based solutions include, for example, deodorant / antiperspirant preparations, after shave preparations, cleansing preparations or anti-acne preparations.

[1158] In a preferred variant, the composition according to the invention is an impregnation solution in the form of an emulsion spray or an alcohol / oil spray for wet wipes.

[1159] The above-mentioned formulations or compositions are prepared according to usual and known methods.

[1160] Cosmetic preparations are preparations for cosmetic and / or non-therapeutic use in personal care, skin protection, skin care, scalp protection, scalp care, hair care, nail care, in particular for the prevention and treatment of skin disorders, intolerances or sensitive skin, skin irritations, skin redness, rashes, pruritus (itching), skin aging, wrinkle formation, loss of skin volume, loss of skin elasticity, pigment spots, pigment abnormalities, dry skin, flaking, oiliness, hypopigmentation and / or hyperpigmentation of the skin; or preparations for animal care.

[1161] Examples of personal care products are preferably anti-aging preparations, skin care lotions, body oils, body lotions, cleansing lotions, face or body balms, after shave balms, after sunscreen balms, deodorant lotions, cationic lotions, body gels, treatment creams, skin protection ointments, moisturizing gels, face and / or body moisturizers, photoprotective preparations (sunscreens), micellar waters, hair sprays, color protection hair care products, skin lightening products, anti-dark spot repair products, etc.

[1162] Cosmetic preparations also include makeup, eye care preparations, eye shadows, mascara, eyeliners, lip care preparations (such as lipsticks, lip glosses), mail care preparations (such as nail polish, nail polish removers),

[1163] Alternatively, the preparation according to the invention is a medicinal preparation.

[1164] The pharmaceutical (especially dermatological) composition according to the invention is preferably a preparation for the prevention and treatment of conditions of the skin, mucous membranes, nails or hair.

[1165] For use, a sufficient amount of the sunscreen product or cosmetic or pharmaceutical (especially dermatological) composition according to the first aspect of the invention is applied to the skin, hair, scalp and / or nails in the usual manner for sunscreen products or cosmetic and dermatological products.

[1166] In addition, the products and formulations according to the present invention are home care products. Home care products typically include laundry detergents (powders, liquids and tablets), fabric conditioners, dishwashing detergents (liquids and tablets), hard floor and surface cleaners, glass cleaners, carpet cleaners, oven cleaners, air fresheners, disinfectants, stain removers, car wash products. These products are typically manufactured in the form of liquids, powders, sprays, granules, etc.

[1167] Surprisingly, it has been found that the addition of a mycosporin-like amino acid compound or a salt thereof as defined herein has the effect of improving the SPF of a formulation comprising an inorganic UV filter and boosting the UVA photoprotection of the formulation. The higher the SPF or UVA-PF, the more protective the sunscreen is.

[1168] Furthermore, by adding mycosporin-like amino acid compounds or salts thereof, the critical wavelength of sunscreen products, cosmetic or pharmaceutical preparations or home care products containing inorganic UV filters can be increased to provide broad spectrum coverage with a critical wavelength greater than 370 nm.

[1169] The advantage of these effects is that sunscreen products or cosmetic or pharmaceutical products can be provided with a broader spectrum protection covering UVA and UVB. In addition, the improved UV filter performance, especially UVA photoprotection, allows to reduce the amount of UV filters (especially inorganic UV filters) without affecting the envisaged SPF.

[1170] As demonstrated in the examples below, SPF and UVA photoprotection are highly improved, i.e. increased, by the addition of a mycosporin-like amino acid compound as defined therein. Control samples not containing a mycosporin-like amino acid compound exhibited average or lower SPF.

[1171] When a mycosporin-like amino acid compound according to formula (V) or formula (VI) as defined herein is added to a sunscreen product, cosmetic or pharmaceutical formulation or home care product comprising inorganic UV filters, an improvement in SPF and / or UVA photoprotection may be observed.

[1172] By adding a mycosporin-like amino acid compound according to the general formula (VI), wherein X is S, SO or SO 2 , a particularly significant SPF and / or UVA light protection boost can be achieved.

[1173] Surprisingly, the mycosporin-like amino acid compounds are particularly effective in improving the SPF and / or UVA photoprotection of sunscreen products, cosmetic or pharmaceutical preparations or home care products when they are in acid form or salt form as described in detail above.

[1174] By adding a mycosporin-like amino acid compound as defined herein, the SPF of a sunscreen product or cosmetic or pharmaceutical formulation comprising inorganic UV filters can be increased by at least 10%, preferably at least 30%, and more preferably at least 50%, as demonstrated in the examples below.

[1175] The addition of MAA-1 in an amount of 1.0 wt.% to the O / W ZnO emulsion as specified in Table 4 resulted in an in vitro SPF of 44.0, which is 42% higher than the in vitro SPF of the reference sample (i.e., the sample without the addition of a mycosporin-like amino acid compound). The addition of MAA-1 in an amount of 3.0 wt.% even resulted in an in vitro SPF of 49.8, which is 60.6% higher than the in vitro SPF of the control sample (i.e., without the addition of a mycosporin-like amino acid compound). The addition of MAA-13 in an amount of 1.0% resulted in an in vitro SPF of 45.2, which is 45.8% higher than the in vitro SPF of the reference sample (i.e., the sample without the addition of a mycosporin-like amino acid compound). The addition of MAA-13 in an amount of 3.0 wt.% even resulted in an in vitro SPF of 44.0, which is 41.9% higher than the in vitro SPF of the reference sample (i.e., the sample without the addition of a mycosporin-like amino acid compound).

[1176] Furthermore, in addition to improving SPF, the addition of certain mycosporin-like amino acid compounds to sunscreen products, cosmetic or pharmaceutical preparations or home care products containing inorganic UV filters also results in a UVA photoprotection (UVA-PF) boost. In particular, the addition of MAA-13 in an amount of 1.0% to the O / W ZnO emulsion as specified in Table 4 results in an 8.4% improvement in UVA-PF compared to the control sample (i.e., without mycosporin-like amino acid compound). The addition of MAA-13 in an amount of 3.0% even results in an improvement in UVA-PF compared to the control sample (i.e., without mycosporin-like amino acid compound) by 30.9% compared to the control sample (i.e., without mycosporin-like amino acid compound).

[1177] The addition of MAA-13 also increases the broad spectrum protection from the critical wavelength of 374 nm to the critical wavelengths of 378 nm and 379 nm, depending on the concentration of MAA-13. Thus, the addition of MAA-13 leads to an improvement in SPF and UVA-PF in sunscreen products, cosmetic or pharmaceutical preparations or home care products comprising inorganic UV filters in the form of oil-in-water emulsions.

[1178] The addition of MAA-1 in an amount of 1.0 wt.% to the W / O ZnO emulsion as specified in Table 5 resulted in an in vitro SPF of 26.45, which is 20.2% higher than the in vitro SPF of the reference sample (i.e., the sample without the addition of a mycosporin-like amino acid compound). The addition of MAA-1 in an amount of 3.0 wt.% even resulted in an in vitro SPF of 42.8, which is 94.5% higher than the in vitro SPF of the control sample (i.e., the sample without the addition of a mycosporin-like amino acid compound). The addition of MAA-13 in an amount of 1.0% resulted in an in vitro SPF of 25.1, which is 14% higher than the in vitro SPF of the reference sample (i.e., the sample without the addition of a mycosporin-like amino acid compound). The addition of MAA-1 in an amount of 3.0 wt.% even resulted in an in vitro SPF of 44.4, which is as much as twice (101.8%) the in vitro SPF of the reference sample (i.e., the sample without the addition of a mycosporin-like amino acid compound).

[1179] Furthermore, in addition to improving the SPF, the addition of certain mycosporin-like amino acid compounds to sunscreen products, cosmetic or pharmaceutical preparations or home care products containing inorganic UV filters also results in a UVA-PF boost. The addition of MAA-1 in an amount of 1.0% leads to an improvement of 5.7% in UVA-PF compared to a control sample (i.e., without mycosporin-like amino acid compound). The addition of MAA-1 in an amount of 3.0% even leads to an improvement of 15.2% in UVA-PF compared to a control sample (i.e., without mycosporin-like amino acid compound). In particular, the addition of MAA-13 in an amount of 1.0% leads to an improvement of 6.5% in UVA-PF compared to a control sample (i.e., without mycosporin-like amino acid compound). The addition of MAA-13 in an amount of 3.0% even leads to an improvement of 30.6% in UVA-PF compared to a control sample (i.e., without mycosporin-like amino acid compound) compared to a control sample (i.e., without mycosporin-like amino acid compound).

[1180] The addition of MAA-1 and MAA-13 also increased broad-spectrum protection from the critical wavelength of 373 nm to the critical wavelengths of 379 nm and 380 nm, depending on the concentration of MAA-13.

[1181] In addition, the addition of MAA-20 at 1.0 wt% in an O / W sunscreen formulation containing ZnO resulted in an in vitro SPF of 51.0, which was 19.2% higher than that of the reference sample (ie, the control example without the addition of the mycosporin-like amino acid compound).

[1182] Furthermore, the addition of MAA-20 at 1.0% resulted in an improvement of 0.16 in UVA-PF compared to the control sample (ie, without the mycosporin-like amino acid compound).

[1183] The addition of MAA-20 also increases broad spectrum protection from the critical wavelength of 373nm to 374nm.

[1184] The addition of MAA-20 therefore leads to an improvement in the SPF and also in the UVA-PF in sunscreen products, cosmetic or pharmaceutical preparations or home care products comprising inorganic UV filters in the form of oil-in-water emulsions.

[1185] As demonstrated in the examples below, the addition of MAA-20 to a W / O ZnO sunscreen formulation also results in an increase in SPF compared to a W / O ZnO sunscreen formulation without MAA-20.

[1186] For the mycosporin-like amino acid compounds MAA-2, MAA-3, MAA-4, MAA-5, MAA-6, MAA-7, MAA-8, MAA-9, MAA-11, MAA-12, MAA-13, MAA-14, MAA-16, MAA-17, and MAA-20 to MAA-39, similar SPF and / or UVA photoprotection improvement effects can be shown. The compounds show an increase in SPF of at least 10% and an increase in UVA-PF of at least 5% relative to an otherwise identical sunscreen product, cosmetic or pharmaceutical preparation or household care product without the mycosporin-like amino acid compound (b).

[1187] Thus, the addition of mycosporin-like amino acid compounds leads to an improvement in the SPF as well as the UVA photoprotection (UVA-PF) in sunscreen products, cosmetic or pharmaceutical preparations or home care products comprising inorganic UV filters.

[1188] Thus, with the formulations according to the invention it is possible to provide sunscreen products or cosmetic or pharmaceutical products with significantly increased SPF, significantly increased UVA photoprotection (UVA-PF) and increased critical wavelength, and thus providing broad spectrum protection with a minimum critical wavelength well above 370 nm compared to products or formulations without the addition of the specified mycosporin-like amino acid compound.

[1189] Therefore, the present invention provides a sunscreen product, a cosmetic or pharmaceutical preparation or a home care product, wherein the SPF is increased by at least 10%, preferably at least 15%, and more preferably at least 20% compared to a sunscreen product, a cosmetic or pharmaceutical preparation or a home care product without a mycosporin-like amino acid compound (b).

[1190] In addition, the sunscreen product, cosmetic or pharmaceutical preparation or home care product according to the present invention provides at least 5% UVA light protection (UVA-PF) increase relative to the otherwise identical formulation without the mycosporin-like amino acid compound (b). In some cases, the sunscreen product, cosmetic or pharmaceutical preparation or home care product provides at least 10%, more preferably at least 15% UVA-PF increase relative to the otherwise identical formulation without the mycosporin-like amino acid compound.

[1191] Thus, improved / enhanced UV filter performance allows reducing the amount of inorganic UV filters without affecting the envisaged Sun Protection Factor (SPF).

[1192] Due to this beneficial effect as described above, the present invention relates in a further aspect to the use of a mycosporin-like amino acid compound or a mixture thereof as defined herein for improving the SPF, UVA photoprotection (UVA-PF) and increasing the critical wavelength of a sunscreen product, a cosmetic or pharmaceutical preparation or a household care product comprising at least one inorganic UV filter.

[1193] By mixing a mycosporin-like amino acid compound or a mixture thereof as defined herein, the SPF of a sunscreen product, cosmetic or pharmaceutical preparation or home care product comprising an inorganic UV filter can be enhanced by at least 10%, preferably at least 15%, and more preferably even at least 20% relative to a sunscreen product, cosmetic or pharmaceutical preparation or home care product not containing the mycosporin-like amino acid compound (b). In addition, the UVA photoprotection (UVA-PF) in a sunscreen product, cosmetic or pharmaceutical preparation or home care product comprising an inorganic UV filter can be enhanced by at least 5%, preferably at least 10%, and most preferably at least 15% relative to an otherwise identical formulation not containing the mycosporin-like amino acid compound.

[1194] In a further aspect, the present invention relates to a method for enhancing or boosting the SPF performance and UVA photoprotection of a sunscreen product, a cosmetic or pharmaceutical preparation or a home care product. In this method, an effective amount of at least one mycosporin-like amino acid as defined herein or a mixture thereof is added to said sunscreen product, cosmetic or pharmaceutical preparation or home care product comprising an inorganic UV filter.

[1195] The invention in a further aspect relates to a method of providing anti-aging benefits to the skin, whitening the skin or preventing skin darkening, improving the appearance of the skin, reducing visible signs of skin aging and improving the radiance and firmness of the skin by topically applying a sunscreen product, cosmetic or pharmaceutical formulation or home care product according to the invention due to its enhanced SPF and / or UVA photoprotection.

[1196] The present invention will now be described in detail with reference to the following examples, which are only intended to illustrate the present invention, and thus the contents of the present invention are not limited by the following examples.

[1197] Example

[1198] Example 1 - Determination of in vitro SPF

[1199] The SPF Boost and UVA-PF Boost tests are performed as an in vitro determination of SPF.

[1200] Principle: The formulation to be tested (emulsion, solution) is weighed on a PMMA plate with the aid of an analytical balance. The formulation is distributed and bound on the plate using a method corresponding to the formulation. The plate thus prepared is then measured on a Labsphere device and the result is calculated as SPF using suitable software.

[1201] 1. Sample preparation:

[1202] A PMMA plate (polymethyl methacrylate) measuring 3 cm×8.5 cm (WW5 plate with a roughness of 5 μ based on ISOethA 24443:2012 “Determination of UVA photoprotection in vitro”, GmbH & Co. AG) ​​for SPF measurement.

[1203] 1.1 Preparation of reference samples:

[1204] A reference sample is obtained by spreading 25 to 28 mg of glycerol (99.5%) on the roughened side of a PMMA plate with the index finger. The glycerol film must be very thin and uniform. The plate is then stored for at least 2 hours.

[1205] The reference plate was measured with the following transmission values:

[1206] 290nm>60% transmission;

[1207] 300nm>69% transmission; and

[1208] 320nm>82% transmission.

[1209] 1.2 Application of samples to be measured:

[1210] The sample to be measured should be mixed evenly with a spatula before application. 1.2 mg / cm2 of the sample is evenly distributed in several rows of dots on the PMMA plate. In order to minimize the evaporation of the sample during the weighing process, this process must be carried out quickly. The sample is then evenly distributed by hand with fingers pre-soaked with the sample material. This distribution is carried out in two stages:

[1211] Phase 1: Spread quickly and evenly with light pressure until the emulsion breaks.

[1212] Phase 2: Massage the sample into the rough surface with strong pressure, and the process should last for 30 seconds. In this context, under strong pressure means when massaging on a scale, which means at least 200m.

[1213] exception:

[1214] Sunscreen: Product quantity is usually 1.3mg / cm 2 For strongly spreading oils, apply less product as the amount of oil cannot be "absorbed" from the plate. The application rate should then be reduced to 1.0 mg / cm 2 -0.75mg / cm 2 The application method here is also the 30s fast / light and 30s strong method.

[1215] Sunscreen spray: The "30 / 30 method" applies here (especially with thicker sprays).

[1216] For a very liquid spray (similar to water):

[1217] Distribute quickly and evenly with slight pressure until the emulsion "breaks".

[1218] This process should take 45s.

[1219] The finished sample plates were stored dust-free and the measurements were taken after 15 minutes at the earliest.

[1220] 2. Measurement on Labsphere:

[1221] The samples were measured using the UV-200S unit using the specified Colipa method. The Labsphere user manual also applies.

[1222] 2.1 Basic settings in the software:

[1223] Open a new "Study" via File and select the "Colipa Guide 2011" method under the heading "Study". In the new window "Colipa Method Options", enter the number of panels (3 panels), the number of measurement points per panel (5 measurement points) and the in vivo SPF, and if required), the irradiance of the external irradiator (Solar Simulator Irradiance).

[1224] As standard, the irradiance set on the external device is 765W / m2. Complete naming of the sample via "Study", "Study Information".

[1225] 2.2 Sample measurement:

[1226] At the beginning of the measurement, a blank value of the glycerol reference sample is measured ("Scan Blank Plate"). In order to determine the SPF of the sample, a total of 15 measurement points (5 measurement points for 3 plates) are then generated ("Scan Positions"). The already scanned plates and measurement points are checked in the upper right window, while the absorbance of the currently measured plate is displayed in the middle window.

[1227] With irradiation:

[1228] After the first measurement run, the device calculates the irradiation dose (irradiation dose / J / cm2) and duration (exposure time) for each plate. The plates are irradiated in an external irradiation device (irradiation duration=average value of 3 plates).

[1229] The calculation of the radiation dose and exposure time is based on the irradiance set on the external device (765W / m 2 ).

[1230] No irradiation:

[1231] If no irradiation device was available or irradiation was not desired, the first plate was started again after 15 individual scans were completed and the measurement was repeated (background: no second measurement, no UVA / UVB balance calculation by the software).

[1232] After the measurement is completed, the "study" is recorded and the data can be printed / exported as a "report".

[1233] 3. Test samples:

[1234] Example 1.1 - O / W ZnO emulsion:

[1235] The formulation samples A to E specified in Table 4 below and the formulation samples A and B specified in Table 5 below were prepared as follows:

[1236] Phase A: Heat the ingredients of Phase A to 85°C to dissolve the ingredients.

[1237] Phase A: Dissolve the pigment in the ingredients of Phase B while stirring and homogenizing (Ultra T25: 10,000rpm / 10min). At the end of homogenization, add and disperse

[1238] Phase B: Mix and dissolve the ingredients of phase B under stirring. The aqueous phase combined with the sodium hydroxide solution will be turbid. Afterwards, heat aqueous phase B to 80°C. Then, add hot phase B to hot phase A and homogenize (Ultra T25: 13,000 rpm / 3 min). Finally, the mixture was cooled to ambient temperature while stirring. Subsequently, the mixture was homogenized for a short time (Ultra T25: 13,000rpm / 1,5min).

[1239] The results of the in vitro SPF determination are shown in Tables 4 and 5.

[1240] Table 4:

[1241]

[1242]

[1243] As can be retrieved from Table 4, the in vitro SPF is highly improved, i.e. increased, by the combination of the formulation with certain mycosporin-like amino acid compounds. The control example without mycosporin-like amino acid compound exhibits an SPF of 31.0. However, the addition of MAA-1 in an amount o...

Claims

1. A sunscreen product, a cosmetic or pharmaceutical preparation or a home care product, comprising or consisting of: (a) at least one inorganic UV filter; and (b) at least one mycosporine-like amino acid compound, The at least one mycosporin-like amino acid compound is represented by the general formula (V): in -Z is selected from the group consisting of O-R2' or amide'; -R1' is selected from the group consisting of CH2, unsubstituted or substituted CH(alkyl), unsubstituted or substituted C(alkyl), unsubstituted or substituted CH(cycloalkyl), unsubstituted or substituted CH(aryl), unsubstituted or substituted CH(heterocycloalkyl), unsubstituted or substituted CH(heteroaryl), CR7'R8', C=O, halogen, O, S, SO, SO2, NH, unsubstituted or substituted N(alkyl), unsubstituted or substituted N(alkenyl), unsubstituted or substituted N(alkynyl), unsubstituted or substituted N(alkoxy), unsubstituted or substituted N(alkylthio), unsubstituted or substituted N(cycloalkyl), unsubstituted or substituted N(aryl), unsubstituted or substituted N(heterocycloalkyl), and unsubstituted or substituted N(heteroaryl), and unsubstituted or substituted C-spiro; -R2' is selected from the group consisting of H, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl; -amide' is selected from the group consisting of NH2, unsubstituted or substituted NH(alkyl), unsubstituted or substituted NH(alkenyl), unsubstituted or substituted NH(alkynyl), unsubstituted or substituted NH(alkoxy), unsubstituted or substituted NH(alkylthio), unsubstituted or substituted NH(cycloalkyl), unsubstituted or substituted NH(aryl), unsubstituted or substituted NH(heterocycloalkyl), unsubstituted or substituted NH(heteroaryl), and unsubstituted or substituted NR9'R10', unsubstituted or substituted -N(O-alkyl)(alkyl)(Weinreb amide), -N(OH)(H)(hydroxamic acid), and unsubstituted or substituted -N(OH)(alkyl)(alkylated hydroxamic acid); -R3' is selected from the group consisting of: H, OH, halogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted alkanoyl / acyl RC(=O)-, -CH2-OH, -R-CH2-OH, -C(=O)-OY, -RC(=O)-OY, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, SO, SO2, NH2, unsubstituted or substituted NH(alkyl), unsubstituted or substituted NH(cycloalkyl), unsubstituted or substituted NH(aryl), unsubstituted or substituted NH(heterocycloalkyl), unsubstituted or substituted NH(heteroaryl), unsubstituted or substituted NR9'R10', and unsubstituted or substituted C-spiro; - the substituents R4', R5' and R6', which may be the same or different, are independently selected from the group consisting of: H, OH, halogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted alkanoyl / acyl RC(=O)-, -CH2-OH, -R-CH2-OH, -C(=O)-OY, -RC(=O)-OY, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted substituted heteroaryl, SO, SO2, -S(=O)2OH, sulfonyl, NH2, unsubstituted or substituted NH(alkyl), unsubstituted or substituted NH(alkenyl), unsubstituted or substituted NH(alkynyl), unsubstituted or substituted NH(alkoxy), unsubstituted or substituted NH(alkylthio), unsubstituted or substituted NH(cycloalkyl), unsubstituted or substituted NH(aryl), unsubstituted or substituted NH(heterocycloalkyl), and unsubstituted or substituted NH(heteroaryl), unsubstituted or substituted NR9'R10', and unsubstituted or substituted C-spiro; - R7' and R8', which may be the same or different, are independently selected from the group consisting of: H, OH, halogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted alkanoyl / acyl RC(=O)-, -CH2-OH, -R-CH2-OH, -C(=O)-OY, -RC(=O)-OY, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, cycloalkyl, unsubstituted or substituted heteroaryl, SO, SO2, NH2, unsubstituted or substituted NH(alkyl), unsubstituted or substituted NH(alkenyl), unsubstituted or substituted NH(alkynyl), unsubstituted or substituted NH(alkoxy), unsubstituted or substituted NH(alkylthio), unsubstituted or substituted NH(cycloalkyl), unsubstituted or substituted NH(aryl), unsubstituted or substituted NH(heterocycloalkyl), unsubstituted or substituted NH(heteroaryl), and unsubstituted or substituted NR9'R10'; - R9' and R10', which may be the same or different, are independently selected from the group consisting of H, OH, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted alkanoyl / acyl RC(=O)-, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycloalkyl and unsubstituted or substituted heteroaryl; -Y is selected from the group consisting of H and unsubstituted or substituted alkyl; and -R is unsubstituted or substituted alkyl; or a tautomer or stereoisomer or salt of the above compounds; Or represented by general formula (VI) in -R1" is selected from the group consisting of CH2, unsubstituted or substituted CH(alkyl), unsubstituted or substituted C(alkyl), unsubstituted or substituted CH(cycloalkyl), unsubstituted or substituted CH(aryl), unsubstituted or substituted CH(heterocycloalkyl), unsubstituted or substituted CH(heteroaryl), -CR7"R8", C=O, halogen, O, S, SO, SO2, NH, unsubstituted or substituted N(alkyl), unsubstituted or substituted N(alkenyl), unsubstituted or substituted N(alkynyl), unsubstituted or substituted N(alkoxy), unsubstituted or substituted N(alkylthio), unsubstituted or substituted N(cycloalkyl), unsubstituted or substituted N(aryl), unsubstituted or substituted N(heterocycloalkyl), unsubstituted or substituted N(heteroaryl), and unsubstituted or substituted C-spiro; -R2" is selected from the group consisting of: H, OH, halogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted alkanoyl / acyl RC(=O)-, -CH2-OH, -R-CH2-OH-C(=O)-OY, -C(=O)-amide", unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl alkyl, SO, SO2, NH2, unsubstituted or substituted NH(alkyl), unsubstituted or substituted NH(alkenyl), unsubstituted or substituted NH(alkynyl), unsubstituted or substituted NH(alkoxy), unsubstituted or substituted NH(alkylthio), unsubstituted or substituted NH(cycloalkyl), unsubstituted or substituted NH(aryl), unsubstituted or substituted NH(heterocycloalkyl), unsubstituted or substituted NH(heteroaryl), unsubstituted or substituted NR9"R10", and unsubstituted or substituted C-spiro; -X is selected from the group consisting of CH2, unsubstituted or substituted CH(alkyl), unsubstituted or substituted CH(alkenyl), unsubstituted or substituted CH(alkynyl), unsubstituted or substituted CH(alkoxy), unsubstituted or substituted CH(alkylthio), unsubstituted or substituted CH(cycloalkyl), unsubstituted or substituted CH(aryl), unsubstituted or substituted CH(heterocycloalkyl), unsubstituted or substituted CH(heteroaryl), -CR7"R8" , C═O, O, S, SO, SO2, NH, unsubstituted or substituted N(alkyl), unsubstituted or substituted N(alkenyl), unsubstituted or substituted N(alkynyl), unsubstituted or substituted N(alkoxy), unsubstituted or substituted N(alkylthio), unsubstituted or substituted N(cycloalkyl), unsubstituted or substituted N(aryl), unsubstituted or substituted N(heterocycloalkyl), unsubstituted or substituted N(heteroaryl), and unsubstituted or substituted C-spiro; - the substituents R4", R5" and R6", which may be the same or different, are independently selected from the group consisting of: H, OH, halogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted alkanoyl / acyl RC(=O)-, -CH2-OH, -R-CH2-OH, -C(=O)-OY, -RC(=O)-OY, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted substituted heteroaryl, SO, SO2, -S(=O)2OH, sulfonyl, NH2, unsubstituted or substituted NH(alkyl), unsubstituted or substituted NH(alkenyl), unsubstituted or substituted NH(alkynyl), unsubstituted or substituted NH(alkoxy), unsubstituted or substituted NH(alkylthio), unsubstituted or substituted NH(cycloalkyl), unsubstituted or substituted NH(aryl), unsubstituted or substituted NH(heterocycloalkyl), and unsubstituted or substituted NH(heteroaryl), unsubstituted or substituted NR9"R10", and unsubstituted or substituted C-spiro; - R7" and R8" which may be the same or different are independently selected from the group consisting of: H, OH, halogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted alkanoyl / acyl RC(=O)-, -CH2-OH, -R-CH2-OH, -C(=O)-OY, -RC(=O)-OY, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, cycloalkyl, unsubstituted or substituted heteroaryl, SO, SO2, NH2, unsubstituted or substituted NH(alkyl), unsubstituted or substituted NH(alkenyl), unsubstituted or substituted NH(alkynyl), unsubstituted or substituted NH(alkoxy), unsubstituted or substituted NH(alkylthio), unsubstituted or substituted NH(cycloalkyl), unsubstituted or substituted NH(aryl), unsubstituted or substituted NH(heterocycloalkyl), unsubstituted or substituted NH(heteroaryl), and unsubstituted or substituted NR9"R10"; -amide" is selected from the group consisting of NH2, unsubstituted or substituted NH(alkyl), unsubstituted or substituted NH(alkenyl), unsubstituted or substituted NH(alkynyl), unsubstituted or substituted NH(alkoxy), unsubstituted or substituted NH(alkylthio), unsubstituted or substituted NH(cycloalkyl), unsubstituted or substituted NH(aryl), unsubstituted or substituted NH(heterocycloalkyl), unsubstituted or substituted NH(heteroaryl), unsubstituted or substituted NR9"R10", unsubstituted or substituted -N(O-alkyl)(alkyl)(Weinreb amide), -N(OH)(H)(hydroxamic acid), and unsubstituted or substituted -N(OH)(alkyl)(alkylated hydroxamic acid); - R9" and R10" which may be identical or different are independently selected from the group consisting of H, OH, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted alkylthio, unsubstituted or substituted alkanoyl / acyl RC(=O)-, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycloalkyl and unsubstituted or substituted heteroaryl; -Y is selected from the group consisting of H and unsubstituted or substituted alkyl; and -R is unsubstituted or substituted alkyl; or a tautomer or stereoisomer or salt of the above compounds; or any mixture of the foregoing compounds; The following compounds are rejected / excluded: Compound 1: Compound 2: Compound 3: Compound 4: Compound 5: Compound 6: Compound 7: Compound 8: Compound 9: and Compound 10:

2. The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to claim 1, wherein the mycosporin-like amino acid compound (b) is represented by the general formula (VII): wherein R1′, R2′, R3′, R4′, R5′ and R6′ have the same meanings as defined for formula (V); Or represented by general formula (VIII) wherein R1′, Amide′, R3′, R4′, R5′ and R6′ have the same meanings as defined for formula (V).

3. The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to claim 1 or claim 2, wherein in the general formula (VI), X is selected from the group consisting of CH2, unsubstituted or substituted CH(alkyl), unsubstituted or substituted C(alkyl), unsubstituted or substituted CH(alkenyl), unsubstituted or substituted CH(alkynyl), unsubstituted or substituted CH(alkoxy), unsubstituted or substituted CH(alkylthio), unsubstituted or substituted CH(cycloalkyl), unsubstituted or substituted CH(aryl), unsubstituted or substituted CH(heterocycloalkyl), unsubstituted or substituted CH(heteroaryl), -CR7"R8", C=O, S, SO, SO2, NH, unsubstituted or substituted N(alkyl), unsubstituted or substituted N(alkenyl), unsubstituted or substituted N(alkynyl), unsubstituted or substituted N(alkoxy), unsubstituted or substituted N(alkylthio), unsubstituted or substituted N(cycloalkyl), unsubstituted or substituted N(aryl), unsubstituted or substituted N(heterocycloalkyl), unsubstituted or substituted N(heteroaryl), and unsubstituted or substituted C-spiro.

4. The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to any one of claims 1 to 3, wherein in the general formula (V), -Z is -O-R2' or amide'; and / or - R1' is selected from the group consisting of: CH2, C(alkyl)2, O, S, SO, SO2, NH and N(alkyl); and / or -R2' is selected from the group consisting of: H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, (2-ethylhexyl) and phenyl; or -amide' is selected from the group consisting of: NH2, NH(alkyl), N(alkyl)2, -N(O-alkyl)(alkyl)(Weinreb amide) and -N(OH)(H)(hydroxamic acid); and / or -R3' is selected from the group consisting of: H, methyl, ethyl, -O-methyl, -C(=O)-OH, -C(=O)-CH3, -C(=O)-C3H7 and -C(=O)-O-methyl; and / or - the substituents R4', R5' and R6' have the same meanings as defined for formula (V); - wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl; Or wherein in the general formula (VII) or (VIII), - R1' is selected from the group consisting of: CH2, C(alkyl)2, O, S, SO, SO2, NH and N(alkyl); and / or -R2' is selected from the group consisting of: H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, (2-ethylhexyl) and phenyl; or -amide' is selected from the group consisting of: NH2, NH(alkyl), N(alkyl)2, -N(O-alkyl)(alkyl)(Weinreb amide) and -N(OH)(H)(hydroxamic acid); and / or -R3' is selected from the group consisting of: H, methyl, ethyl, -O-methyl, -C(=O)-OH, -C(=O)-CH3, -C(=O)-C3H7 and -C(=O)-O-methyl; and / or - the substituents R4', R5' and R6' have the same meanings as defined for formulae (VII) and (VIII); - wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl; Or wherein in the general formula (VI), -R1" is selected from the group consisting of: CH2, C(alkyl)2, O, S, SO, SO2, NH and N(alkyl); and / or -R2" is selected from the group consisting of: -CH2-OH, -C(=O)-OY and -C(=O)-amide"; and / or -X is selected from the group consisting of: CH2, C=O, O, S, SO, SO2, NH and N(alkyl); and / or -Y is selected from the group consisting of H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, (2-ethylhexyl) and phenyl; and / or -amide" is selected from the group consisting of: NH2, NH(alkyl), N(alkyl)2, -N(O-alkyl)(alkyl)(Weinreb amide) and -N(OH)(H)(hydroxamic acid); and / or - the substituents R4", R5" and R6" have the same meanings as defined for formula (VI); - wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

5. The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to any one of claims 1 to 4, wherein in the general formula (V), -Z is -O-R2' or amide'; and / or - R1' is selected from the group consisting of CH2 and C(methyl)2; and / or -R2' is selected from the group consisting of: H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, (2-ethylhexyl) and phenyl; or -amide' is selected from the group consisting of: NH2, NH(alkyl), N(alkyl)2, -N(O-alkyl)(alkyl)(Weinreb amide) and -N(OH)(H)(hydroxamic acid); and / or -R3' is selected from the group consisting of: H, methyl, ethyl, -O-methyl, -C(=O)-OH, -C(=O)-CH3, -C(=O)-C3H7 and -C(=O)-O-methyl; and / or - the substituents R4', R5' and R6' have the same meanings as defined for formula (V); - wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl; Or wherein in the general formula (VII) or (VIII), -R1' is selected from the group consisting of CH2 and C(methyl)2; -R2' is selected from the group consisting of: H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, (2-ethylhexyl) and phenyl; or -amide' is selected from the group consisting of: NH2, NH(alkyl), N(alkyl)2, -N(O-alkyl)(alkyl)(Weinreb amide) and -N(OH)(H)(hydroxamic acid); and / or -R3' is selected from the group consisting of: H, methyl, ethyl, -O-methyl, -C(=O)-OH, -C(=O)-CH3, -C(=O)-C3H7 and -C(=O)-O-methyl; and / or - the substituents R4', R5' and R6' have the same meanings as defined for formulae (VII) and (VIII); - wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl; and / or Or wherein in the general formula (VI), -R1" is selected from the group consisting of CH2 and C(methyl)2; and / or -R2" is selected from the group consisting of: -CH2-OH, -C(=O)-OY and -C(=O)-amide"; and / or -X is selected from the group consisting of: CH2, C=O, O, S, SO, SO2, NH and N(alkyl); and / or -Y is selected from the group consisting of H, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, (2-ethylhexyl) and phenyl; and / or -amide" is selected from the group consisting of: NH2, NH(alkyl), N(alkyl)2, -N(O-alkyl)(alkyl)(Weinreb amide) and -N(OH)(H)(hydroxamic acid); and / or - the substituents R4", R5" and R6" have the same meanings as defined for formula (VI); - wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.

6. The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to any one of claims 1 to 5, wherein the mycosporin-like amino acid compound (b) is selected from the group consisting of the following compounds I-1 to I-128 according to the general formula (V) and the following compounds II-1 to II-192 according to the general formula (VI): wherein in the above-mentioned mycosporin-like amino acid compound, the benzene ring can be unsubstituted or substituted, and R4', R5', R6', R4", R5", R6", amide', Y, amide", and alkyl have the same meanings as in any one of the preceding claims, or a tautomer or stereoisomer or salt of the above-mentioned compound; Or wherein the mycosporin-like amino acid compound is selected from the group consisting of: MAA-A: MAA-B: and MAA-C: wherein alkyl is methyl or ethyl or propyl or butyl, preferably methyl, or a tautomer or stereoisomer or salt of the above compounds; or any mixture of the above compounds.

7. A sunscreen product, cosmetic or pharmaceutical preparation or home care product according to any one of claims 1 to 6, wherein in the general formulae (VI), (IX) and (X), X is S, SO or SO2, and / or wherein in the general formulae (V) to (X), n=1.

8. A sunscreen product, cosmetic or pharmaceutical preparation or home care product according to any one of claims 1 to 7, wherein in the general formulae (V), (VII) and (VIII), the substituents R4', R5' and R6', which may be the same or different, are independently selected from the group consisting of: H, OH, alkyl, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl or tert-butyl, alkoxy, preferably O-methyl, O-ethyl or O-butyl, -S(=O)2OH and sulfonyl; or In the general formulae (VI), (IX) and (X), the substituents R4", R5" and R6" which may be the same or different are independently selected from the group consisting of: H, OH, alkyl, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl or tert-butyl, alkoxy, preferably O-methyl, O-ethyl or O-butyl, -S(=O)2OH and sulfonyl.

9. The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to any one of claims 1 to 8, wherein in the general formulae (V) to (X), the substituted phenyl group bonded to the imino functional group is selected from the group consisting of: The dotted lines indicate the binding sites.

10. A sunscreen product, cosmetic or pharmaceutical preparation or home care product according to any one of claims 1 to 9, wherein in the general formulae (V), (VII) and (VIII), the substituents R4', R5', R6', which may be the same or different, are independently selected from the group consisting of: H, OH, alkyl, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl or tert-butyl, and alkoxy, preferably O-methyl, O-ethyl or O-butyl, -S(=O)2OH and sulfonyl; provided that if the substituted benzene ring is monosubstituted, ... The substituent is located in the ortho or meta position of the imino functional group; or wherein in the general formula (VI), (IX) and (X), the substituents R4", R5", R6", which can be the same or different, are independently selected from the group consisting of: H, OH, alkyl, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, or tert-butyl, and alkoxy, preferably O-methyl, O-ethyl or O-butyl, -S(=O)2OH and sulfonyl; provided that if the substituted benzene ring is monosubstituted, the substituent is located in the ortho or meta position of the imino functional group.

11. The sunscreen, cosmetic or pharmaceutical preparation or home care product according to any one of claims 1 to 10, wherein the mycosporin-like amino acid compound (b) is selected from the group consisting of: or a tautomer or stereoisomer or salt of the above compounds; or any mixture of the above compounds.

12. A sunscreen product, cosmetic or pharmaceutical preparation or home care product according to any one of claims 1 to 11, wherein the at least one inorganic UV filter (a) is selected from the group consisting of titanium dioxide (TiO2) (amorphous or crystalline, rutile and / or anatase form), zinc oxide (ZnO), iron oxide (Fe2O3), zirconium oxide (ZrO2), silicon dioxide (SiO2), manganese oxide (e.g. MnO), aluminum oxide (Al2O3), cerium oxide (Ce2O3), barium carbonate (BaCO3), calcium carbonate (CaCO3), all of the above inorganic UV filters in non-nanopigments, nanopigments, treated non-nanopigments and treated nanopigments form, and mixtures thereof.

13. The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to any one of claims 1 to 12, further comprising at least one additional primary organic UV filter, wherein the additional primary organic UV filter is selected from the group consisting of: camphor benzalkonium methylsulfate, homosalate, benzophenone-3, phenylbenzimidazole sulfonic acid, terephthalylidene dicamphor sulfonic acid, butyl methoxydibenzoylmethane, benzalkonium camphor sulfonic acid, octocrylene, polyacrylamidomethylbenzylidene camphor, ethylhexyl methoxycinnamate, PEG-25 PABA, isoamyl p-methoxycinnamate, ethylhexyl triazone, drometrizole trisiloxane, diethylhexyl butamido triazone, 4-methylamino Benzyl camphor, ethylhexyl salicylate, dimethyl PABA ethylhexyl ester, benzophenone-4, benzophenone-5, methylene bis-benzotriazolyl tetramethylbutylphenol (nano), disodium phenyl dibenzimidazole tetrasulfonate, bis-ethylhexyloxyphenol methoxyphenyl triazine, polysilicone-15, diethylamino hydroxybenzoyl hexyl benzoate, tris-biphenyl triazine (nano), phenylene bis-diphenyl triazine, methoxypropylaminocyclohexenylene ethoxyethyl cyanoacetate, bis-(diethylamino hydroxybenzoyl benzoyl) piperazine, TEA-salicylate, benzophenone-8, PABA, dimethyl PABA ethylhexyl ester, menthyl anthranilate, and any mixture thereof.

14. The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to any one of claims 1 to 13, comprising the inorganic UV filter (a) or a mixture thereof in an amount of 0.5 to 60.0 wt.-%, particularly in an amount of 0.3 to 55.0 wt.-%, more particularly in an amount of 0.1 to 50.0 wt.-%, most particularly in an amount of 1.0 to 45 wt.-%, based on the total weight of the product or preparation.

15. The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to any one of claims 1 to 14, comprising the mycosporin-like amino acid compound (b) or a mixture thereof in an amount of 0.001 to 15.0 wt.-%, particularly in an amount of 0.01 to 10.0 wt.-%, more particularly in an amount of 0.05 to 7.5 wt.-%, most particularly in an amount of 0.1 to 5.0 wt.-%, based on the total weight of the product or preparation.

16. The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to any one of claims 1 to 15, further comprising at least one 1,2-alkanediol or one 2,3-alkanediol having 5 to 12 carbon atoms, wherein the 1,2-alkanediol is preferably selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol, 1,2-nonanediol, 1,2-decanediol, 1,2-undecanediol, 1,2-dodecanediol, and wherein the 2,3-alkanediol is selected from the group consisting of 2,3-pentanediol, 2,3-hexanediol, 2,3-heptanediol, 2,3-octanediol, 2,3-nonanediol, 2,3-decanediol, 2,3-undecanediol, 2,3-dodecanediol and any mixtures thereof.

17. The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to any one of claims 1 to 16, further comprising one or more antimicrobial agents, preferably wherein the antimicrobial agent is selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol, 1,2-nonanediol, 1,2-decanediol, 1,2-undecanediol, 1,2-dodecanediol, 2,3-pentanediol, 2,3-hexanediol, 2,3-heptanediol, 2,3-octanediol, 2,3-nonanediol, 2,3-decanediol, 2,3-undecanediol, 2,3-dodecanediol, 2-benzylheptanol, 2-hydroxyacetophenone, 2-methyl 5-cyclohexylpentanol, 3-hydroxypropyl 2-hydroxybenzoate, 4-hydroxyacetophenone and any mixture thereof.

18. The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to any one of claims 1 to 17, further comprising at least one excipient and / or active substance selected from the group consisting of: carriers, oil components, rheological additives, hydrotropes, solubilizers, powders, film formers, water resistance improvers, skin moisturizing and / or water retention substances, emollient substances, physiological cooling agents, alkanediols, antioxidants, anti-skin aging agents, matrix-metalloproteinase inhibitors (MMPI), anti-inflammatory agents, TRPV1 antagonists, emulsifiers, antimicrobials, preservatives, antibacterial or antifungal active substances, chelating agents, surfactants, fragrances / fragrances or perfume oils and any mixtures of two or more of the above substances.

19. The sunscreen product, cosmetic or pharmaceutical preparation or home care product according to any one of claims 1 to 18, which is in the form of (i) dispersions, preferably wherein the cosmetic or pharmaceutical preparation is in the form of an emulsion, in particular an O / W emulsion, a W / O emulsion, a multiple emulsion, an aqueous dispersion gel, a balm, a water-in-oil (W / O / W) or oil-in-water (O / W / O) multiple emulsion, a PIT emulsion, a Pickering emulsion, a microemulsion, a liquid, a lotion, a suspension, a milk, an ointment, a paste, a gel, a cream-based, oil-based or liposome-based formulation or an aerosol, in particular a foam and a spray, including all types of silicone-based emulsions; (ii) anhydrous formulations; or (iii) Solutions based on water or water / alcohol, in particular water / ethanol, or water / glycol, or alcohol / glycol, in particular ethanol / glycol.

20. The sunscreen product or cosmetic or pharmaceutical preparation according to any one of claims 1 to 19 for use as a cosmetic in personal care, in particular for skin care, skin protection, sun protection, scalp protection, scalp care, hair care, nail care, as a medicament in animal care or for household care.

21. A sunscreen product, cosmetic or pharmaceutical preparation or home care product according to any one of claims 1 to 20, wherein the SPF is increased by at least 10%, preferably at least 15%, more preferably at least 20% relative to a sunscreen product, cosmetic or pharmaceutical preparation or home care product not containing the mycosporin-like amino acid compound (b); and / or wherein the UVA light protection (UVA-PF) is increased by at least 5%, preferably at least 10%, and more preferably at least 15% relative to a sunscreen product, cosmetic or pharmaceutical preparation or home care product not containing the mycosporin-like amino acid compound (b).

22. Use of a mycosporin-like amino acid compound as defined in any one of claims 1 to 11 or a mixture thereof for increasing the SPF and / or UVA photoprotection (UVA-PF) of a sunscreen product, a cosmetic or pharmaceutical preparation or a home care product comprising at least one inorganic UV filter.

23. A method for enhancing or boosting the SPF performance and UVA photoprotection of a sunscreen product, a cosmetic or pharmaceutical preparation or a home care product comprising at least one inorganic UV filter, said method comprising adding to said sunscreen product, cosmetic or pharmaceutical preparation or home care product an effective amount of a mycosporin-like amino acid compound as defined in any one of claims 1 to 11 or a mixture thereof.

24. A method of providing anti-aging benefits to the skin, whitening the skin or preventing skin darkening, improving the appearance of the skin, reducing visible signs of skin aging and improving the radiance and firmness of the skin by topically applying a sunscreen product, cosmetic or pharmaceutical formulation according to any one of claims 1 to 20.

Images